Document:

EX-10.16

 Exhibit 10.16 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 LICENSE AND COLLABORATION AGREEMENT 

THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), entered into as of May 31, 2021 (the “Effective
Date”), is entered into by and among LianBio Inflammatory Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Lian”)
LianBio, a corporation organized under the laws of the Cayman Islands (“LianBio”) (for purposes of Sections 2.9(a) (By Lian) and 14.17 (LianBio Guarantee)) and Lyra Therapeutics, Inc., a Delaware corporation
(“Lyra”). 
 INTRODUCTION 

WHEREAS, Lian wishes to obtain from Lyra and Lyra wishes to grant to Lian certain rights and licenses under intellectual property owned or
controlled by Lyra to Develop, have Manufactured, and Commercialize the Licensed Product in the Field in the Territory (each as defined below), subject to the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless the context clearly indicates
otherwise, the following terms used in this Agreement will have the meanings set forth in this Article 1 (Definitions): 
  

	1.1	 “Accounting Standards” means, with respect to a Person, as applicable, (a) generally
accepted accounting principles (“GAAP”) as practiced in the United States or (b) the International Financial Reporting Standards issued by the International Financial Reporting Standards Foundation and the International
Accounting Standards Board, in each case, consistently applied. 

  

	1.2	 “Acquired Party” has the meaning set forth in Section 2.9(c) (Business Combinations).

  

	1.3	 “Acquirer” means, collectively, the Third Party referenced in the definition of Change of
Control and such Third Party’s Affiliates, other than the applicable Party in the definition of Change of Control and such Party’s Affiliates, determined as of immediately prior to the closing of such Change of Control.

  

	1.4	 “Action” means any claim, action, cause of action, or suit (whether in contract or tort or
otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority.

  

	1.5	 “Adverse Event” or “AE” has the meaning set forth in the PRC Measures for the
Administration of Reporting and Surveillance of Drug Adverse Events (effective as of July 1, 2011) or the equivalent applicable Laws in any relevant Region, and generally means any untoward medical occurrence associated with the use of a
product in human subjects, whether or not considered related to such product. An AE does not necessarily have a causal relationship with a product, that is, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with the use of such product. 

	1.6	 “Affiliate” means, with respect to any Person, any entity controlling, controlled by or under
common control with such first Person, at the time that the determination of affiliation is made and for as long as such control exists. For purposes of this definition, “control” means (a) direct or indirect ownership of more
than 50% of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted
under such Laws; provided, however, that such ownership interest provides actual control over such Person), (b) status as a general partner in any partnership, or (c) the possession, directly or indirectly, of the power to direct,
or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. Affiliates of a Party exclude Persons who are financial investors of such Party or under common
control of such financial investors other than such Party and its subsidiary entities. 

  

	1.7	 “Agreement” has the meaning set forth in the Preamble. 

 

	1.8	 “Alliance Manager” has the meaning set forth in Section 5.7(a) (Appointment).

  

	1.9	 “Anti-Corruption Laws” means laws, regulations, or orders prohibiting the provision of a
financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, the US Foreign Corrupt Practices Act (FCPA), the Anti-Unfair Competition Law of the PRC
and the Criminal Law of the PRC, and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable in the applicable territory. 

 

	1.10	 “Assigned Invention” has the meaning set forth in Section 7.1(a) (Inventions).

  

	1.11	 “Bankruptcy Code” means Title 11 of the United States Code, Section 101, et seq.,
as amended. 

  

	1.12	 “Breaching Party” has the meaning set forth in Section 12.3(a) (Termination of Material
Breach). 

  

	1.13	 “Business Day” means any day, other than a Saturday or a Sunday, on which the banks in Boston,
New York, Beijing, Hong Kong, and Cayman Islands are open for business. 

  

	1.14	 “Calendar Quarter” means each of the three month periods ending on March 31,
June 30, September 30, and December 31 of any Calendar Year; provided, however: (a) the first Calendar Quarter of the Term will extend from the Effective Date to the end of the Calendar Quarter in which the
Effective Date occurs; and (b) the last Calendar Quarter will extend from the beginning of the Calendar Quarter in which this Agreement expires or terminates until the effective date of such expiration or termination. 

 

	1.15	 “Calendar Year” means, for the first Calendar Year, the period beginning on the Effective Date
and ending on December 31, 2021, and for each Calendar Year thereafter each 12-month period commencing on January 1, and ending on December 31, except that the last Calendar Year will commence
on January 1 of the year in which this Agreement expires or terminates and end on the effective date of such expiration or termination. 

  

	1.16	 “Change of Control” means, with respect to a Party, (a) a merger or consolidation of such
Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than 50% of the
combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) 

  
 2 

	 	
a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of more than 50% of the combined voting power
of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party’s and its controlled Affiliates’ assets. Notwithstanding the foregoing, any transaction or
series of transactions effected for the primary purpose of financing the operations of the applicable Party (including the issuance or sale of securities for financing purposes) or changing the form or jurisdiction of organization of such Party will
not be deemed a “Change of Control” for purposes of this Agreement. 

  

	1.17	 “Clinical Trial” means a trial in which human subjects or patients are dosed with a drug,
whether approved or investigational. 

  

	1.18	 “Clinical Supply Agreement” has the meaning set forth in Section 4.1 (Supply Agreement).

  

	1.19	 “CMC” means the Chemistry, Manufacturing, and Controls portion of any Regulatory Filing.

  

	1.20	 “CMC Data” means any data included in the CMC or in any supporting development reports
thereto, in each case, with respect to any Licensed Product in any country in the world. 

  

	1.21	 “Commercial Plan” has the meaning set forth in Section 4.4(b) (Commercial Plan).

  

	1.22	 “Commercial Supply Agreement” has the meaning set forth in Section 4.1 (Supply
Agreement). 

  

	1.23	 “Commercialization” means any and all activities related to the
pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, bidding and listing, pricing and reimbursement, distribution, storage, handling, offering for sale, selling,
having sold, importing and exporting for sale, having imported and exported for sale, distribution, having distributed, customer service and support, and post-marketing safety surveillance and reporting of a product (including the Licensed Product),
but not including Development activities or Manufacturing. “Commercializing” or “Commercialize” will be construed accordingly. 

 

	1.24	 “Commercially Reasonable Efforts” means, [***]. 

 

	1.25	 “Competing Product” means [***]. 

 

	1.26	 “Confidential Information” means (a) all trade secrets or confidential or proprietary
information (including any tangible materials embodying any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed (directly or indirectly) to the other Party or any of its Affiliates in connection with this Agreement or
disclosed in connection with the Term Sheet, (b) “Confidential Information” (as defined in the Prior CDA) that was disclosed by or on behalf of a Party or any of its Affiliates to the other Party or an y of its Affiliates under the Prior
CDA and (c) the terms and conditions of this Agreement (which shall be deemed the Confidential Information of both Parties); provided, however, that Confidential Information will not include information that:

  

	 	(i)	 is published by a Third Party or otherwise is or hereafter becomes part of the public domain by public use,
publication, general knowledge, or the like through no breach of this Agreement on the part of the receiving Party or its Affiliates; 

  

	 	(ii)	 is in the receiving Party’s or its Affiliates’ possession prior to disclosure by the disclosing Party
hereunder, and not through a prior disclosure by the disclosing Party, without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party’s written records or other competent evidence);

  
 3 

	 	(iii)	 is subsequently received by the receiving Party from a Third Party without restriction and without breach of
any agreement between such Third Party and the disclosing Party; or 

  

	 	(iv)	 is independently developed by or for the receiving Party without reference to, or use or disclosure of, the
disclosing Party’s Confidential Information (as evidenced by the receiving Party’s or such Affiliate’s written records or other competent evidence). 

 

	1.27	 “Contract Manufacturing Organization” or “CMO” means any Third Party contract
manufacturing organization. 

  

	1.28	 “Control” or “Controlled” means the possession by a Party of the legal
authority or right (whether by ownership, license, or otherwise other than pursuant to this Agreement), (a) with respect to any tangible Know-How, to provide such tangible
Know-How to the other Party on the terms set forth herein, or (b) with respect to Patent Rights, Regulatory Approvals, Regulatory Filings, intangible Know-How, or
other Intellectual Property, to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Approvals, Regulatory Filings, intangible Know-How,
or other Intellectual Property on the terms set forth herein, in each case ((a) and (b)), without (i) breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its
Affiliates would first be required hereunder to grant the other Party such access, right to use, licenses, or sublicense or (ii) paying any consideration to any Third Party, except for any Know-How,
Patent Right, Regulatory Filing, Regulatory Approval or other property right that a Party in-licenses and under which the other Party elects to take a sublicense and agrees to make any associated payments to
the applicable Third Party to the extent directly and specifically attributable to such other Party’s activities or exercise of its license to such Know-How, Patent Right, Regulatory Fling, Regulatory
Approval or other property right, which will be considered under the Control of such Party, provided that any such payments made by Lian under such a sublicense will be subject to Section 6.3(c) (Third Party Payments).
Notwithstanding anything in this Agreement to the contrary, a Party will be deemed not to Control any Patent Rights, Know-How, Regulatory Filing, Regulatory Approval, or other property right that are owned or in-licensed by an Acquirer except (A) with respect to any such Patent Rights, Know-How, Regulatory Filing, Regulatory Approval, or other property right arising from
active participation by employees or consultants of the Acquirer in the Development, Manufacture, or Commercialization of Licensed Products in the Field after such Change of Control, or (B) to the extent that any such Patent Rights, Know-How, Regulatory Filing, Regulatory Approval, or other property right are actually included in or used in furtherance of the Development, Manufacture, or Commercialization of Licensed Products in the Field by
the Acquirer after such Change of Control. 

  

	1.29	 “Cost of Goods Sold” means a Party’s actual costs for the Manufacture of Licensed
Products (or any component, precursor, or intermediate thereof), calculated in accordance with a Party’s internal accounting policies and principles (in accordance with its Accounting Standards, consistently applied). The Cost of Goods Sold for
Manufacturing activities with respect to such Licensed Product (or any component, precursor, or intermediate thereof) includes costs for the following, in each case, directly allocable to the Manufacture of such Licensed Products:

  

	 	(a)	 [***]t; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  
 4 

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; and 

  

	 	(i)	 [***]; 

but excludes [***]. 
  

	1.30	 “Cover,” “Covering,” or “Covered” means, when referring to
the Licensed Product: (a) with respect to an issued Patent Right, that, in the absence of a license granted to a Person under an issued claim included in such Patent Right, the manufacture, use, sale, offer for sale or import by such Person of
a specified activity with respect to such Licensed Product would infringe such claim, or (b) with respect to an application for Patent Rights, that, in the absence of a license granted to a Person under a claim included in such application, the
manufacture, use, sale, offer for sale or import by such Person of a specified activity with respect to such Licensed Product would infringe such claim if such patent application were to issue as a patent. 

 

	1.31	 “CRO” means a Third Party contract research organization. 

 

	1.32	 “CRS” means chronic rhinosinusitis. 

 

	1.33	 “Deficient Site” has the meaning set forth in Section 3.4(b) (Clinical Trial Audits).

  

	1.34	 “Development” means all internal and external (a) Clinical Trials and activities in
support of Clinical Trials (including non-clinical and preclinical activities), and (b) preparation, submission, review, and development of data or information for the purpose of submission to a
Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical or biologic product and interacting with Regulatory Authorities following receipt of Regulatory
Approval in the applicable country or region for such pharmaceutical or biologic product regarding the foregoing, but excluding activities directed to Manufacturing or Commercialization. Development will include development and regulatory activities
for additional indications for a pharmaceutical product after receipt of Regulatory Approval of such product (including label expansion), including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be
conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved indication (such as post-marketing studies, observational studies,
implementation and management of registries and analysis thereof, in each case, if required by any Regulatory Authority in any region in the Territory to support or maintain Regulatory Approval for a pharmaceutical or biologic product in such
region). “Develop,” “Developing,” and “Developed” will be construed accordingly.  

  

	1.35	 “Development Milestone Event” has the meaning set forth in Section 6.1(b) (Development
Milestone Payment). 

  

	1.36	 “Development Milestone Payment” has the meaning set forth in Section 6.1(b) (Development
Milestone Payment). 

  

	1.37	 “Development Plans” means the Territory-Specific Development Plan and the Global Development
Plan, collectively. 

  
 5 

	1.38	 “Dollars” or “US$” means United States dollars. 

 

	1.39	 “Drug Matrix” has the meaning set forth in Section 1.79
(LYR-210 Product). 

  

	1.40	 “Effective Date” has the meaning set forth in the Preamble. 

 

	1.41	 “Export Control Laws” means all applicable U.S. laws and regulations relating to
(a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the
Export Administration Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act,
22 U.S.C. §§ 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 

  

	1.42	 “FDA” means the United States Food and Drug Administration or any successor agency thereto.

  

	1.43	 “Field” means all palliative and therapeutic uses or indications in humans.

  

	1.44	 “First Commercial Sale” means with respect to the Licensed Product in any Region in the
Territory, the first sale for monetary value for use or consumption by the end user of such Licensed Product in such Region after Marketing Authorization for such Licensed Product has been obtained in such Region. First Commercial Sale excludes any
sale or transfer of Licensed Product (a) to or between Lian, its Affiliates or its or their Sublicensees for further sale by such entity (but includes the subsequent sale by such entity to a Third Party that is not a Selling Party) or
(b) as bona fide samples, as charitable donations, or for Clinical Trial or other Development purposes, any expanded access program, any compassionate sales or use program (including named patient program or single patient program), or
any indigent program, in each case, where the Licensed Product is supplied at or below cost. 

  

	1.45	 “Force Majeure” has the meaning set forth in Section 14.9 (Force Majeure).

  

	1.46	 “GCP” or “Good Clinical Practice” means all applicable then-current standards
for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable, (a) as set forth in the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products, (b) the Declaration of Helsinki
(2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications thereto, (c) as set forth in the PRC Good Clinical Practice for Pharmaceuticals effective as of September 1,
2003 and its subsequent amendments, (d) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), and (e) the equivalent applicable
Laws in any relevant Region, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights,
integrity, and confidentiality of trial subjects. 

  

	1.47	 “Generic Product” means, with respect to a particular Licensed Product in a Region, any
product that (a) (i) contains the same or similar active pharmaceutical ingredient(s) as such Licensed Product and (ii) qualifies as a generic or is bioequivalent to and exchangeable with the Licensed Product, as determined by the
applicable Regulatory Authority under the applicable Laws in such Region, (b) has received Regulatory Approval for use in such Region from the relevant Regulatory Authority in such Region, where such Regulatory Approval relied on or
incorporated the Regulatory Approval for such Licensed Product in such Region or any 

  
 6 

	 	
clinical data contained in such Regulatory Approval, (c) during the Royalty Term is not owned or licensed by Lian under this Agreement; and (d) is sold in the same Region as the
relevant Licensed Product by a Third Party that is not a Sublicensee or Affiliate of Lian and that did not purchase such product in a chain of distribution that included Lian or its Affiliates or its or their Sublicensees. 

 

	1.48	 “Global Development Plan” has the meaning set forth in Section 3.3(b) (Global Development
Plan). 

  

	1.49	 “Global Phase III Trial” means the second of two planned global registrational Phase III
Trials for the Licensed Product, as referenced in the Territory-Specific Development Plan as “Ph3-II”. 

  

	1.50	 “GLP” or “Good Laboratory Practice” means all applicable then-current
standards for laboratory activities for pharmaceuticals, as set forth in the FDA’s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, the PRC Good Clinical Practice effective as of September 1, 2003, or the Good
Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the equivalent applicable Laws in the
relevant Region and other organizations and governmental agencies in countries in which the Licensed Product is intended to be sold by the Party that is subject to such standards. 

 

	1.51	 “GMP” or “Good Manufacturing Practice” means all applicable
then-current standards for Manufacturing, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. §§ 201, 211, 600 and 610 and all applicable FDA guidelines and requirements,
(b) European Directive 2003/94/EC for medicines and investigational medicines for human use and the applicable guidelines stated in the Eudralex guidelines, (c) Pharmaceutical Good Manufacturing Practice of the PRC effective as of
March 1, 2011 and its appendices, (d) the principles detailed in the applicable ICH guidelines, (e) the conduct of an inspection by a Qualified Person (as defined therein) and the execution by such Qualified Person of an appropriate
certification of inspection and (f) the equivalent applicable Laws in any relevant Region, each as may be amended and applicable from time to time. 

  

	1.52	 “Governmental Authority” means any multinational, federal, national, state, provincial,
local or other entity, office, commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, exercising executive, judicial, legislative, police,
regulatory, administrative, or taxing authority or functions of any nature pertaining to government. 

  

	1.53	 “ICH” means the International Council for Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. 

  

	1.54	 “IND” means (a) an Investigational New Drug Application as defined in the United States
Federal Food, Drug, and Cosmetic Act, as amended, and regulations promulgated thereunder, or any successor application or procedure required to initiate clinical testing of a drug in humans in the United States, (b) a clinical trial
application filed with the NMPA to commence human clinical trials in the PRC, or (c) any equivalent application to the applicable Regulatory Authority, the filing of which is required to initiate clinical testing of a drug or device in humans
in such Region. 

  

	1.55	 “Indemnified Party” means a Person entitled to indemnification under Article 10
(Indemnification; Damages). 

  

	1.56	 “Indemnifying Party” means a Party from whom indemnification is sought under Article
10 (Indemnification; Damages). 

  
 7 

	1.57	 “Indication” means each separate and distinct disease, disorder, illness, health
condition, or interruption, cessation or disruption of a bodily function, system, tissue type or organ, for which a separate Clinical Trial is performed and a separate Regulatory Approval Application (or a supplement to an existing Regulatory
Approval Application) is required to be filed to obtain Regulatory Approval. By way of example, CRS and allergic rhinitis constitute separate “Indications”. 

 

	1.58	 “Infringement” has the meaning set forth in Section 7.3(a) (Notice).

  

	1.59	 “Infringement Action” has the meaning set forth in Section 7.3(b) (Lian First
Right). 

  

	1.60	 “Infringement Claim” has the meaning set forth in Section 7.4 (Claimed
Infringement). 

  

	1.61	 “Intellectual Property” means all Patent Rights, rights to Inventions, copyrights,
design rights, trademarks, trade secrets, Know-How, materials, and all other intellectual property rights (whether registered or unregistered), and all applications and rights to apply for any of the foregoing
anywhere in the world. 

  

	1.62	 “Invention” has the meaning set forth in Section 7.1(a) (Inventions).

  

	1.63	 “Joint Know-How” means Know-How developed or invented jointly by a Party’s or its Affiliates’, licensees’, Sublicensees’, or subcontractors’ employees, agents, or independent contractors, or any persons
contractually required to assign or license such Know-How to such Party or any Affiliate of such Party, on the one hand, and the other Party’s or its Affiliates’, licensees’, Sublicensees’,
or subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such Know-How to such Party or any Affiliate of such Party, on the other hand,
in the performance of activities under this Agreement during the Term. 

  

	1.64	 “Joint Patent Right” means any Patent Right claiming any Invention conceived jointly by
a Party’s or its Affiliates’, licensees, Sublicensees, or subcontractors’ employees, agents or independent contractors, or any persons contractually required to assign or license such Invention to such Party or any Affiliate of such
Party, on the one hand, and the other Party’s or its Affiliates’, licensees’, Sublicensees’, or subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such
Invention to such Party or any Affiliate of such Party, on the other hand. 

  

	1.65	 “JSC” has the meaning set forth in Section 5.1 (Formation; Purposes and
Principles). 

  

	1.66	 “Know-How” means all proprietary chemical and
biological materials and other tangible materials, inventions, practices, methods, protocols, formulae, knowledge, know-how, trade secrets, processes, procedures, assays, skills, experience, techniques,
information, data and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical and quality control data, whether patentable or
otherwise. 

  

	1.67	 “Law” or “Laws” means all laws, statutes, rules, codes, regulations,
orders, decrees, judgments or ordinances of any Governmental Authority, or any license, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. 

 

	1.68	 “Lian” has the meaning set forth in the Preamble. 

 

	1.69	 “Lian Indemnified Party” has the meaning set forth in Section 10.1
(Indemnification by Lyra). 

  

	1.70	 “Lian Obligations” has the meaning set forth in Section 14.17
(LianBio Guarantee). 

  
 8 

	1.71	 “Lian Technology” means the Patent Rights and
Know-How Controlled by Lian, its Affiliates or Sublicensees (including Product Inventions and Patent Rights that claim any such Product Inventions) as of the Effective Date or during the Term of this
Agreement, that are actually used by Lian, its Affiliates, or Sublicensees in the Development, Manufacture or Commercialization of the Licensed Product in the Field. 

 

	1.72	 “LianBio” has the meaning set forth in the Preamble. 

 

	1.73	 “Licensed Know-How” means any and all Know-How Controlled by Lyra or any of its Affiliates as of the Effective Date or during the Term that is necessary or reasonably useful for the Development, Manufacture, or Commercialization of the Licensed Product
in the Field, including any Assigned Inventions, but excluding any Joint Know-How. The Licensed Know-How as of the Effective Date includes the Know-How listed in Schedule 1.73 (Licensed Know-How). 

  

	1.74	 “Licensed Mark(s)” means any mark(s) that Lyra or its Affiliates registers with a
Governmental Authority in any Region in the Territory to be used in connection with the Commercialization of a Licensed Product. 

  

	1.75	 “Licensed Patent Rights” means any and all Patent Rights Controlled by Lyra or any of
its Affiliates as of the Effective Date or during the Term that (a) Cover the Licensed Know-How or (b) are otherwise necessary or reasonably useful for the Development, Manufacture, or
Commercialization of the Licensed Product in the Field in the Territory. The Licensed Patent Rights as of the Effective Date are listed in Schedule 1.75 (Licensed Patents). The Licensed Patent Rights exclude any Joint Patent Rights.

  

	1.76	 “Licensed Product” means (a) LYR-210
Product and (b) any improvements or updates thereto made by or on behalf of Lyra or its Affiliates using [***]. 

  

	1.77	 “Licensed Technology” means collectively Licensed Patent Rights, Licensed Know-How and Lyra or its Affiliates’ interests in the Joint Know-How and Joint Patent Rights. 

 

	1.78	 “Losses” means damages, losses, liabilities, costs (including costs of investigation,
defense), fines, penalties, taxes, expenses, or amounts paid in settlement (in each case, including reasonable attorneys’ and experts’ fees and expenses), in each case, resulting from an Action. 

 

	1.79	 “LYR-210 Product” means
Lyra’s proprietary therapeutic combination product referred to by Lyra as “LYR-210”, comprised of [***] (the “Drug Matrix”) [***], as further described on Schedule 1.79 (LYR-210 Product) attached hereto. 

  

	1.80	 “LYR-220 Product” means
Lyra’s proprietary therapeutic combination product referred to by Lyra as “LYR-220”, comprised of a [***], as further described on Schedule 1.80
(LYR-220 Product), [***]. 

  

	1.81	 “Lyra” has the meaning set forth in the Preamble. 

 

	1.82	 “Lyra Indemnified Party” has the meaning set forth in Section 10.2
(Indemnification by Lian). 

  

	1.83	 “Manufacture” means all activities directed to manufacturing, processing, packaging,
labeling, filling, finishing, assembly, quality assurance, quality control, testing, and release, shipping, or storage of any pharmaceutical product (or any components or delivery systems thereof), including process development, qualification, and
validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, product characterization, and stability testing, but excluding
activities directed to Development or Commercialization. “Manufacturing” or “Manufactured” will be construed accordingly. 

  
 9 

	1.84	 “Marketing Authorization” means the grant of all necessary final or conditional
permits, registrations, authorizations, licenses, and approvals (or waivers) required for the Commercialization of the Licensed Product for use in the Field and in the Territory, including any Regulatory Approval for sale or marketing, and, where
applicable, Pricing and Reimbursement Approvals. 

  

	1.85	 “Milestone Payments” means Development Milestone Payments and Sales Milestone Payments.

  

	1.86	 “Net Sales” means, with respect to a Licensed Product in a Region for any period, the
total amounts invoiced for sales of such Licensed Product in such Region for such period by Lian or any of its Affiliates or its or their Sublicensees (for the purpose of this definition, “Sublicensees” will not include any distributors or
wholesalers) (each of the foregoing Persons, a “Selling Party”) to Third Parties that are not Selling Parties in the Territory, in bona fide arm’s length transactions, less the following deductions calculated in
accordance with the Accounting Standards, related specifically to such Licensed Product and actually taken, paid, accrued, allowed, included, or allocated by the Selling Party in accordance with the Selling Party’s Accounting Standards,
consistently applied, and not otherwise recovered by or reimbursed to the Selling Party, as set forth below (collectively, “Permitted Deductions”): 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; and 

  

	 	(f)	 [***]. 

No amount for which deduction is permitted pursuant to the above shall be deducted more than once. In addition, to the extent any amounts deducted pursuant to
the above are subsequently recovered by or reimbursed to the Selling Party, such recovered amounts shall be [***]; provided that, [***]. 
 Net Sales
will be calculated only once for the first bona fide arm’s length sale of the Licensed Product to a Third Party that is not a Selling Party. Net Sales does not include (a) [***], (b) [***], or (c) [***], in each case, where the Licensed
Product is [***]. 
 Subject to the above, Net Sales will be calculated in accordance with the standard internal policies and procedures of the Selling
Party, if any, and copies of such policies and procedures will be furnished to Lyra upon request. 
  

	1.87	 “NMPA” means the National Medical Product Administrations of the PRC, or its successor.

  

	1.88	 “Non-Breaching Party” has the meaning set forth in
Section 12.3(a) (Termination by Material Breach). 

  

	1.89	 “Party” means either Lyra or Lian; “Parties” means Lyra and Lian,
collectively. 

  

	1.90	 “Party Vote” has the meaning set forth in Section 5.5 (Decision-Making; Escalation to
Senior Officers). 

  

	1.91	 “Patent Challenge” has the meaning set forth in Section 12.3(d) (Patent Challenge).

  
 10 

	1.92	 “Patent Rights” means the rights and interests in and to (a) all patents and patent
applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part,
re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of
any of the foregoing, (b) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and
the like of any of the foregoing, and (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents
and certificates of invention. 

  

	1.93	 “Permitted Deductions” has the meaning set forth in Section 1.86 (Net Sales).

  

	1.94	 “Person” means any natural person, corporation, general partnership, limited partnership,
joint venture, proprietorship or other business organization or a Governmental Authority. 

  

	1.95	 “Pharmacovigilance Agreement” has the meaning set forth in Section 3.10
(Pharmacovigilance). 

  

	1.96	 “Phase III Trial” means a Clinical Trial of an investigational product in subjects that
incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable
Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States. 

  

	1.97	 “PRC” means the People’s Republic of China, which for the purposes of this Agreement,
excludes Hong Kong, Macau and Taiwan. 

  

	1.98	 “Preclinical Development” means all internal and external
non-clinical or preclinical activities related to pharmaceutical products, including non-clinical testing and research, toxicology testing and studies, preclinical
studies. 

  

	1.99	 “Pricing and Reimbursement Approval” means, with respect to the Licensed Product, the
governmental approval, agreement, determination, or decision establishing the price or level of reimbursement for such Licensed Product in a given Region in the Territory prior to the sale of such Licensed Product in such Region in the Field in the
Territory. 

  

	1.100	 “Prior CDA” means the Mutual Confidential Disclosure Agreement, executed on February 25,
2019, by and between LianBio and Lyra. 

  

	1.101	 “Product Inventions” means any Inventions, other than Assigned Inventions, that are necessary
or reasonably useful for the Development, Manufacture, or Commercialization of the Licensed Product in the Field. 

  

	1.102	 “Prosecution” or “Prosecute” means, with respect to a particular Patent
Right, all activities associated with the preparation, filing, prosecution, and maintenance of such Patent Right, as well as supplemental examinations, re-examinations, reissues, supplementary protection
certificates and the like with respect to such Patent Right, together with the conduct of interferences, derivation proceedings, inter partes review, post-grant review, the defense of oppositions, and other similar proceedings with respect to
such Patent Right. 

  

	1.103	 “Region” means each of the PRC, Hong Kong, Macau, Taiwan, Singapore, South Korea, and
Thailand. 

  

	1.104	 “Regulatory Approval” means the final or conditional approval of the applicable Regulatory
Authority necessary for the marketing and sale of a Licensed Product in the Field in a country(ies) or Region(s), excluding separate Pricing and Reimbursement Approval that may be applicable in a Region. 

  
 11 

	1.105	 “Regulatory Approval Application” means an application to seek regular or expedited Regulatory
Approval of the Licensed Product for sale or marketing in any country(ies) or Region(s) in the Territory, as defined in the applicable Laws and filed with the Regulatory Authority of such country(ies) or Region(s). 

 

	1.106	 “Regulatory Authority” means any multinational, federal, national, state, provincial, or local
regulatory agency, department, bureau, or other Governmental Authority with authority over the clinical development, Manufacture, marketing or sale of the Licensed Product in a Region, including the NMPA. 

 

	1.107	 “Regulatory Exclusivity” means, with respect to a Licensed Product in a Region, the period of
time during which: (a) a Party or its Affiliates or its or their Sublicensees has been granted the exclusive legal right by a Regulatory Authority in such Region to market and sell such Licensed Product; or (b) the data and information
submitted by a Party or its Affiliates or its or their sublicensees to the relevant Regulatory Authority in such Region for purposes of obtaining Regulatory Approval of such Licensed Product in such Region may not be disclosed, referenced, or relied
upon in any way by a Third Party or such Regulatory Authority (including by relying upon the Regulatory Authority’s previous findings regarding the safety or effectiveness of the Licensed Product) to support the Regulatory Approval of any
product of a Third Party in such Region. 

  

	1.108	 “Regulatory Filing” means any documentation comprising or relating to or supporting any filing
or application with any Regulatory Authority with respect to the Licensed Product, including any documents submitted to any Regulatory Authority, including INDs, Regulatory Approval Applications, and all correspondence with any Regulatory Authority
with respect to any Licensed Product (including minutes of any meetings, telephone conferences, or discussions with any Regulatory Authority). 

  

	1.109	 “Reversion License” has the meaning set forth in Section 12.5(c)(i) (License Grant to
Lyra). 

  

	1.110	 “ROFR” has the meaning set forth in Section 2.10 (Right of First Refusal for LYR-220 Product). 

  

	1.111	 “ROFR Terms” has the meaning set forth in Section 2.10 (Right of First Refusal for LYR-220 Product). 

  

	1.112	 “Royalty Term” has the meaning set forth in Section 6.2(b) (Royalty Term).

  

	1.113	 “Rules” has the meaning set forth in Section 13.2 (Arbitration). 

 

	1.114	 “Safety Data” means any Adverse Event information from Clinical Trials and all results from non-clinical safety studies, including toxicology and carcinogenicity data (if any), with respect to the Licensed Product required by one or more Regulatory Authorities to be collected or to be reported to such
Regulatory Authorities under applicable Laws, but excluding any information related to the efficacy of the Licensed Product. 

  

	1.115	 “Sales Milestone Event” has the meaning set forth in Section 6.1(c) (Sales Milestone
Payments). 

  

	1.116	 “Sales Milestone Payment” has the meaning set forth in Section 6.1(c) (Sales Milestone
Payments). 

  
 12 

	1.117	 “Securitization Transaction” has the meaning set forth in Section 14.1(b)
(Securitization). 

  

	1.118	 “Sell-Off Period” has the meaning set forth in
Section 12.5(g)(ii) (Sell-Off Period). 

  

	1.119	 “Selling Party” has the meaning set forth in Section 1.86 (Net Sales).

  

	1.120	 “Senior Officers” means the Chief Executive Officer of each Party. If the position of
any of the Senior Officers identified in this definition no longer exists due to a corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, then the applicable title of the Senior
Officer set forth herein will be replaced with the title of another executive officer with responsibilities and seniority comparable to the eliminated Senior Officer, and the relevant Party will promptly provide notice of such replacement title to
the other Party. 

  

	1.121	 “Sublicense” means a grant of rights from Lian to a Sublicensee or an Affiliate under any of
the rights licensed to Lian by Lyra under Section 2.1 (License Grants; Right of Reference). 

  

	1.122	 “Sublicensee” means a Third Party sublicensee to which a Party or its Affiliates has granted
rights under this Agreement or a Third Party licensee of rights with respect to the Licensed Product, which rights are retained by a Party under this Agreement with respect to such Licensed Product, or any further sublicensee of such rights
(regardless of the number of tiers, layers, or levels of sublicenses of such rights). 

  

	1.123	 “Supply Agreements” has the meaning set forth in Section 4.1 (Supply Agreement).

  

	1.124	 “Supply Failure” means, for a given [***], that Lyra has failed to supply or cause to be
supplied to Lian those quantities of Licensed Product ordered in accordance with the terms of the applicable Supply Agreement, and [***]. 

  

	1.125	 “Tax Withholdings” has the meaning set forth in Section 6.5 (Tax Withholding).

  

	1.126	 “Term” has the meaning set forth in Section 12.1 (Term). 

 

	1.127	 “Term Sheet” means that certain non-binding (except
with respect to confidentiality obligations therein) term sheet by and between Lian and Lyra, dated as of March 4, 2021. 

  

	1.128	 “Territory” means the PRC, Hong Kong, Macau, Taiwan, Singapore, South Korea, and Thailand.

  

	1.129	 “Territory-Specific Development Plan” has the meaning set forth in Section 3.3(a)
(Territory-Specific Development Plan). 

  

	1.130	 “Third Party” means any Person other than a Party or any of its Affiliates.

  

	1.131	 “Third Party Claim” has the meaning set forth in Section 10.3(a) (Notice).

  

	1.132	 “Third Party Losses” means Losses resulting from an Action by a Third Party.

  

	1.133	 “Trademark” means all registered and unregistered trademarks, service marks, trade dress,
trade names, logos, insignias, domain names, symbols, designs, and combinations thereof. 

  

	1.134	 “Two-Invoice Policy” means the policy described in
“the Opinion on the Implementation of the ‘Two-Invoices’ System in the Procurement of Pharmaceutical Products by Public Medical Institutions (trial)” (Guoyigaibanfa [2016] No. 4),
officially released on 9 January 2017 and in any other applicable Laws that mandates public hospitals or any other purchaser of drugs in mainland China to purchase drugs from the distributor that purchases the drugs directly from the drug
manufacturer, limiting the total number of invoices to two. 

  
 13 

	1.135	 “United States” or “U.S.” or “US” means the United States
and its territories, possessions and commonwealths. 

  

	1.136	 “Valid Claim” means either: (a) a claim of an issued and unexpired patent included within
the Licensed Patent Rights that (i) has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction; and
(ii) has not been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise, or (b) a claim included in a patent application that has not been irretrievably cancelled, withdrawn, or abandoned, nor been pending for
more than [***]. 

 ARTICLE 2     

LICENSE GRANTS 
  

	2.1	 License Grants; Right of Reference. 

 

	 	(a)	 License Grants to Lian. Subject to the terms and conditions of this Agreement, Lyra hereby grants to
Lian: 

  

	 	(i)	 an exclusive (even with respect to Lyra and its Affiliates, subject to this Section 2.1(a) (License Grants
to Lian) and Section 2.5 (Lyra Right of Access and Reference)), sublicensable (solely as permitted under Section 2.2(a)) (Lian Right to Sublicense), non-transferable (except as provided
Section 14.1 (Assignment)), royalty-bearing license under the Licensed Technology to Develop, and Commercialize and otherwise, use, offer for sale, sell, have sold, and import the Licensed Product in the Field in the Territory; and

  

	 	(ii)	 a non-exclusive,
non-transferable (except as provided Section 14.1 (Assignment)), sublicensable (solely as permitted under Section 2.2(a)) (Lian Right to Sublicense) worldwide license under the Licensed Technology to
Manufacture the Licensed Product solely for (1) Development solely for purposes of obtaining Regulatory Approval of the Licensed Product in the Field in the Territory; and (2) Commercialization of the Licensed Product in the Field in the
Territory, provided that Lian will not practice under the license granted in this Section 2.1(a)(ii) unless and until the occurrence of (A) [***] or (B) [***], following the completion of the technology transfer described in
Section 4.3 (Manufacturing Technology Transfer), subject to the terms set forth in Section 4.3 (Manufacturing Technology Transfer). 

  

	 	(b)	 Lian Right of Access and Reference. Lyra hereby grants Lian and its Affiliates and Sublicensees access
to, and a right of reference with respect to, (i) the Regulatory Filings, Regulatory Approvals, Marketing Authorizations, and (ii) all data generated by or on behalf of Lyra or its Affiliates or licensees relating to the Licensed Product,
including clinical and preclinical data (including any such data generated from any Clinical Trial performed by or on behalf of Lyra or its Affiliates), Safety Data, and CMC Data, in each case, contained or referenced in any such Regulatory Filings,
Regulatory Approvals or Marketing Authorizations, in each case ((i) and (ii)), Controlled by Lyra or its Affiliates as of the Effective Date or at any time during the Term and to the extent reasonably useful or necessary for Developing, seeking, and
securing Regulatory Approval and Marketing Authorization for the Development, Manufacture, or Commercialization of the Licensed Product in the Field in the Territory. The foregoing rights include the right for Lian and, to the extent permitted

  
 14 

	 	
under this Agreement, its Affiliates and Sublicensees, to make copies of and reproduce such documentation and information for the sole purposes set forth in this Section 2.1(b) (Lian Right
of Access and Reference). Lyra will promptly provide to Lian all data generated by or on behalf of it or its Affiliates from any Clinical Trial or other non-clinical or
pre-clinical study, in each case, for a Licensed Product that is necessary or reasonably useful to Lian or its Affiliates or Sublicensees for securing Regulatory Approval and Marketing Authorization for the
Development, Manufacture, or Commercialization of the Licensed Product in Field and in the Territory. 

  

	2.2	 Sublicensing and Subcontracting. 

 

	 	(a)	 Lian Right to Sublicense. Lian will have the right to grant Sublicenses (through multiple tiers) to
(i) its Affiliates and to independent contractors engaged pursuant to Section 2.3 (Performance by Independent Contractors) of any and all rights granted to Lian by Lyra pursuant to Section 2.1 (License Grants; Right of Reference)
[***], and (ii) to Third Parties, [***], subject to the requirements of Section 2.2(b) (Sublicense Requirements); provided that any such sublicense to an Affiliate will terminate if such sublicensee ceases to be an Affiliate of
Lian. 

  

	 	(b)	 Sublicense Requirements. Each Sublicense granted by Lian to a Third Party pursuant to
Section 2.2(a) (Lian Right to Sublicense) will be in writing and will be consistent with the relevant terms and conditions set forth in this Agreement. Any sublicense granted to a Third Party under this Section 2.2 (Sublicensing and
Subcontracting) must [***], and provided that [***]. Lian shall keep Lyra informed through the JSC of each sublicense granted to an Affiliate or Third Party, specifying the name of the Sublicensee and the material terms (including duration)
of the sublicense. No Sublicense will diminish, reduce or eliminate any obligation of either Party under this Agreement. Lian will be liable for any act or omission of its Sublicensees as if such Sublicensees were Lian hereunder and Lyra will have
the right to proceed directly against Lian without any obligation to first proceed against such Sublicensee. Without limiting the foregoing, each Sublicense granted by Lian or its Affiliates to a Sublicensee will contain (i) confidentiality and
non-use provisions at least as restrictive or protective as those set forth in Section 8.1 (Confidential Information) with respect to Lyra’s Confidential Information, (ii) if such Sublicense
contains a right to Commercialize Licensed Products, such Sublicense will also contain the following provisions: (A) a requirement that the Sublicensee submit applicable sales or other reports to Lian to the extent necessary or relevant to the
reports required to be made or records required to be maintained by Lian under this Agreement, and (B) audit requirements in favor of Lian consistent with those set forth in Section 6.4 (Audits), (iii) invention ownership and assignment
provisions consistent with and no less restrictive than those set forth in Section 7.1 (Ownership of Intellectual Property), and (iv) if possible under applicable Law, Lian will use reasonable efforts to include in such Sublicense
assignment and transfer of possession of, or a right to reference (which right of reference shall be sublicensable (through multiple tiers)) to, all Regulatory Filings and Regulatory Approvals Controlled by such Sublicensee pertaining to any
Licensed Product Developed or Commercialized by such Sublicensee (which assignment or right of reference may also be provided to Lian); provided that, if despite using reasonable efforts Lian is unable to obtain such assignment and transfer
of, or a right of reference to, such Regulatory Filings and Regulatory Approvals, then Lian will include in such Sublicense that upon termination of such Sublicense, Lian obtains such assignment and transfer of, or a right of reference to, such
Regulatory Filings and Regulatory Approvals. Lian will provide Lyra with a copy of any such Sublicense agreement it enters into with a Third Party (other than Third Party subcontractors), within [***]days after the execution thereof, provided
that [***]. 

  
 15 

	 	(c)	 Sublicense Survival. Upon the termination of this Agreement by Lyra pursuant to Sections 12.3(a)
(Termination for Material Breach), 12.3(c) (Termination for Bankruptcy), 12.3(d) (Patent Challenge), or 12.3(e) (Termination for Cessation of Development or Commercialization), at the written request of any Sublicensee (other than Third Party
subcontractors) who is not then in breach of its sublicense agreement, Lyra agrees to enter into a direct license agreement with such Sublicensee under the same terms and conditions of this Agreement (except for Section 6.1(a)) (Upfront
Payment), effective upon the date that notice of such written request. If Lian terminates this Agreement pursuant to Section 12.3(b) (Termination by Lian for Convenience), then Lyra agrees to consider in good faith any request from any
Sublicensee (other than Third Party subcontractors) to enter into a direct license agreement with such Sublicensee. 

  

	2.3	 Performance by Independent Contractors. Lian may contract or delegate any portion of its obligations
hereunder to a contractor subject to the terms and condition of Section 14.8 (Affiliates, Sublicensees, and Contractors); provided that Lian [***]. Lyra is responsible for the compliance of its Affiliates and contractors with the terms
and conditions of this Agreement, and any act or omission of an Affiliate or contractor that would be a breach of this Agreement if performed by Lyra will be deemed to be a breach by Lyra under this Agreement. For clarity, Lian shall have no right
to contract or delegate its obligations hereunder to any Affiliate of Lian or any contractor, CMO or other Third Party, in each case, under terms permitting the performance of any activities related to any Licensed Product outside the Territory,
including any Manufacture (for any purpose) of any Licensed Product outside the Territory. 

  

	2.4	 License Grant to Lyra. Lian hereby grants to Lyra and its Affiliates a
non-exclusive, sublicensable (through multiple tiers), royalty-free, fully paid up, perpetual, and irrevocable license under any Product Inventions invented or otherwise developed or generated during the Term
by or on behalf of Lian (including its Affiliates, or any of its or their employees, Sublicensees, independent contractors, or agents) to (a) Develop, Manufacture, and Commercialize and otherwise, make, have made, use, offer for sale, sell,
have sold, and import the Licensed Product in the Field outside the Territory and (b) with prior written notice to Lian, conduct Preclinical Development and Development in the Territory (subject to the same restrictions with respect to
Lyra’s retained rights under the Licensed Technology in the third sentence in Section 2.7 (No Implied Licenses; Reservation of Rights)) for the purposes of Preclinical Developing, Developing, and Commercializing the Licensed Product
outside of the Territory. 

  

	2.5	 Lyra Right of Access and Reference. Lian hereby grants Lyra and its Affiliates and Sublicensees access
to, and a right of reference with respect to, (a) the Regulatory Filings, Regulatory Approvals, Marketing Authorizations and (b) all data generated by or on behalf of Lian or its Affiliates or Sublicensees relating to the Licensed Product,
including clinical and preclinical data (including any such data generated from any Clinical Trial performed by or on behalf of Lian or its Affiliates), Safety Data, and CMC Data, in each case, contained or referenced in any such Regulatory Filings,
Regulatory Approvals or Marketing Authorizations, in each case ((a) and (b)), Controlled by Lian or its Affiliates as of the Effective Date or at any time during the Term and to the extent reasonably useful or necessary for Developing, seeking, and
securing Regulatory Approval and Marketing Authorization for the Development, Manufacture, or Commercialization of the Licensed Product in the Field in or outside the Territory. The foregoing rights include the right for Lyra and, to the extent
permitted under this Agreement, its Affiliates and Sublicensees, to make copies of and reproduce such documentation and information for the sole purposes set forth in this Section 2.5 (Lyra Right of Access and Reference). Without limiting the
foregoing, Lian shall use reasonable efforts to [***]. Lian will promptly provide to Lyra all data generated by or on behalf of it or its Affiliates from any Clinical Trial for a Licensed Product that is necessary or reasonably useful to Lyra or its
Affiliates or Sublicensees for securing Regulatory Approval and Marketing Authorization for the Development, Manufacture, or Commercialization of the Licensed Product in Field outside the Territory. 

  
 16 

	2.6	 Rights in Bankruptcy. 

 

	 	(a)	 All rights and licenses now or hereafter granted by Lyra to Lian under or pursuant to this Agreement,
including, for the avoidance of doubt, the licenses granted to Lian pursuant to Section 2.1 (License Grants; Right of Reference) are, for all purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual
property” as defined in the Bankruptcy Code. Upon any filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, upon the appointment of a receiver or trustee over all or substantially all property, or upon an
assignment of a substantial portion of the assets for the benefit of creditors by Lyra, Lyra agrees that Lian, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy
Code, to the extent applicable. Without limiting the generality of the foregoing, Lyra and Lian intend and agree that any sale of Lyra’s assets that are necessary for the rights and licenses granted by Lyra to Lian under or pursuant to this
Agreement (including, for the avoidance of doubt, the licenses granted to Lian pursuant to Section 2.1 (License Grants; Right of Reference)) under Section 363 of the Bankruptcy Code shall be subject to Lian’s rights under
Section 365(n), that Lian cannot be compelled to accept a money satisfaction of its interests in the Intellectual Property licensed pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser “free and
clear” of Lian’s rights under this Agreement and Section 365(n) without the express, contemporaneous consent of Lian. Lyra will, during the Term, create and maintain current copies or, if not amenable to copying,
detailed descriptions or other appropriate embodiments, to the extent feasible, of all Intellectual Property licensed by Lyra under this Agreement. Lyra acknowledges and agrees that “embodiments” of Intellectual Property within the meaning
of Section 365(n) include laboratory notebooks, product samples and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of reference therein, the Licensed Know-How, Licensed Patent Rights, and all information related to the Licensed Know-How or Licensed Patent Rights. If (i) a case under the Bankruptcy Code is commenced by
or against Lyra, (ii) this Agreement is rejected in such case as provided in the Bankruptcy Code and (iii) Lian elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, Lyra (in any capacity,
including debtor-in-possession) and its successors and assigns (including a trustee) will: (A) provide Lian with all such Intellectual Property (including all
embodiments thereof) held by Lyra and such successors and assigns, or otherwise available to them, immediately upon Lian’s written request. Whenever Lyra or any of its successors or assigns provides to Lian any of the Intellectual Property
licensed hereunder (or any embodiment thereof) pursuant to this Section 2.6(a) (Rights in Bankruptcy), Lian will have the right to perform Lyra’s obligations hereunder with respect to such Intellectual Property, but neither such provision
nor such performance by Lian will release Lyra from liability resulting from rejection of the license or the failure to perform such obligations, except to the extent such release is provided under Section 365(n) or by operation of another
provision of the Bankruptcy Code; and (B) not interfere with Lian’s rights under this Agreement, or any agreement supplemental hereto, to such Intellectual Property (including such embodiments), including any right to obtain such
Intellectual Property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the Bankruptcy Code. Following Lian’s exercise of its election under Section 365(n) of the Bankruptcy Code to retain its
rights under this Agreement, Lian shall comply with and perform its obligations pursuant to Sections 365(n)(2)(B) and (2)(C) of the Bankruptcy Code. 

  
 17 

	 	(b)	 All rights, powers and remedies of Lian provided in this Section 2.6 (Rights in Bankruptcy) are in
addition to and not in substitution for any other rights, powers, and remedies now or hereafter existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code with respect to Lyra.
The Parties intend the following rights to extend to the maximum extent permitted by applicable Law, and to be enforceable to the extent permitted under the Bankruptcy Code, including under Bankruptcy Code Section 365(n): (i) the right of
access to any Intellectual Property (and all embodiments thereof) of Lyra or any Third Party that is licensed or sublicensed to Lian under this Agreement; and (ii) the right to contract directly with any Third Party to complete the contracted
work. 

  

	2.7	 No Implied Licenses; Reservation of Rights. No rights, other than those expressly set forth in this
Agreement, are granted to either Party under this Agreement, and no additional rights will be deemed granted to either Party by implication, estoppel, or otherwise, with respect to any intellectual property rights. All rights not expressly granted
by either Party or its Affiliates to the other Party under this Agreement are reserved. Notwithstanding anything to the contrary set forth in this Agreement, Lyra reserves the right (on behalf of itself, its Affiliates and its licensees, other than
Lian and its Sublicensees) under the Licensed Technology, with the right to grant licenses and sublicenses through multiple tiers, to (a) conduct or have conducted Preclinical Development, Development, and Manufacturing of the Licensed Product
anywhere in the world (including the Territory) for the purposes of Preclinical Developing, Developing and Commercializing the Licensed Product outside the Territory, provided that (i) Lyra will provide prior written notice to
Lian of any Preclinical Development of the Licensed Product by or on behalf of Lyra within the Territory and (ii) any clinical Development of the Licensed Product by or on behalf of Lyra within the Territory will be subject to Lian’s prior
written consent, not to be unreasonably withheld, and (b) perform, and have performed, its obligations under any Development Plan. Neither Party nor any of its Affiliates will use or practice under any Patent Rights licensed or provided
to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement. 

 

	2.8	 Transfer of Licensed Know-How. [***], Lyra will disclose and
make available to Lian the Licensed Know-How that exists as of the Effective Date. Lyra may make such Licensed Know-How available in such reasonable form as Lyra
determines and is reasonably acceptable to Lian, including in the form such Licensed Know-How is maintained by Lyra. In addition, Lyra will provide periodic updates throughout the Term to Lian of any Know-How that Lyra or its Affiliates comes to Control that constitutes Licensed Know-How, and Lyra will (a) make available to Lian all such Licensed Know-How not previously provided to Lian hereunder, and (b) for a period of [***] after the initial Licensed Know-How transfer, provide Lian with reasonable assistance to
facilitate the successful transfer of such Licensed Know-How; provided that [***]. 

  

	2.9	 Non-Compete. 

 

	 	(a)	 By Lian. During the Term and subject to the terms of this Agreement, neither LianBio will, nor any of
LianBio’s Affiliates will, nor Lian, nor any of its Affiliates will, directly or indirectly, Commercialize any Competing Product anywhere in the Territory, nor collaborate with, enable, or otherwise authorize, license, or grant any right to any
Third Party to Commercialize any Competing Product anywhere in the Territory, in each case, in the field of [***]. Notwithstanding the foregoing, this Section 2.9(a) (By Lian) shall no longer apply to LianBio nor any of its Affiliates in the
event that LianBio is no longer an Affiliate of Lian. 

  

	 	(b)	 By Lyra. Subject to the terms of this Agreement, prior to the [***] neither Lyra will, nor any of its
Affiliates will, directly or indirectly, Commercialize any Competing Product anywhere in the Territory, nor collaborate with, enable, or otherwise authorize, license, or grant any right to any Third Party to Commercialize any Competing Product
anywhere in the Territory, in each case, in the field of [***]. 

  
 18 

	 	(c)	 [***]. 

  

	 	(d)	 [***]. 

  

	2.10	 Right of First Refusal for LYR-220 Product. If, at any time
prior to the [***] anniversary of the Effective Date, Lyra decides to grant to a Third Party a license to Develop or Commercialize the LYR-220 Product in the Territory, and the material terms of which have
been substantially agreed by Lyra, as reflected in a term sheet, letter of intent or other written documentation (“ROFR Terms”) then, prior to entering into any agreement with respect to any such license in the Territory, Lyra will
provide written notice to Lian of such potential transaction, including [***]. Lian will have a right of first refusal (“ROFR”) with respect to obtaining such license in the Territory on the ROFR Terms, exercisable no later than
[***] after Lian’s receipt of such notice. If Lian provides written notice to Lyra of its exercise of such right of first refusal within the applicable period, then Lian will have [***] from the date of Lyra’s receipt of such notice to
negotiate and execute an amendment to this Agreement adding the LYR-220 Product to this Agreement [***]. [***]. If Lyra and Lian fail to reach a definitive agreement with respect to the Development or
Commercialize of the LYR-220 Product in the Territory, then Lyra or any of its Affiliates will be free to enter into a definitive agreement with any Third Party with respect to the Development or
Commercialization of LYR-220 Product in the Territory [***], provided that, if Lyra does not enter into such a definitive agreement with a Third Party, then [***]. Notwithstanding the foregoing, the
obligations set forth in this Section 2.10 (Right of First Refusal for LYR-220 Product) will not apply to (a) a transaction that is a Change of Control of Lyra, (b) any agreement between Lyra or
its Affiliates and any academic, government, or not-for-profit Third Party, and (c) any agreement between Lyra or its Affiliates and any CRO, CMO, or other Third
Party under which such Third Party performs contract services on behalf of Lyra or its Affiliates that would grant such Third Party any license relating to the LYR-220 Product in all or any portion of the
Territory. 

 ARTICLE 3     

DEVELOPMENT 
  

	3.1	 Development Responsibilities in General. 

 

	 	(a)	 Development Diligence. Lian (directly, or through their respective Affiliates, Sublicensees and
contractors) will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for the Licensed Product in the Territory, and Lyra (directly, or through its respective Affiliates, Sublicensees and contractors) will use Commercially
Reasonable Efforts to (i) complete the planned Global Phase III Trial for the Licensed Product (subject to Lian’s compliance with its diligence obligations in this Section 3.1(a) (Development Diligence) with respect to such Global
Phase III Trial), and (ii) seek and obtain Regulatory Approval for the Licensed Product in the U.S. Without limiting the foregoing and subject to Lyra’s compliance with its diligence obligations in the foregoing sub-clauses (i) and (ii) (but not, for clarity, dependent upon the prior completion of the activities in the foregoing sub-clauses (i) and (ii)), Lian will [***]
engage Clinical Trial sites in the Territory and enroll up to [***] of the total number of Clinical Trial subjects in the planned Global Phase III Trial for the Licensed Product to be conducted by Lyra and Lian; provided that, [***].

  
 19 

	 	(b)	 Development Responsibilities. Subject to the terms and conditions of this Agreement, including this
Article 3 (Development) and Section 5.5 (Decision-Making; Escalation to Senior Officers), Lian will have sole authority to, at its own costs and expense, Develop the Licensed Product for the purpose of obtaining Regulatory Approval in the Field
in the Territory. Lian will be responsible for the day-to-day implementation of any Development activities for which it (or any of its Affiliates) is assigned
responsibility under this Agreement (including under the Development Plans) and will keep Lyra reasonably informed as to the progress of such activities in accordance with Section 3.5(b) (Reporting). 

 

	3.2	 Development Activities. 

 

	 	(a)	 Regulatory Guidance. Promptly (and in any event within [***] months) following the Effective Date, Lian
will seek NMPA guidance as to the classification of the Licensed Product as either a drug or device. 

  

	 	(i)	 Drug Classification. If the NMPA provides guidance that the Licensed Product will be classified as a
drug, then, [***]. 

  

	 	(ii)	 Device Classification. If the NMPA provides guidance that the Licensed Product will be classified as a
device, then, [***]. 

  

	 	(b)	 Development in the Territory. Subject to the terms and conditions of this Agreement, Lian will lead
Development activities for the Licensed Product in the Territory as required to obtain, support and maintain the Regulatory Approval of the Licensed Product for CRS in the Territory. Lian will have the right to determine after considering in good
faith Lyra’s suggestions from which Regions all patients in any Clinical Trial for the Licensed Product conducted in the Territory are enrolled, provided that such sites selected by Lian for the Regions do not [***] under the Global
Development Plan, and otherwise, the Parties will agree upon (i) [***]; provided however, if the NMPA requires or recommends additional study endpoints, a different study design, or other study protocol changes for the Phase III Trial that
are not consistent with the study endpoints, study design, or study protocol contemplated by the IND in the U.S., and Lyra reasonably determines that accommodating such modifications in the Global Phase III Trial would materially delay Regulatory
Approval of the Licensed Product in the U.S., then Lyra shall have the right to [***], and (ii) [***]. Notwithstanding anything to the contrary herein, if Lian does not provide its Clinical Trial data from the Global Phase III Trial in the PRC to
Lyra prior to the date set forth in the Global Development Date for the U.S. data read-out for the Global Phase III Trial (which such date will be discussed and approved by the JSC), then Lyra shall have the
right, [***]. 

  

	3.3	 Development Plans. 

 

	 	(a)	 Territory-Specific Development Plan. All Development of the Licensed Product in the Territory will be
conducted pursuant to a written a plan (the “Territory-Specific Development Plan”), the initial draft of which will be prepared by Lian and submitted to the JSC within [***] after the Effective Date [***]. The Territory-Specific
Development Plan will contain in reasonable detail (i) [***], (ii) [***], and (iii) [***]. Lian will update the Territory-Specific Development Plan not less than [***], and either Party may propose modifications to the Territory-Specific Development
Plan at any time, including with respect to the inclusion of any additional Indication (subject to Section 3.2(b) (Development in the Territory)), subject in each case [***]. [***], each update to the Territory-Specific Development Plan will
become effective and supersede the then-current Territory-Specific Development Plan. In the event of any proposed change to the Territory-Specific Development Plan as a result of any interaction with any Regulatory Authority, the JSC will meet as
promptly as practicable to review and discuss any such proposed changes and determine an appropriate revision 

  
 20 

	 	
(if any) to the Territory-Specific Development Plan. If Lian is delayed in performing (or fails to perform) an obligation assigned to Lian in the Territory-Specific Development Plan as a result
of Lyra’s failure to timely perform any of its obligations under this Agreement, then the timelines for the performance of Lian’s obligations under the Territory-Specific Development Plan will be extended commensurate with the delay caused
by Lyra. 

  

	 	(b)	 Global Development Plan. Lyra’s global Development of the Licensed Product outside of the Territory
and, [***], clinical Development within the Territory will be conducted pursuant to a written plan (the “Global Development Plan”). [***], Lyra will provide to the JSC for its review and discussion the initial Global Development
Plan. The Global Development Plan will include an outline of all major Development activities for the Licensed Product to be conducted throughout the world by Lyra. From time to time, Lyra may propose updates to the then-current Global Development
Plan for the Licensed Products, to the JSC to review and discuss and, solely to the extent relating to activities to be conducted by Lian in the Territory, to determine whether to approve such activities. 

 

	3.4	 Clinical Trial Audits. 

 

	 	(a)	 Upon reasonable notification by Lyra and [***] based on an audit scope agreed upon by the Parties, [***] may
conduct an audit, to the extent permitted under Lian’s applicable agreements, of Lian’s Sublicensees, subcontractors and all Clinical Trial sites engaged by Lian or its Affiliates or Sublicensees to perform Lian’s obligations under
any Development Plans to ensure that the applicable Clinical Trials are conducted in compliance with such Development Plans, GCP, and applicable Law and meet Lyra’s Clinical Trial standards provided by Lyra from time to time during the Term.
Lian will use Commercially Reasonable Efforts to obtain such audit rights from its Sublicensees, subcontractors and Clinical Trial sites engaged by Lian or its Affiliates and Sublicensees to enable [***] to audit such Persons in accordance with this
Section 3.4 (Clinical Trial Audits), provided that if Lian is unable to obtain such audit rights, Lian will obtain the right to conduct substantially equivalent audits itself and, [***]. No later than [***] days after preparing or
receiving the audit report, Lyra will provide Lian with a written summary of Lyra’s findings of any deficiencies or other areas of remediation that Lyra identifies during any such audit. Lian will [***] remediate any deficiencies identified in
an audit report [***] within [***] days (or a reasonably longer, mutually agreed period (not to exceed [***] days) depending upon the deficiencies) following Lian’s receipt of such report, [***]. [***].  

  

	 	(b)	 If either Party reasonably determines that any deficiencies with respect to a Global Phase III Clinical Trial
site identified pursuant to Section 3.4 (Clinical Trial Audits) (each, a “Deficient Site”) may cause a Regulatory Authority to reject or otherwise deem deficient the Clinical Trial data from the conduct of any such Global Phase
III Clinical Trial at such Deficient Site, or if the any such deficiencies are not remediated within the time period for remediation specified in Section 3.4(a), then such Party will notify the other Party of such Deficient Site and the Parties
will discuss, attempt to agree upon, and implement a remediation plan for such Deficient Site. If the Parties do not agree to such a remediation plan for a Deficient Site that is participating in a global Clinical Trial, then [***].

  

	 	(c)	 Lian will provide Lyra with copies of all quality oversight or audit reports prepared in connection with any
audit that Lian or its Affiliates or Sublicensees conduct of any Sublicensee, subcontractor, or Clinical Trial site that Lian or its Affiliates or Sublicensees have engaged or are evaluating to potentially engage to fulfill Lian’s obligations
under a Global Development Plan or a Territory-Specific Development 

  
 21 

	 	
Plan no later than [***] days after receiving or preparing any such report (as applicable), to the extent permitted under the applicable agreement and subject to redaction as Lian reasonably
believes appropriate to protect confidential business information and other sensitive information as applicable. If Lyra believes in good faith that any such quality oversight or audit report may be necessary in connection with obtaining,
supporting, or maintaining one or more Regulatory Approvals for a Licensed Product or for other communications with Regulatory Authorities outside of the Territory, then upon Lyra’s request, Lian will provide a certified translation thereof at
Lyra’s sole cost and expense. 

  

	 	(d)	 Compliance. Lian will conduct, and will ensure that all of its Affiliates, Sublicensees, and other Third
Party subcontractors conduct, Development of the Licensed Product in the Field in the Territory in compliance with applicable Laws and, with respect to any such Development activities conducted as part of the Global Phase III Trial, in compliance
with applicable FDA requirements to the extent necessary for the submission of data generated from such activities in Regulatory Filings. 

  

	3.5	 Development Records and Reporting. 

 

	 	(a)	 Records. Lian will maintain complete and accurate records of Development activities conducted by Lian in
furtherance of seeking Regulatory Approval for the Licensed Product in the Field in the Territory. Such records will be maintained in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance
with applicable Laws. 

  

	 	(b)	 Reporting. Lian will provide a written report to the JSC for review and discussion, at least [***], in
English, describing in reasonable detail Lian’s activities and progress related to the pursuit of Regulatory Approval for the Licensed Product in the Field in the Territory. Lian will respond to the JSC’s reasonable questions or requests
for additional information relating to such activities in a timely manner. Any copies of Regulatory Submissions that Lian provides or presents to the JSC shall be in the local language, provided that Lian will also provide to the JSC
summaries of such documentation in English. 

  

	3.6	 Development Costs. Except as set forth in this Section 3.6 (Development Costs), each Party will
bear 100% of the costs and expenses it incurs in connection with its respective Development activities. With respect to the Development activities in support of the Global Phase III Trial for the Licensed Product to be conducted by Lyra and Lian in
the Territory, Lian will be responsible for: (a) [***], and (b) [***]. As reasonably requested by Lian, Lyra will provide training in English to Lian’s Clinical Trial sites in the Territory. Lian will reimburse Lyra’s reasonable (a) [***]
and (b) [***]. 

  

	3.7	 Regulatory Submissions and Approvals; Communications; Meetings. 

 

	 	(a)	 Regulatory Filings and Approvals. Lian, or its relevant Affiliates or Sublicensees, will have the sole
and exclusive right to file and hold all Regulatory Filings, and to apply for and maintain all Regulatory Approvals and Pricing and Reimbursement Approvals, in each case, for all Licensed Products in the Field in the Territory at Lian’s cost
and expense in the name of Lian or any of its Affiliates and Sublicensees. The Parties will use good faith efforts to cooperate to effectuate this Section 3.7(a) (Regulatory Filings and Approvals), and if, after the Parties’ use of good
faith efforts, Lian, or its Affiliate or Sublicensee [***]. Subject to the terms and conditions of this Agreement, Lian will be responsible, at its sole cost and expense, for all regulatory activities leading up to and including the obtaining of
Regulatory Approvals and any Pricing and Reimbursement Approvals, as applicable, for Licensed Products in the Field from 

  
 22 

	 	
Regulatory Authorities or Governmental Authorities in the Territory. Lian will conduct such activities (and any and all regulatory activities delegated to Lian in this Agreement) (A) in its
own name, if Lian is the legal and beneficial owner of the Regulatory Approvals for the Licensed Products in the Field in the Territory, [***]. 

  

	 	(b)	 Regulatory Communications. Subject to applicable Law and this Section 3.7 (Regulatory Submissions
and Approvals; Communications; Meetings), (i) Lian will oversee, monitor, and manage all interactions and communications with Regulatory Authorities with respect to the Licensed Products in the Field in the Territory and (ii) Lian will have
final decision-making authority regarding all regulatory activities for the Licensed Products in the Field in the Territory, including the labeling strategy and the content of Regulatory Filings for Licensed Products. Lian will promptly provide Lyra
with copies of all material communications or correspondence with Regulatory Authorities with respect to the Licensed Product in the Field in the Territory that are received by Lian from any Regulatory Authority or submitted by Lian to any
Regulatory Authority. Lian will provide proposed material submissions by Lian to any Regulatory Authority to Lyra for review and comment sufficiently in advance of submission. Lian shall not unreasonably refuse to incorporate any of Lyra’s
comments to such submissions. 

  

	 	(c)	 Regulatory Meetings. Until such time as Lian obtains Regulatory Approval for the Licensed Product in the
Field in the Territory, to the extent legally permissible and practicable, Lian will provide Lyra with reasonable prior written notice of all substantive meetings with Regulatory Authorities in the Territory regarding the Licensed Product if
permitted by applicable Law or the Regulatory Authority. Lyra will have the right to request to be present as an observer at or participant in all such meetings with Regulatory Authorities to the extent permitted under applicable Law [***], and Lian
will use reasonable efforts to permit Lyra to be present at, or participate in, any such meetings, as applicable.  

  

	 	(d)	 Termination or Suspension of Clinical Trials. Notwithstanding any provision to the contrary set forth in
this Agreement or the Pharmacovigilance Agreement, the Parties hereby agree that Lian may terminate or suspend any Clinical Trial relating to the Licensed Products in the Field in the Territory, and Lyra may terminate or suspend any Clinical Trial
outside of the Territory, in each case, without the approval or consent of the JSC or the other Party and without violation or default under any provision set forth in this Agreement, if (i) a Regulatory Authority, institutional review board,
or safety data review board for such Clinical Trial has required or recommended such termination or suspension or (ii) following review and discussion with the JSC, the Party seeking such termination believes in good faith that such termination
or suspension is warranted because of observed safety risks to the study subjects. In either case, such Party will promptly notify the other Party in writing of such termination or suspension.  

 

	 	(e)	 Regulatory Investigation or Inquiry. If any Regulatory Authority (i) contacts Lian or its Affiliate
with respect to the alleged improper Development, Manufacture, or Commercialization of any Licensed Product, (ii) conducts, or gives notice of its intent to conduct, an inspection at Lian’s or its Affiliate’s facilities used in the
Development of the Licensed Product, or (iii) takes, or gives notice of its intent to take, any other regulatory action with respect to any activity of Lian or its Affiliate that could reasonably be expected to adversely affect any Development,
Manufacture, or Commercialization activities with respect to the Licensed Product outside of the Territory, then Lian will promptly notify Lyra in writing of such contact, inspection or notice. 

  
 23 

	3.8	 No Harmful Actions. Each Party will promptly notify the other Party of all material communications or
correspondence with Regulatory Authorities with respect to any Licensed Product in such Party’s territory that (a) are received by such Party or its Affiliates, Sublicensees, or other licensees (to the extent that such Party has the right
to disclose such material communications or correspondence of other licensees and provided that such Party uses reasonable efforts to obtain such right from such other licensees) from any Regulatory Authority or submitted by such Party, its
Affiliates or other licensees to any Regulatory Authority and (b) would reasonably be expected to impact the other Party’s Development, Manufacture, or Commercialization of the Licensed Products in the Field in the other Party’s
territory. If either Party believes that the other Party is taking or intends to take any action with respect to a Licensed Product in such other Party’s territory that could have a material adverse impact upon the regulatory status of any
Licensed Product in such Party’s territory, then such Party will have the right to bring the matter to the attention of the JSC and the Parties will discuss in good faith the views and suggestions of the JSC to minimize the impact of such
action with respect to a Licensed Product in the other Party’s territory. 

  

	3.9	 Development of the Licensed Products outside the Territory. Lyra retains the exclusive right and will be
solely responsible and have sole discretion and control over the Development activities (including regulatory activities) of the Licensed Products anywhere in the world, other than in Territory. Lyra will, in its sole discretion, oversee, monitor
and manage all interactions and communications with Regulatory Authorities with respect to such Licensed Products outside of the Territory. Lyra will have final decision-making authority regarding all regulatory activities, including the labeling
strategy and the content of Regulatory Filings with respect to such Licensed Products outside of the Territory. 

  

	3.10	 Pharmacovigilance. No later than [***] prior to (a) [***] or (b) [***], the Parties will negotiate in
good faith and finalize the actions that the Parties will employ with respect to the Licensed Products to protect patients and promote their well-being in a written pharmacovigilance agreement (the “Pharmacovigilance Agreement”).
These responsibilities will include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of Adverse Event reports and any other information concerning the
safety of any Licensed Product, including recall and withdrawal responsibilities, processes, and procedures. Such guidelines and procedures will be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting
obligations under applicable Law. Furthermore, such agreed procedure will be consistent with relevant ICH guidelines, except where such guidelines may conflict with existing local regulatory reporting safety reporting requirements, in which case
local reporting requirement will prevail. Lian will be responsible for reporting quality complaints, Adverse Events, and safety data related to the Licensed Products in the Field to applicable Regulatory Authorities in the Territory, as well as
responding to safety issues and to all requests of Regulatory Authorities relating to Licensed Products in the Field in the Territory. Lyra will be responsible for reporting quality complaints, Adverse Events, and safety data related to Licensed
Product to applicable Regulatory Authorities outside the Territory, as well as responding to safety issues and to all requests of Regulatory Authorities relating to Licensed Product outside the Territory. The Pharmacovigilance Agreement will also
provide for a worldwide safety database to be maintained by Lyra at its sole cost and expense, which worldwide safety database will be accessible by Lian and its Affiliates, Sublicensees, and contractors to the full extent necessary for Lian to
exercise its rights under this Agreement, comply with its obligations under this Agreement, and comply with all applicable Law. Each Party will comply with its respective obligations under such Pharmacovigilance Agreement and will cause its
Affiliates and Sublicensees and contractors to comply with such obligations. 

  
 24 

 ARTICLE 4 

MANUFACTURE, SUPPLY, AND COMMERCIALIZATION 
  

	4.1	 Supply Agreements. Within [***] following the JSC’s approval of the Territory-Specific
Development Plan, the Parties will negotiate in good faith and enter into a supply agreement for the Manufacture and supply of clinical quantities of Licensed Products by Lyra to Lian for use solely in connection with Clinical Trials and other
Development of Licensed Products in the Field in the Territory (the “Clinical Supply Agreement”) and, no later than [***] prior to the date Lian anticipates its First Commercial Sale of the Licensed Products in the Territory, a
supply agreement for the Manufacture and supply of commercial quantities of Licensed Products by Lyra to Lian for the commercial sale and distribution of Licensed Products in the Field in the Territory (the “Commercial Supply
Agreement” and, together with the Clinical Supply Agreement, the “Supply Agreements”). Unless otherwise agreed or required by applicable Laws, the Supply Agreements will specify that Lyra will (or will cause its Affiliates
to) Manufacture and supply, and Lian will purchase from Lyra, all of Lian’s, its Affiliates’ and Sublicensees’ requirements for the Licensed Products for the Development or Commercialization (as applicable) in the Field in the
Territory in their finished form and at a price equal to (a) under the Clinical Supply Agreement, [***] and (b) under the Commercial Supply Agreement, [***]; provided [***]. 

 

	4.2	 Two-Invoice Policy. The Parties agree that in the event, under
the Two-Invoice Policy and tendering policies and applicable Laws in a given province in the PRC, neither Lian nor any of its Affiliates can, based on their existing qualifications, distribute the Licensed
Products for such province directly or indirectly to its distributors for the PRC, then, the Parties will use reasonable efforts to discuss in good faith alternative arrangements for the distribution of the Licensed Product in such province that
complies with the Two-Invoice Policy as implemented in such province and that maintains the economic interests of the Parties as agreed under this Agreement. 

 

	4.3	 Manufacturing Technology Transfer. In the event of (a)[***] or (b) [***], upon Lian’s written
notice to Lyra, (i) the Parties will discuss in good faith and prepare a technology transfer plan pursuant to which Lyra will (A) provide access, and transfer, to Lian or a CMO designated by Lian that is approved by Lyra (which approval
may not be unreasonably withheld, conditioned, or delayed) the Licensed Know-How Controlled by Lyra or its Affiliates that is necessary or reasonably useful for Lian or such CMO to Manufacture the Licensed
Product in the Field in the Territory, and (B) provide all other reasonably necessary assistance and services to Lian [***] to enable Lian or its designated CMO to Manufacture the Licensed Product in substantially the same manner as Lyra or its
Affiliates or CMOs (as applicable) Manufactures the Licensed Product for Lian; (ii) following agreement on such plan, Lyra will perform and execute the technology transfer plan in accordance with its terms at Lian’s cost and expense, and
(iii) Lian will have the right to Manufacture or have Manufactured Licensed Products to satisfy the needs of Lian and its permitted Sublicensees and distributors in the Territory. 

 

	4.4	 Commercialization. 

 

	 	(a)	 Commercialization Diligence. Upon receipt of Marketing Authorization for the Licensed Product in the
Field in a given Region in the Territory, Lian (directly, or through its Affiliates, Sublicensees, or contractors) will use Commercially Reasonable Efforts to Commercialize the Licensed Product in the Field in such Region in the Territory. Lian will
have sole decision-making authority and control over the Commercialization of the Licensed Product in the Field in the Territory. [***]. 

  
 25 

	 	(b)	 Commercial Plan. All Commercialization of the Licensed Product in the Territory will be conducted
pursuant to a Commercial Plan. No later than [***] prior to the [***], Lian will prepare a draft of a standard commercial plan for the Commercialization of the Licensed Product in the Field in such Region, including details with respect to (i)
[***], (ii) [***], and (iii) [***] (the “Commercial Plan”). Such draft Commercial Plan and any material changes to the Commercial Plan, including proposed changes to the Commercial Plan as a result of any interaction with any
Regulatory Authority, will be submitted to the JSC for review, discussion, and approval pursuant to Section 5.2 (Specific Responsibilities), subject to the decision-making and escalation procedures set forth in Section 5.5
(Decision-Making; Escalation to Senior Officers). 

  

	 	(c)	 Reporting Obligations. Lian will update the JSC at the JSC’s regularly-scheduled meetings regarding
Lian’s significant Commercialization activities for the Licensed Products in the Territory. Without limiting the foregoing, on [***] basis, beginning with the [***] following the first Regulatory Approval of a Licensed Product in the Field in
the Territory (for the period ending December 31 of the prior Calendar Year), summarizing in reasonable detail Lian’s material Commercialization activities for such Licensed Product performed to date (or updating such report for activities
performed since the last such report was given hereunder, as applicable). 

  

	 	(d)	 Trademarks. 

  

	 	(i)	 Subject to review and discussion by the JSC, Lian will have the right to brand the Licensed Products in the
Field in the Territory using Lian related Trademarks and any other Trademarks and trade names it determines appropriate for the Licensed Products, which branding may vary by Region or within a Region. Lian will own all rights in such Trademarks and
register and maintain such Trademarks in the countries and regions within the Territory, where and how it determines appropriate. 

  

	 	(ii)	 Lian will also have the right to brand the Licensed Products in the Field and in the Territory using the
Licensed Marks, and Lian will comply with Lyra’s reasonable trademark usage guidelines and quality control guidelines in effect from time to time as provided by Lyra. Lyra will own and retain all rights to the Licensed Marks (together with all
goodwill associated therewith) in the Territory, and will prepare, file, prosecute, and maintain all Licensed Marks in the Territory at its own expense; provided, however, Lyra will provide to Lian copies of all applications,
submissions, communications, and correspondence intended to be sent to, sent to or received by Governmental Authorities or Third Parties in connection with such filing, prosecution, and maintenance of the Licensed Marks in the Territory so that Lian
may review and comment thereon (which will be provided with sufficient advanced notice so that Lian may meaningfully review and comment, to the extent practicable), and will incorporate any reasonable comments provided by Lian with respect to such
applications, submissions, communications, or correspondence. Subject to terms and conditions of this Agreement, Lyra will grant and hereby grants an exclusive, sublicensable (subject to Section 2.2) (Sublicensing and Subcontracting), fully paid-up, royalty free, non-transferrable (subject to Section 14.1 (Assignment)) license under the Licensed Marks for Lian to Commercialize the Licensed Products in the
Field in the Territory. 

  

	 	(iii)	 Diversion. Subject to applicable Law, each Party hereby covenants and agrees that (A) it and its
Affiliates will not, and it will contractually obligate (and use reasonable efforts to enforce such contractual obligation) its licensees, Sublicensees and contractors not to, directly or indirectly, actively promote, market, distribute, import,
sell or have sold any Licensed Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like, in the other Party’s territory, and (B) neither Party

  
 26 

	 	
will engage, nor permit its Affiliates, Sublicensees, or contractors to engage, in any advertising or promotional activities relating to any Licensed Product for use directed primarily to
customers or other buyers or users of such product located in any country, Region or jurisdiction in the other Party’s territory, or solicit orders from any prospective purchaser located in any country, Region or jurisdiction in the other
Party’s territory. If Lyra or Lian or any of its Affiliates or sublicensees receives any order for Licensed Product for use from a prospective purchaser located in a country or jurisdiction outside such Party’s territory, then such Party,
its Affiliates or sublicensees shall immediately refer that order to the other Party and shall not accept any such orders. Neither Lyra nor Lian shall, nor permit its Affiliates or sublicensees to, deliver or tender (or cause to be delivered or
tendered) any Licensed Product for use in the other Party’s territory. 

  

	 	(e)	 Marking. To the extent permitted by applicable Law, Lian shall use reasonable efforts to include on all
packaging for each Licensed Product a designation (i) that the Licensed Product incorporates the Licensed Patent Rights, including the word “patent” or the abbreviation “pat.” and either the relevant Licensed Patent Rights
or a web address that is freely accessible to the public and that lists the relevant Licensed Patent Rights and (ii) if applicable, that the Licensed Product is Manufactured by Lyra, which designations must be in accordance with applicable Laws
in the Territory. Lian shall use reasonable efforts to ensure that all Sublicensees and applicable subcontractors mark the Licensed Product accordingly. 

  

	 	(f)	 No Violation. Notwithstanding any provision to the contrary set forth herein, Lian (including its
Affiliates, Sublicensees, and contractors) will not be obligated to undertake or continue any Commercialization activities with respect to Licensed Products if Lian (or its Affiliates, Sublicensees or contractors, as applicable) reasonably
determines that performance of such Commercialization activity would violate applicable Laws or infringe any Third Party Patent Rights. 

ARTICLE 5 
 GOVERNANCE;
JOINT STEERING COMMITTEE 
  

	5.1	 Formation; Purposes and Principles. [***], Lyra and Lian will form a joint steering committee (the
“JSC”) to provide oversight and to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement. 

 

	5.2	 Specific Responsibilities. In addition to its overall responsibility to provide strategic oversight and
to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement, the JSC will: 

  

	 	(a)	 coordinate and share information with respect to the Development and Commercialization of the Licensed Product
by Lian in the Territory and by Lyra outside the Territory; 

  

	 	(b)	 coordinate and share information with respect to the Manufacture of the Licensed Products by Lyra, for so long
as Lyra is supplying Licensed Products to Lian; 

  

	 	(c)	 keep each Party reasonably informed of the other Party’s Development and Commercialization activities and
interactions with Regulatory Authorities in the other Party’s territory, by receiving updates from the Party conducting such activities to the extent that such activities materially impact or would reasonably be expected to materially impact
the other Party’s Development, Manufacture or Commercialization of the Licensed Products in the Territory; 

  
 27 

	 	(d)	 [***]; 

  

	 	(e)	 keep Lyra informed of each sublicense granted, and each subcontract entered into, by Lian, as described in
Section 2.2(a) (Sublicense Requirements) and Section 2.3 (Performance by Independent Contractors); 

  

	 	(f)	 [***]; 

  

	 	(g)	 review and discuss the initial Global Development Plan, and each update thereto, as described in
Section 3.3(b) (Global Development Plan); 

  

	 	(h)	 review, discuss, and determine whether to approve (i) any activities to be conducted by Lian in the
Territory under the Global Development Plan, as described in Section 3.3(b) (Global Development Plan) and (ii) the date for the U.S. data read-out for the Global Phase III Trial under the Global
Development Plan ; 

  

	 	(i)	 review and discuss the termination or suspension of any Clinical Trial relating to the Licensed Product in
light of observed safety risks to the study subjects, as described in Section 3.7(d) (Termination or Suspension of Clinical Trials); 

  

	 	(j)	 review, discuss, and determine matters that may have a material adverse impact upon the regulatory status of
the Licensed Products, as described in Section 3.8 (No Harmful Action); 

  

	 	(k)	 [***]; 

  

	 	(l)	 [***]; 

  

	 	(m)	 review and discuss the Trademarks and trade names used for the Licensed Products for each Region, as described
in Section 4.4(d)(i) (Trademarks); 

  

	 	(n)	 review and discuss proposed publications that cover the results of Development or Commercialization of Licensed
Products in the Field in the Territory for which a Party has concerns of a potential competitive advantage, and resolve such concerns, as described in Section 8.2(b) (Publicity); and 

 

	 	(o)	 perform such other functions as are assigned to it in this Agreement or as appropriate to further the purposes
of this Agreement to the extent agreed to in writing by the Parties. 

  

	5.3	 Membership. The JSC will be composed of a total of [***] representatives of each Party, which will be
appointed by each of Lyra and Lian, respectively. Each individual appointed by a Party as a representative to the JSC will be an employee of such Party with sufficient seniority and decision-making authority within the applicable Party to provide
meaningful input and make decisions arising within the scope of the JSC’s responsibilities, and have knowledge and expertise in the Development and Commercialization of products similar to the Licensed Products under this Agreement. The JSC may
change its size from time to time by consent of its members, provided that the JSC will consist at all times of an equal number of representatives of each Party, unless otherwise agreed by the Parties in writing. Each Party may replace any of
its JSC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party’s co-chairperson. The JSC
will be co-chaired by one designated representative of each Party. The co-chairperson of the JSC will cast its Party’s vote on the JSC and such designee will have
the authority to make decisions on behalf of such Party. Each co-chairperson will alternate being responsible for each meeting for (a) calling and conducting meetings, (b) preparing and circulating
an agenda in advance of 

  
 28 

	 	
each meeting; provided, however, that the applicable co-chairperson will include any agenda items proposed by either Party on such agenda,
(c) preparing minutes of each meeting that reflect the material decisions made and action items identified at such meetings promptly thereafter, and (d) sending draft meeting minutes to each member of the JSC for review and approval within
[***] days after each JSC meeting. Meeting minutes issued in accordance with clause (d) of this Section 5.3 (Membership) will be deemed approved unless [***] members of the JSC objects to the accuracy of such minutes within [***] Business
Days of receipt. The Alliance Managers will work with the chairpersons to prepare and circulate agendas and to ensure the preparation and approval of minutes. Each JSC representative will be subject to confidentiality obligations no less stringent
than those in Article 8 (Confidentiality and Publicity). 

  

	5.4	 Meetings; Reports. The JSC will hold meetings at least [***] per Calendar Quarter during the Term for so
long as the JSC exists, unless the Parties agree in writing to a different frequency. No later than [***] Business Days prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the applicable co-chairperson will prepare and circulate an agenda for such meeting. Either Party may also call a special meeting of the JSC by providing at least [***] Business Days prior written notice to the other Party if such
Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the applicable co-chairperson of the JSC and the Alliance
Managers to provide the members of the JSC no later than [***] Business Day prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered. The JSC may
meet in person or by audio or video conference as its representatives may agree. Other representatives of the Parties, their Affiliates, or Third Parties involved in the Development, Manufacture, or Commercialization of Licensed Products may be
invited by the members of the JSC to attend meetings as non-voting observers if such representatives are subject to confidentiality obligations no less stringent than those set forth in Article 8
(Confidentiality and Publicity). No action taken at a meeting will be effective unless at least [***] of each Party (which [***] not such Party’s Alliance Manager) is present or participating. Neither Party will unreasonably withhold attendance
of at least one representative of such Party at any meeting of the JSC for which reasonable advance notice was provided. 

  

	5.5	 Decision-Making; Escalation to Senior Officers. The Parties will endeavor in good faith
and in compliance with this Agreement to reach unanimous agreement with respect to all matters within the JSC’s authority. Each Party’s representatives on the JSC will collectively have one vote, (the “Party Vote”) and no
action or decision will be taken by the JSC without unanimous Party Vote (i.e., the affirmative Party Vote of each Party). If the JSC is not be able to reach agreement with respect to a matter at a duly called meeting of the JSC, then either
Party may refer such matter to the Senior Officers for resolution, and the Senior Officers will attempt to resolve the matter in good faith. If the Senior Officers fail to resolve such matter within [***] Business Days after the date on which the
matter is referred to the Senior Officers (unless a longer period is agreed to by the Parties), then Lian will have the final decision-making authority as to all matters relating to [***], except for (a) [***], (b) [***] (i) [***], (ii) [***], or
(iii) [***] (A) [***] or (B) [***]; and (c) [***]. Lyra will have final decision-making authority over [***]. The status quo with respect to any matter that is not subject to a Party’s final decision-making authority, and is not resolved at the
JSC or by escalation to the Senior Officers as described above, will [***]. 

  

	5.6	 Limitations. Notwithstanding anything to the contrary, neither Party will have the final decision-making
authority on amending or updating the Development Plans in any way that would materially alter the scope of the other Party’s obligations hereunder, increase the other Party’s financial obligations hereunder, or result in the disclosure of
the Confidential Information of the other Party, in each case, without the other Party’s prior written consent. Notwithstanding any provision of this Article 5 (Governance; Joint Steering Committee) to the contrary, the JSC will not have the
authority to amend the terms or conditions of this Agreement.  

  
 29 

	5.7	 Alliance Managers. 

 

	 	(a)	 Appointment. Each Party will appoint a person to oversee interactions between the Parties for all
matters related to the Development and Commercialization of Licensed Products between meetings of the JSC (each, an “Alliance Manager”). The Alliance Managers will have the right to attend all meetings of the committees as non-voting participants and may bring to the attention of the JSC any matters or issues either Alliance Manager reasonably believes should be discussed and will have such other responsibilities as the Parties may
agree in writing. Each Party may replace its Alliance Manager at any time or may designate different Alliance Managers with respect to Development and Commercialization matters, respectively, by notice in writing to the other Party.

  

	 	(b)	 Responsibility. The Alliance Managers will have the responsibility of creating and maintaining a
constructive work environment within the JSC and between the Parties for all matters related to this Agreement. Without limiting the generality of the foregoing, each Alliance Manager will: 

 

	 	(i)	 provide a single point of communication within the Parties’ respective organizations and between the
Parties with respect to this Agreement; 

  

	 	(ii)	 coordinate cooperative efforts, internal communications and external communications between the Parties with
respect to this Agreement; and 

  

	 	(iii)	 take such other steps as may be required to ensure that meetings of the JSC occur as set forth in this
Agreement, that procedures are followed with respect to such meetings (including working with the co-chairpersons with respect to the giving of proper notice and the preparation and approval of minutes) and
that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 

 ARTICLE
6 
 FINANCIAL PROVISIONS 
  

	6.1	 Upfront Payment; Milestone Payments.

 

	 	(a)	 Upfront Payment. Subject to the terms and conditions of this Agreement, Lian will pay Lyra a non-refundable, non-creditable, and not subject to set-off payment in the amount of $ 12,000,000 U.S. Dollars, which upfront payment
will be due and payable to Lyra within [***] Business Days following the Effective Date. 

  

	 	(b)	 Development Milestone Payment. During the Term, upon the achievement by or on behalf of a Party or its
Affiliates or Sublicensees of any milestone event set forth below in Table 6.1(b) (Development Milestone Payments) (each, a “Development Milestone Event”) for the Licensed Product, the achieving Party will notify the other Party
promptly after the occurrence thereof, and Lian will pay Lyra a non-refundable, non-creditable, and not subject to set-off,
milestone payment set forth in the table below (each, a “Development Milestone Payment”) no later than [***] days after its achievement of such milestone event. Each of the milestone payments set forth below in Table 6.1(b)
(Development Milestone Payment) is payable [***]. 

  
 30 

					
	 Table 6.1(b) (Development Milestone
Payments)
	 
	 Development Milestone Event
	  	Development Milestone
Payment (in Dollars)	 
	 1.  [***]
	  	 	[	***] 
	 2.  [***]
	  	 	[	***] 
	 4.  [***]
	  	 	[	***] 
	 5.  [***]
	  	 	[	***] 
	 6.  [***]
	  	 	[	***] 
	 Total
	  	 	[	***] 

  

	 	(c)	 Sales Milestone Payments. During the Term, Lian will notify Lyra in writing of its achievement of each
of the sales milestones below within [***] days after the [***] in which the cumulative Net Sales of all Licensed Products in the Territory first exceed the indicated Dollar value set forth below in Table 6.1(c) (Sales Milestone Events) (each, a
“Sales Milestone Event”). Lian will pay to Lyra each of the non-refundable, non-creditable, and not subject to
set-off, Sales Milestone Payments set forth below in Table 6.1(c) (Sales Milestone Events) within [***] days of providing notice of each Sales Milestone Event (each, a “Sales Milestone
Payment”). Each of the milestone payments set forth in Table 6.1(c) (Sales Milestone Payments) is payable only upon the first achievement of such Sales Milestone Event and none of the Sales Milestone Payments will be payable more than once
regardless of how many times such Sales Milestone Event is achieved. For clarity, the Sales Milestone Payments are additive, such that if more than one Sales Milestone Events are achieved in the same time period, then the Sales Milestone Payments
for all such Sales Milestone Events shall be payable. 

  

					
	 Table 6.1(c) (Sales Milestone Payments)
	 
	 Sales Milestone Event
	  	Sales Milestone
Payment (in Dollars)	 
	 1.  [***]
	  	 	[	***] 
	 2.  [***]
	  	 	[	***] 
	 3.  [***]
	  	 	[	***] 
	 4.  [***]
	  	 	[	***] 
	 Total
	  	 	[	***] 

  
 31 

	6.2	 Royalties. 

  

	 	(a)	 Royalty Rate. Subject to the terms and conditions of this Agreement, during the Royalty Term, Lian will
pay to Lyra a tiered royalty on the Net Sales of all Licensed Products in the Territory that is the product of the aggregate annual Net Sales of all Licensed Products in the Territory and the applicable royalty rate in the following Table 6.2
(Royalty Rates), subject to the provisions of Section 6.3 (Royalty Payment Adjustments). 

  

					
	 Table 6.2 (Royalty
Rates)
	 
	 Portion of the Annual Net Sales of the Licensed Products in the
Territory
	  	Royalty Rate	 
	 1.  [***]
	  	 	[	***] 
	 2.  [***]
	  	 	[	***] 
	 3.  [***]
	  	 	[	***] 
	 4.  [***]
	  	 	[	***] 

  

	 	(b)	 Royalty Term. Royalties will be due under this Section 6.2 (Royalties), on a Licensed Product-by-Licensed Product and Region-by-Region basis, during the period commencing upon the
First Commercial Sale of such Licensed Product in such Region and ending upon the latest to occur of (i) the expiration of the last-to-expire Valid Claim of a
Licensed Patent Right Covering the making, using, selling, offering for sale or importing of such Licensed Product in such Region, (ii) the expiry of the applicable Regulatory Exclusivity for such Licensed Product in such Region; or
(iii) the [***] anniversary of the First Commercial Sale of such Licensed Product in such Region (such period, the “Royalty Term”). 

  

	 	(c)	 Royalty Payments and Reports. [***]. Within [***] days following the end of each [***] following the
First Commercial Sale of a Licensed Product, Lian shall furnish to Lyra a written report for the [***] showing [***]. Such written report shall include [***]. Lian shall pay Lyra the royalty due for such Calendar Quarter calculated in
accordance with this Agreement within [***] days of delivery of the written report to Lyra. 

  

	6.3	 Royalty Payment Adjustments. The following will apply to all royalties paid pursuant to
Section 6.2(a) (Royalty Rate): 

  

	 	(a)	 Expiration of Valid Claims. On a Licensed Product-by-Licensed Product and Region by Region basis, if at any time during the Royalty Term in a given Region in the Territory, there is no Valid Claim of a Licensed Patent Right Covering the composition
of matter of such Licensed Product that would be infringed by the sale of such Licensed Product in such Region, then the applicable royalty rate in effect with respect to such Licensed Product in such Region as specified in Section 6.2(a)
(Royalty Rate) will be reduced by [***] for the remainder of the Royalty Term for such Licensed Product in such Region. 

  

	 	(b)	 Generic Entry. On a [***] basis, if, at any time during the Royalty Term subsequent to the first
commercial sale of a Generic Product with respect to a Licensed Product in a Region, [***], then the applicable royalty rates in effect with respect to such Licensed Product in such Region as specified in Section 6.2(a) (Royalty Rate) will be
reduced by [***] for [***] for such Licensed Product in such Region. For clarity, such reduction will be applied in each [***] for the remainder of the Royalty Term for such 

  
 32 

	 	
Licensed Product in such Region in which (i) [***] and (ii) [***]. For purposes of this Section 6.3(b) (Generic Entry), a “first commercial sale” of a Generic Product in a Region
means the first sale for monetary value in an arm’s length transaction for use or consumption by an end user of such Generic Product in such Region after the marketing authorization of such Generic Product has been obtained in such Region.

  

	 	(c)	 Third Party Payments. If Lian makes a payment under any agreement with a Third Party pursuant to which
Lian obtains a license or sublicense under Patent Right(s) or Patent Right(s) together with Know-How owned or controlled by such Third Party in a given Region that is necessary or reasonably useful to Develop,
Manufacture, or Commercialize one or more Licensed Products in such Region, then Lian may offset against [***] due to Lyra for such Licensed Product in such Region covered by such license an amount equal to [***] of the amounts paid to such Third
Party under such agreement, subject to Section 6.4(d) (Cumulative Deductions). 

  

	 	(d)	 Cumulative Deductions. Notwithstanding the foregoing, in no event will the deductions set forth in
Section 6.3(a) (Expiration of Valid Claims) through Section 6.3(c) (Third Party Payments) reduce the royalties otherwise payable to Lyra as specified in Section 6.2(a) (Royalty Rate) by more than [***]. To the extent the foregoing
limitation limits the reduction Lian is permitted to take during a Calendar Quarter, Lian will be entitled to carryforward the amount of the reduction Lian was unable to take during such Calendar Quarter and apply such amounts to royalties payable
to Lyra in future Calendar Quarters within the following three Calendar Years. 

  

	6.4	 Audits. Each Party will maintain and will cause its Affiliates and all Sublicensees to maintain,
complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the calculation of royalties, Milestone Payments, Cost of Goods Sold calculations, and other payments under this Agreement. Upon reasonable prior
notice, but not more than once per Calendar Year and not more than once with respect to any records, such records will be available during regular business hours for a period of [***] years from the end of the Calendar Year to which they pertain for
examination at the expense of the requesting Party by an independent certified public accountant selected by the requesting Party and reasonably acceptable to the other Party, for the sole purpose of verifying the accuracy of the financial reports
and correctness of the payments furnished by the other Party pursuant to this Agreement. Any such auditor will not disclose the other Party’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of
the financial reports furnished by the other Party or the amount of payments due by the other Party under this Agreement. The accountant’s report will be disclosed simultaneously to both Parties, and such report will be the Confidential
Information of the audited Party and subject to the terms of Article 8 (Confidentiality and Publicity). Any amounts shown to be owed but unpaid will be paid within [***] days from the accountant’s report. Any amounts shown to have been overpaid
will be refunded within [***] days from the accountant’s report. The requesting Party will bear the full cost of such audit unless such audit discloses an underpayment by the other Party of more than [***] of the amount due, in which case the
other Party will bear the full cost of such audit. The audit rights in this Section 6.4 (Audits) will survive the Term for [***] following the effective date of any termination or expiration of this Agreement. 

 

	6.5	 Tax Withholding. In the event any withholding, value added, or other tax (including any tax based on
income to Lyra) (“Tax Withholdings”) is required to be withheld and deducted from payments by Lian (or its Affiliate paying on behalf of Lian) pursuant to this Agreement under applicable Laws, notwithstanding any provision to the
contrary set forth under this Agreement, Lian (or its Affiliate paying on behalf of Lian) will make such deduction and withholding [***]. Any amounts so withheld and deducted will be remitted by Lian (or its Affiliate paying on behalf of Lian) on a
timely basis to the appropriate Governmental Authority for the account of Lyra and Lian (or its Affiliate paying on behalf of Lian) will provide Lyra reasonable evidence of the remittance within [***] days thereof and for the purposes of this
Agreement, Lian will be deemed to have fulfilled all of its payment obligations to Lyra with respect to such payments paid to the such Governmental Authority. Lian may satisfy its withholding, value added or other tax obligations under this
Section 6.5 (Tax Withholding) through its Affiliates. 

  
 33 

	6.6	 Currency of Payments. All amounts payable and calculations under this Agreement will be in Dollars. As
applicable, Net Sales and any royalty reductions will be translated into Dollars using the average of the applicable daily foreign exchange rates published in the Wall Street Journal (or any other qualified source that is acceptable to both
Lyra and Lian) for [***] in which such Net Sales occurred. All payments under this Agreement will be paid in Dollars by wire transfer to an account designated by the receiving Party (which account the receiving Party may update from time to time in
writing). 

  

	6.7	 Late Payments. Without limiting any other rights or remedies available to Lyra hereunder, any late
payment by Lian will bear interest, to the extent permitted by Laws, at an annual rate of [***] or the highest rate permitted by applicable Law (whichever is lower), computed from the dated such payment was due until the date Lian makes the payment.

 ARTICLE 7 

INTELLECTUAL PROPERTY OWNERSHIP, 

PROTECTION AND RELATED MATTERS 
  

	7.1	 Ownership of Intellectual Property. 

 

	 	(a)	 Inventions. Lyra will own all Inventions developed or generated by or on behalf of Lian (including by
its Affiliates, or any of its employees, Sublicensees, independent contractors, or agents) that are solely related to the Licensed Product and not related to any other product Controlled by Lian (“Assigned Inventions”), and
otherwise ownership will follow inventorship for any and all inventions, Know-How, developments, or discoveries, whether patentable or non-patentable, invented or
otherwise developed or generated by either Party alone (including its Affiliates, or any of its or their employees, Sublicensees, independent contractors, or agents) or jointly by both Parties (including jointly by their Affiliates, or any of its or
their employees, Sublicensees, independent contractors, or agents) the performance of a Party’s obligations or exercise of its rights under this Agreement (collectively, “Inventions”) and such inventorship will be determined in
accordance with United States patent Laws. 

  

	 	(b)	 Assignment Obligation. Each Party will assign, and will cause its Affiliates to assign, its rights, and
cause all employees of such Party or Affiliate who perform activities for such Party or Affiliate under this Agreement to be under an obligation to assign their rights, in any Patent Rights and Know-How,
whether or not patentable, resulting therefrom to such Party or Affiliate to effectuate the terms and conditions set forth in Section 7.1(a) (Inventions). Without limiting the foregoing, Lian will and hereby does assign to Lyra all of
Lian’s rights, title, and interests in and to any Assigned Inventions, and Lyra hereby accepts such assignment. With respect to any activities of a Party or its Affiliate or exercise of its or their rights under this Agreement that are
subcontracted to a Person that is not an employee, the Party or such Affiliate retaining such subcontractor will include in the applicable subcontract an assignment to such Party or such Affiliate of all rights in Patent Rights and Know-How developed or generated by such subcontractor resulting from such activities or exercise of its rights, and in any event will include in the applicable subcontract a license to such Party or Affiliate that
is sublicensable (through multiple tiers) to the other Party under this Agreement, of any Patent Rights and Know-How developed or generated by such contractor or subcontractor resulting from such activities.
Lian and its Affiliates shall ensure that its and their Sublicensees provide Lian with sufficient rights in all Assigned Inventions so that Lian can assign to Lyra all rights and title in and to all Assigned Inventions, as provided herein.

  
 34 

	7.2	 Prosecution and Maintenance of the Licensed Patent Rights and Joint Patent Rights.

  

	 	(a)	 In the Territory. As between the Parties, Lyra will have the first right, at its expense, to Prosecute
the Licensed Patent Rights and Joint Patent Rights in all Regions in the Territory, at Lyra’s sole cost and expense. Lyra will keep Lian reasonably informed of all steps with regard to and the status of such Prosecution of such Patent Rights,
including by providing Lian with (i) copies of all correspondence and material communications it sends to or receives from any patent office or agency in the Territory relating to such Patent Rights, (ii) a draft copy of all applications,
in each case ((i) and (ii)), sufficiently in advance of filing or response to permit reasonable review and comment by Lian, and (iii) a copy of applications as filed, together with notice of its filing date and serial number. Before Lyra
submits any material filing, including a new patent application, or response to such patent authorities with respect to any Licensed Patent Rights or Joint Patent Rights, Lyra will provide Lian with a reasonable opportunity to review and comment on
such filing or response and will incorporate any reasonable and timely comments or suggestions provided by Lian regarding the Prosecution of such Licensed Patent Rights or Joint Patent Rights under this Section 7.2(a) (In the Territory). For
clarity, Lyra may deem unreasonable (and, therefore, have no obligation to incorporate) any comments from Lian that Lyra reasonably believes would be detrimental to Lyra’s Prosecution strategy of such Licensed Patent Rights outside of the
Territory (even if such comments may be considered reasonable to incorporate regarding such Prosecution in the Territory). 

  

	 	(b)	 Step-In Right. If Lyra elects not to continue to Prosecute a
given Patent Right within the Licensed Patent Rights or Joint Patent Rights in the Territory pursuant to Section 7.2(a) (In the Territory), then Lyra will give Lian notice thereof within a reasonable period (but not less than [***] days) prior
to allowing such Patent Rights to lapse or become abandoned or unenforceable, and Lian will have the right, but not the obligation, to assume the Prosecution of such Patent Rights in such Region, including paying any required fees to maintain such
Patent Rights in such Region, all at Lian’s sole expense and through patent counsel or agents of its choice. Upon transfer of Lyra’s responsibility for Prosecuting any of the Patent Rights to Lian under this Section 7.2(b) (Step-In Right), (i) Lyra will promptly deliver to Lian copies of all necessary files related to the Patent Rights with respect to which responsibility has been transferred and will take all actions and execute all
documents reasonably necessary for Lian to assume such Prosecution, and (ii) such Patent Right shall no longer extend the Royalty Term pursuant to Section 6.2(b) (Royalty Term). 

 

	 	(c)	 Cooperation. Each Party will, and will cause its Affiliates to, reasonably cooperate, with the other
Party with respect to the Prosecution of Licensed Patent Rights and Joint Patent Rights pursuant to this Section 7.2 (Prosecution and Maintenance of the Licensed Patent Rights and Joint Patent Rights), including with respect to obtaining patent
term restoration, supplemental protection certificates or their equivalents, and patent terms extension with respect to the Licensed Patent Rights and Joint Patent Rights in any Region where applicable. 

 

	 	(d)	 Patents Controlled by One Party. Except as otherwise provided under this Agreement, as between Lyra and
Lian, each Party will have the sole right (but not the obligation) to Prosecute, at its own cost and expense, all Patent Rights that are Controlled by such Party or its Affiliates. 

  
 35 

	7.3	 Third Party Infringement. 

 

	 	(a)	 Notice. Each Party will promptly notify the other in writing if such Party becomes aware of any
(i) suspected, threatened, or actual infringement by any Third Party of any Licensed Patent Right or Joint Patent Right in the Territory or (ii) unauthorized use or misappropriation of any Licensed
Know-How by any Third Party that impacts or may impact the other Party’s rights granted hereunder, and, in each case, will provide the other Party with all evidence in such Party’s possession or
control supporting such infringement or unauthorized use or misappropriation (each, an “Infringement”). 

  

	 	(b)	 Lian First Right. As between the Parties, Lian will have the first right, but not the obligation, using
counsel of its choosing and at its sole expense, to institute any Action alleging Infringement of the Licensed Technology within the scope of the exclusive license granted to Lian in Section 2.1(a)(i) or the
non-exclusive license granted to Lian in Section 2.1(a)(ii) (subject to the restrictions set forth therein) or any Joint Patent Rights in the Field in the Territory (any such Action, an
“Infringement Action”). Lyra shall have the right, at its own cost and expense, to be represented in any Infringement Action by counsel of its own choice. Lian will notify Lyra of its decision to commence an Infringement Action,
will keep Lyra apprised in writing of any such Infringement Action and will consider Lyra’s reasonable interests and requests regarding such Infringement Action. 

 

	 	(c)	 Lyra Right. If Lian fails to commence a suit to enforce the Licensed Technology or Joint Patent Rights
against such Infringement Action (or to settle or otherwise secure the abatement of such Infringement Action) within (i) [***] after its receipt or delivery of notice under Section 7.3 (Third Party Infringement), or (ii) [***] before the time
limit, if any, set forth in the appropriate Laws for the filing of such actions, whichever comes first, or ceases to diligently pursue such Infringement Action, then Lyra will have the right, but not the obligation, at its own expense to institute
such Infringement Action against the applicable Third Party infringer(s). 

  

	 	(d)	 Cooperation. In any Infringement Action brought under the Licensed Technology or Joint Patent Rights
pursuant to Section 7.3(b) (Lian First Right) and Section 7.3(c) (Lyra Right), each Party will, and will cause its Affiliates to, reasonably cooperate with each other, in good faith, relative to the other Party’s efforts to protect
the Licensed Technology and Joint Patent Rights, and will join such suit as a party, if requested by the other Party. Furthermore, the Party initiating any Infringement Action pursuant to Section 7.3(b) (Lian First Right) or Section 7.3(c)
(Lyra Right) will consider in good faith all reasonable and timely comments from the other Party on any proposed arguments asserted or to be asserted in litigation related to the enforcement or defense of any such Patent Rights. Neither Party will
have the right to settle any Infringement Action under this Section 7.3 (Third Party Infringement) in a manner that diminishes the rights or interests of the other Party under this Agreement without the consent of such other Party, which
consent will not be unreasonably withheld. 

  

	 	(e)	 Allocation of Recoveries. Any settlements, damages or monetary awards recovered by either Party pursuant
to any Infringement Action will (i) first be allocated to reimbursing the Parties for their reasonable out-of-pocket expenses in making such recovery (which amounts
will be allocated pro rata if insufficient to cover the totality of such expenses), and (ii) (A) [***] or (B) [***]. 

  

	7.4	 Claimed Infringement. Each Party will promptly notify the other Party if a Third Party brings any Action
alleging patent infringement by Lian or Lyra or any of their respective Affiliates or Sublicensees with respect to the Development, Manufacture or Commercialization of any Licensed Product or Joint Patent Rights (any such Action, an
“Infringement Claim”) in the 

  
 36 

	 	
Territory. Lian will have the right, but not the obligation, to control the defense and response to any such Infringement Claim in the Field in the Territory with respect to Lian’s
activities, at Lian’s sole cost and expense, and Lyra will have the right, at its own expense, to be represented in any such Infringement Claim in the Territory by counsel of its own choice. Lyra will have the sole right, but not the
obligation, to control the defense and response to any such Infringement Claim with respect to Lyra’s activities, including any such Infringement Claim in the Territory or outside of the Territory. Upon the request of the Party controlling the
response to the Infringement Claim, the other Party will reasonably cooperate with the controlling Party in the reasonable defense of such Infringement Claim. The other Party will have the right to consult with the controlling Party concerning any
Infringement Claim and to participate in and be represented by independent counsel in any associated litigation. If the Infringement Claim is brought against both Parties, then each Party will have the right to defend against the Infringement Claim.
The Party defending an Infringement Claim under this Section 7.4 (Claimed Infringement) will (a) consult with the other Party as to the strategy for the prosecution of such defense, (b) consider in good faith any comments from the
other Party with respect thereto and (c) keep the other Party reasonably informed of any material steps taken and provide copies of all material documents filed, in connection with such defense. The Party controlling the defense against an
Infringement Claim will have the right to settle such Infringement Claim on terms deemed reasonably appropriate by such Party, provided, that, neither Party will have the right to settle any Infringement Claim under this Section 7.4
(Claimed Infringement) in a manner that diminishes the rights or interests of the other Party under this Agreement without the consent of such other Party, which consent will not be unreasonably withheld. 

 

	7.5	 Common Interest. All information exchanged between the Parties regarding the Prosecution, enforcement,
and defense, of Licensed Patent Rights and Joint Patent Rights under this Article 7 (Intellectual Property Ownership, Protection and Related Matters) will be deemed Confidential Information of the disclosing Party. In addition, the Parties
acknowledge and agree that, with regard to such Prosecution, enforcement, and defense, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are
legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patent Rights under this Article 7 (Intellectual Property Ownership, Protection
and Related Matters), including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding any provision to the contrary set forth in this Agreement, to the extent a Party has a good faith belief that any
information required to be disclosed by such Party to the other Party under this Article 7 (Intellectual Property Ownership, Protection and Related Matters) is protected by attorney-client privilege or any other applicable legal privilege or
immunity, such Party will not be required to disclose such information, and the Parties will in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a “for
counsel eyes only” basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. 

ARTICLE 8     

CONFIDENTIALITY AND PUBLICITY 
  

	8.1	 Confidential Information. 

 

	 	(a)	 Confidentiality Obligation. During the Term and for a period of [***] years after any termination or
expiration of this Agreement, each Party agrees to, and will cause its Affiliates and Sublicensees and contractors to, keep in confidence and not to disclose to any Third Party, or use for any purpose, except to exercise its rights or perform its
obligations under this Agreement, any Confidential Information of the other Party, without the prior written consent of such disclosing Party. The Parties agree that (i) 

  
 37 

	 	
the existence and terms of this Agreement are the Confidential Information of each Party; (ii) the reports provided by Lian to Lyra pursuant to Section 3.5(b) (Reporting) and
Section 4.4(c) (Reporting Obligation) are the Confidential Information of Lian; and (iii) the Licensed Know-How, unpublished applications within the Licensed Patent Rights, and Assigned Inventions
are the Confidential Information of Lyra. 

  

	 	(b)	 Permitted Disclosures. Each Party agrees that it and its Affiliates will provide or permit access to the
other Party’s Confidential Information only to the receiving Party’s employees, consultants, advisors, licensees, collaboration partners, and Sublicensees, and to the employees, consultants and advisors of the receiving Party’s
Affiliates, in each case on a need to know basis who are subject to obligations of confidentiality and non-use with respect to such Confidential Information no less stringent than the obligations of
confidentiality and non-use of the receiving Party pursuant to this Section 8.1 (Confidential Information). Each Party will remain responsible for any failure by its Affiliates, licensees, collaboration
partners, or Sublicensees, and its and its Affiliates’ respective employees, consultants and advisors, to treat such Confidential Information as required under this Section 8.1 (Confidential Information) as if such Affiliates, employees,
consultants, advisors, licensees, collaboration partners, and Sublicensees were parties directly bound to the requirements of this Section 8.1 (Confidential Information). 

 

	 	(c)	 Confidentiality Limitation. Notwithstanding any provision to the contrary set forth in this Agreement,
each Party may use and disclose the other Party’s Confidential Information as follows: (i) under appropriate written confidentiality and non-use obligations substantially equivalent to those in this
Agreement, to its Affiliates, bona fide potential or actual collaboration partners, licensors, Sublicensees, licensees, strategic partners or securitization partners, and to employees, directors, agents, consultants, and advisers of any other
Third Parties, (ii) to its financial advisors, attorneys and accountants, bona fide actual or potential acquisition partners, financing sources or investors and underwriters on a need to know basis, in each case under appropriate
confidentiality and non-use obligations (which may include professional ethical obligations) no less stringent than those in this Agreement, but of duration customary in confidentiality agreements entered into
for a similar purpose; provided, however, that each Party will remain responsible for any failure by any of the foregoing individuals to treat such Confidential Information as required under Section 8.1 (Confidential Information)
as if such individuals were parties directly bound to the requirements of this Section 8.1 (Confidential Information), (iii) as required by any court or other governmental body or as otherwise required by applicable Laws (including any such
disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, Pricing and Reimbursement Approval, import authorization for any Licensed Product in the Territory, or the rules or regulations of the United
States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing entity (including in connection with the public sale of securities)); provided, that,
notice is promptly given to the other Party and the disclosing Party cooperates with reasonable requests from the other Party to seek a protective order or other appropriate remedy to protect the Confidential Information, (v) with the
disclosing Party’s prior written consent, to the extent such use or disclosure is reasonably necessary for the Prosecution of the Licensed Patent Rights. Notwithstanding any provision to the contrary contained in this Article 8 (Confidentiality
and Publicity), Confidential Information that is permitted or required to be disclosed will remain otherwise subject to the confidentiality and non-use provisions of Section 8.1(b) (Permitted Disclosures)
and this Section 8.1(c) (Confidentiality Limitation). If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar Governmental Authority in a country other than the
United 

  
 38 

	 	
States, then such Party will, a reasonable time prior to any such filing, provide the other Party with a copy of such agreement showing any provisions hereof as to which the Party proposes to
request confidential treatment, will provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such Party’s reasonable comments into consideration before filing
such agreement and use reasonable efforts to have terms identified by such other Party afforded confidential treatment by the applicable Regulatory Authority. 

  

	 	(d)	 Secrecy of Licensed Know-How. Without limiting the generality of
Section 8.1(a) (Confidentiality Obligation), during the Term, each Party will protect, and will cause, to the extent applicable, its Affiliates and Sublicensees, and its and their respective officers, directors, employees, and agents to
protect, the secrecy and confidentiality of the Licensed Know-How, Assigned Inventions, Product Inventions and unpublished applications within the Patent Rights using at least the same degree of care as it
uses to prevent the disclosure of its own other confidential information of like importance and in any event a reasonable duty of care. 

  

	8.2	 Publicity. The Parties acknowledge the importance of supporting each other’s efforts to publicly
disclose results and significant developments regarding the Licensed Product in the Field in the Territory, and each Party may make such disclosures from time to time, subject to the terms and conditions of this Agreement, including this
Section 8.2 (Publicity). Such disclosures may include achievement of milestones, significant events in the Development process with respect to Licensed Products, or Commercialization activities with respect to Licensed Products.

  

	 	(a)	 On a date to be agreed by the Parties, the Parties will jointly issue a press release regarding the signing of
this Agreement. Except as set forth in the preceding sentence and for disclosures permitted in accordance with Section 8.1(b) (Permitted Disclosures), whenever either Party elects to make any public disclosure regarding milestones or other
significant events in the Development or Commercialization of the Licensed Products in the Field in the Territory, it will first notify the other Party of such planned press release or public announcement and provide a draft for review no less than
[***] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Laws, with as much advance notice as possible under the circumstances if
it is not possible to provide notice at least [***] in advance). Each Party will have the right to review and approve any such planned press release or public announcement proposed by the other Party with respect to Licensed Products in the Field in
the Territory, or that includes Confidential Information of the other Party. In such case, (i) the reviewing Party will attempt to provide such approval as soon as reasonably possible and will not unreasonably withhold such approval;
(ii) the reviewing Party will provide explanations of its disapproval of such press release; and (iii) a Party desiring to make such public disclosure may issue such press release or public announcement without such prior review by the
other Party if (A) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by such Party, and (B) such press release or public announcement is consistent with
the previously issued press release or other publicly available information; and provided that [***]. The Party reviewing a press release provided under this clause (i) of this Section 8.2(a) (Publicity) will review and approve or
disapprove such press release within [***] Business Days after its receipt thereof. 

  
 39 

	 	(b)	 In the event that either Party proposes to publish or present the results of Development or Commercialization
carried out on the Licensed Product in the Field in the Territory, including any oral presentation or abstract that contain clinical data or pertain to results of Clinical Trials or other studies in the Field in the Territory, such publication or
presentation will be subject to the prior review by the other Party for protection of such other Party’s Confidential Information and to identify concerns regarding competitive disadvantage arising from such publication or presentation. Each
Party will provide to the other Party the opportunity to review a draft of any proposed publication that covers the results of Development or Commercialization of Licensed Products in the Field in the Territory during the Term, and the submitting
Party (i) will remove from such proposed publication any Confidential Information of the other Party as reasonably requested by the other Party and (ii) will not submit such publication or presentation until the concerns of the other Party
regarding any such potential competitive disadvantage are resolved by the JSC. 

 ARTICLE 9 

REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS 
  

	9.1	 Mutual Representations and Warranties. Each Party represents, warrants, and covenants to the other Party
that, as of the Effective Date: 

  

	 	(a)	 Organization. It is a corporation duly organized, validly existing, and in good standing under the Laws
of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

  

	 	(b)	 Authority. It has full right, power and authority to enter into this Agreement and to perform its
respective obligations under this Agreement, it has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such
Party’s charter documents, bylaws or other organizational documents. 

  

	 	(c)	 Consents. Except for any Marketing Authorizations, Regulatory Approvals, Regulatory Filings,
Manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be
obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained. 

  

	 	(d)	 No Conflict. It is not under any obligation, contractual or otherwise, to any Person that would
materially affect the diligent and complete fulfillment of obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the performance of such Party’s obligations under this Agreement (as contemplated as
of the Effective Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (i) do not conflict with or violate any requirement of Laws applicable to such Party, (ii) do not conflict with or violate any
order, writ, judgment, injunction, decree, determination, or award of any court or Governmental Authority presently in effect applicable to such Party, and (iii) do not conflict with, violate, breach or constitute a default under, or give rise
to any right of termination, cancellation or acceleration of, any contractual obligations of such Party or any of its Affiliates. 

  

	 	(e)	 Enforceability. This Agreement is a legal and valid obligation binding upon it and is enforceable
against it in accordance with its terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Laws affecting the
enforcement of creditors’ rights generally. 

  

  
 40 

	 	(f)	 Compliance with Laws. The Parties will, and will ensure that their respective Affiliates and
Sublicensees will, comply in all material respects with all applicable Laws in exercising their rights and fulfilling their obligations under this Agreement. Without limiting the generality of the foregoing, the Parties will conduct all Development,
and Commercialization activities relating to the Licensed Product under this Agreement in accordance with applicable Laws (including data privacy Laws, current international regulatory standards, including, as applicable, GMP, GLP, GCP, and other
rules, regulations and requirements), Export Control Laws, Anti-Corruption Laws and all other applicable Laws concerning bribery, money laundering, or corrupt practices or that in any manner prohibit the giving of anything of value to any official,
agent, or employee of any government, political party, or public international organization, candidate for public office, health care professional, or to any officer, director, employee, or representative of any other organization specifically
including the U.S. Foreign Corrupt Practices Act, and the UK Bribery Act, in each case, in connection with the activities conducted pursuant to this Agreement. The Parties will cause all permitted collaborators, contractors, subcontractors,
Sublicensees, or other Persons that provide services to such Party in connection with this Agreement to comply with such Party’s obligations under this Section 9.1(f) (Compliance with Laws). 

 

	9.2	 Additional Representations and Warranties of Lyra. Lyra represents and warrants to Lian that, as of the
Effective Date: 

  

	 	(a)	 Licensed Patent Rights. All Licensed Patent Rights as of the Effective Date are listed in Schedule 1.75
(Licensed Patents). Lyra is the sole and exclusive owner of the Licensed Patent Rights, all of which are free and clear of any claims, liens, charges or encumbrances. All Licensed Patent Rights have been filed and Prosecuted in good faith in the
patent offices in accordance with applicable Laws, and all applicable fees have been paid on or before the due date for payment. All issued Licensed Patent Rights are valid and, to Lyra’s knowledge, subsisting and enforceable.

  

	 	(b)	 Licensed Know-How. Lyra Controls the Licensed Know-How, and has the right to grant the licenses under the Licensed Know-How to Lian on and the terms set forth in this Agreement. Lyra has the right to use and disclose (in
each case, under appropriate circumstances of confidentiality) the Licensed Know-How free and clear of any claims, liens, charges or encumbrances. 

 

	 	(c)	 Licensed Technology. Lyra has not granted to any Third Party, including any academic organization or
agency, any license, option or other rights to research, Develop, Manufacture, use or Commercialize the Licensed Product in the Field in the Territory. No Third Party has any license, option or other rights or interest in or to the Licensed
Technology in the Field in the Territory other than the rights that are expressly reserved or contingent under this Agreement. 

  

	 	(d)	 Control. Lyra or its Affiliates Controls all Patent Rights and
Know-How owned, invented, or licensed by Lyra as of the Effective Date that are necessary or actually used as of the Effective Date to Develop, Commercialize, Manufactured and otherwise, use, offer for sale,
sell, have sold, and import the Licensed Products. 

  

	 	(e)	 Licensed Marks. Lyra owns or Controls the Licensed Marks, and has the right to grant the licenses under
the Licensed Marks to Lian on the terms set forth in this Agreement. 

  

	 	(f)	 Delivery of Documentation. Prior to the Effective Date, Lyra has made available to Lian true, complete,
and correct copies of: (i) all existing material Regulatory Filings in its possession and control relating to Licensed Products, (ii) all material adverse information with respect to the safety and efficacy of the Licensed Products in
Lyra’s or its Affiliates’ (to the extent applicable, in accordance with Section 2.1(b)) (Lian Right of Access and Reference) possession and control, and (iii) all material data and results relating to the Development of the
Licensed Products in Lyra’s or its Affiliates’ possession and control (to the extent applicable, in accordance with Section 2.1(b)) (Lian Right of Access and Reference). 

  
 41 

	 	(g)	 Third Party Challenges. There are no claims, judgments, or settlements against, or amounts with respect
thereto, made against Lyra or any of its Affiliates relating to the Licensed Patent Rights or the Licensed Know-How, and no claim or litigation has been received by Lyra or its Affiliates or, to Lyra’s
knowledge, threatened by any Person (i) alleging that the Licensed Patent Rights are invalid or unenforceable, (ii) asserting the misuse of any of the Licensed Patent Rights, (iii) challenging Lyra’s Control of the Licensed
Patent Rights (i.e., alleging that a Third Party has a right or interest in or to the Licensed Technology), or (iv) alleging misappropriation of the Know-How of any Third Party used in the Development,
Manufacture or Commercialization of Licensed Products by or on behalf of Lyra prior to the Effective Date. 

  

	 	(h)	 Non-Infringement of Third Party IP. To Lyra’s knowledge,
the Development, Manufacture, or Commercialization of the Licensed Product, as conducted by Lyra, its Affiliates, or its or their Sublicensees on or prior to the Effective Date does not infringe any Patent Right or misappropriate or otherwise
violate or misappropriate any Know-How of any Person (in the case of pending Patent Rights, evaluating them as if issued). No claim of infringement of the Patent Rights or misappropriation of the Know-How of any Third Party has been received by the Lyra, or to Lyra’s knowledge, threatened, against Lyra, any of its Affiliates or its or their Sublicensees with respect to the Development, Manufacture or
Commercialization of Licensed Products. To Lyra’s knowledge, the Development, Manufacture, or Commercialization of the Licensed Product will not infringe, misappropriate or otherwise violate any Intellectual Property of any Third Party.

  

	 	(i)	 Absence of Litigation. There are no judgments or settlements against or owed by Lyra or its Affiliates
or Sublicensees, or, to Lyra’s knowledge, pending litigation against Lyra or its Affiliates or Sublicensees, or litigation threatened against Lyra or its Affiliates or Sublicensees, in each case, related to the Licensed Product, including any
such litigation any relating to any Regulatory Filings, Regulatory Approvals, or Marketing Authorizations Controlled by Lyra, its Affiliates or its Sublicensees. 

 

	 	(j)	 Maintenance of Regulatory Filings, Good Laboratory, and Clinical Practices. Lyra Controls
all Regulatory Filings pertaining to the Licensed Product in the Field in the Territory. Lyra and its Affiliates and Sublicensees have generated, prepared, maintained, and retained all Regulatory Filings and Marketing Authorizations relevant to
Licensed Products in the Field in the Territory in its control that are required to be maintained or retained pursuant to and in material compliance with applicable Laws, and have conducted in material compliance with applicable Laws, including GLP
and GCP all Development of Licensed Products in the Field conducted prior to the Effective Date. 

  

	 	(k)	 Confidentiality of Know-How. Lyra has taken commercially
reasonable measures consistent with its usual business practice (but in any event no less than industry standard practices) to protect the secrecy, confidentiality, and value of all Licensed Know-How. To
Lyra’s knowledge, the Licensed Know-How existing as of the Effective Date has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality. 

 

  
 42 

	 	(l)	 Assignment of Third Party Rights; Third Party Consents. 

 

	 	(i)	 Lyra has obtained from each of its employees and agents, and from the employees and agents of its Affiliates,
who are performing Development activities under the Global Development Plan for Licensed Products, rights to any and all Know-How created by such employees and agents in the course of such activities that
relates to Licensed Products, such that Lian will, by virtue of this Agreement, receive from Lyra, without payments beyond those required by Article 6 (Financial Provisions), all licenses and other rights granted to Lian under this Agreement.

  

	 	(ii)	 Each Person who has or has had any ownership rights in or to any Licensed Patent Rights purported to be owned
solely by Lyra, has assigned and has executed an agreement assigning its entire rights, title, and interests in and to such Licensed Patent Rights to Lyra, and to Lyra’s knowledge, no current officer, employee, agent, or consultant of Lyra or
any of its Affiliates is in violation of any term of any assignment or other agreement, in each case, regarding the protection of the Licensed Patent Rights. 

  

	 	(iii)	 Prior to the Effective Date, Lyra has obtained all consents from Third Parties necessary to grant Lian the
licenses and rights Lyra purports to grant to Lian under this Agreement. 

  

	 	(m)	 Statements to Regulatory Authorities. Neither Lyra nor any of its Affiliates, nor, to Lyra’s
knowledge, its Sublicensees nor any of its or their respective officers, employees, or agents has made an untrue statement of material fact or fraudulent statement to any Regulatory Authority with respect to the Development or Commercialization of
Licensed Products, or failed to disclose a material fact required under applicable Laws to be disclosed to any Regulatory Authority with respect to the Development or Commercialization of Licensed Products. 

 

	 	(n)	 Compliance with Laws. All of the studies, tests, and
pre-clinical and Clinical Trials of Licensed Products conducted prior to, or being conducted as of, the Effective Date by or on behalf of Lyra have been and are being conducted in all material respects in
accordance with applicable Laws. 

  

	 	(o)	 No Other Disclosures. To Lyra’s knowledge, (i) there are no scientific or technical facts or
circumstances that have not been disclosed to Lian that would adversely affect the scientific, therapeutic, or commercial potential of the Licensed Products; (ii) there is nothing within Lyra’s Control that has not been disclosed to Lian
and that could adversely affect the acceptance, or the subsequent approval, by any Regulatory Authority of any Regulatory Filing; and (iii) there are no safety, efficacy, or regulatory issues that would preclude Lian from exploiting the
Licensed Products in the Territory in accordance with this Agreement and applicable Law. 

  

	9.3	 No Conflict. During the Term, Lyra and its Affiliates will not grant any interest in the Licensed
Technology that is inconsistent with the terms and conditions of this Agreement. 

  

	9.4	 No Debarment. Each of Lyra and Lian represents and warrants that neither it nor any of its or its
Affiliates’ employees or agents performing under this Agreement has ever been, or is currently: (a) debarred under 21 U.S.C. § 335a or by any Regulatory Authority; (b) excluded, debarred, suspended, or otherwise ineligible to
participate in federal health care programs or in federal procurement or non-procurement programs; (c) listed on the FDA’s Disqualified and Restricted Lists for clinical investigators; or
(d) convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. Each of Lyra and Lian
further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates’ employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to
that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, then such Party will promptly notify the other Party. This provision will survive termination or expiration of this Agreement.

  
 43 

	9.5	 NO OTHER WARRANTIES. EXCEPT AS EXPRESSLY STATED IN SECTION 9.1 (MUTUAL REPRESENTATIONS AND WARRANTIES),
SECTION 9.2 (ADDITIONAL REPRESENTATIONS AND WARRANTIES OF LYRA) AND SECTION 9.4 (NO DEBARMENT), NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF
TITLE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY WITH RESPECT TO THE LICENSED PRODUCT, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. 

 ARTICLE 10 

INDEMNIFICATION; DAMAGES 
  

	10.1	 Indemnification by Lyra. Lyra will defend, indemnify and hold harmless Lian, its Affiliates and
their respective directors, officers, employees and agents (each, a “Lian Indemnified Party”), from, against and in respect of any and all Third Party Losses incurred or suffered by any Lian Indemnified Party to the extent resulting
from or relating to: (a) any breach of any representation or warranty made by Lyra in this Agreement, or any breach by Lyra of any obligation, covenant, or agreement in this Agreement; (b) the gross negligence or intentional misconduct of
Lyra or any of its Affiliates, Sublicensees, or contractors, or any of their respective directors, officers, employees, or agents, in performing Lyra’s obligations or exercising Lyra’s rights under this Agreement; (c) activities
conducted by or on behalf of Lyra or its Affiliates or (sub)licensees or contractors related to the Development, Manufacture, or Commercialization of Licensed Products anywhere in the world prior to the Effective Date; (d) the Development,
Manufacture, or Commercialization of the Licensed Products by or on behalf of Lyra, any of its Affiliates, Sublicensees (other than Lian), or contractors outside the Territory; or (e) Lyra’s or its Affiliate’s status as an applicant
or a holder of any Regulatory Approval for the Licensed Products; provided, however, that Lyra’s obligations pursuant to this Section 10.1 (Indemnification by Lyra) will not apply to the extent such Third Party Losses result
from Third Party Losses for which Lyra has an obligation to indemnify Lian pursuant to Section 10.2 (Indemnification by Lian). 

  

	10.2	 Indemnification by Lian. Lian will defend, indemnify and hold harmless Lyra, its Affiliates, and
each of their respective directors, officers, employees and agents (each, a “Lyra Indemnified Party”) from, against and in respect of any and all Third Party Losses incurred or suffered by any Lyra Indemnified Party to the extent
resulting from or relating to: (a) any breach of any representation or warranty made by Lian in this Agreement, or any breach by Lian of any obligation, covenant, or agreement in this Agreement, (b) the gross negligence or intentional
misconduct of, or violation of Laws by, Lian, any of its Affiliates, Sublicensees, or contractors, or any of their respective directors, officers, employees, or agents, in performing Lian’s obligations or exercising Lian’s rights under
this Agreement, (c) the Development, Manufacture, or Commercialization of the Licensed Product by or on behalf of Lian or its Affiliates or Sublicensees (other than Lyra) or contractors; or (d) Lian’s or its Affiliate’s status as
an applicant or a holder of any Regulatory Approval for the Licensed Products; provided, however, that Lian’s obligations pursuant to this Section 10.2 (Indemnification by Lian) will not apply to the extent such Third Party
Losses result from Third Party Losses for which Lyra has an obligation to indemnify Lian pursuant to Section 10.1 (Indemnification by Lyra). 

  
 44 

	10.3	 Claims for Indemnification. 

 

	 	(a)	 Notice. An Indemnified Party entitled to indemnification under Section 10.1 (Indemnification by
Lyra) or Section 10.2 (Indemnification by Lian) will give prompt written notification to the Indemnifying Party from whom indemnification is sought of the commencement of any Action by a Third Party for which indemnification may be sought (a
“Third Party Claim”) or, if earlier, upon the assertion of such Third Party Claim by a Third Party; provided, however, that failure by an Indemnified Party to give notice of a Third Party Claim as provided in this
Section 10.3(a) (Notice) will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is materially prejudiced as a result of such failure to give
notice. 

  

	 	(b)	 Defense. Within [***] days after delivery of a notice of any Third Party Claim in accordance with
Section 10.3(a) (Notice), the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party. If the
Indemnifying Party does not assume control of such defense, then the Indemnified Party may control such defense (with counsel reasonably selected by the Indemnified Party and approved by the Indemnifying Party, such approval not to be unreasonably
withheld). The Party not controlling such defense may participate therein at its own expense. 

  

	 	(c)	 Cooperation. The Party controlling the defense of any Third Party Claim will keep the other Party
advised of the status and material developments of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto. The other Party will reasonably cooperate with the Party
controlling such defense and its Affiliates and agents in defense of the Third Party Claim, with all out-of-pocket costs of such cooperation to be borne by the Party
controlling such defense. 

  

	 	(d)	 Settlement. The Indemnified Party will not agree to any settlement of such Third Party Claim without the
prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. The Indemnifying Party will not agree to any settlement of such Third Party Claim or consent to any judgment in respect thereof that does not include a
complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party (other than a monetary obligation on the Indemnifying Party), without the prior
written consent of the Indemnified Party, which will not be unreasonably withheld (unless such compromise or settlement involves (i) any admission of legal wrongdoing by the Indemnified Party, (ii) any payment by the Indemnified Party
that is not indemnified under this Agreement, or (iii) the imposition of any equitable relief against the Indemnified Party (in which case, (i) through (iii), the Indemnified Party may withhold its consent to such settlement in its
sole discretion)). 

  

	 	(e)	 Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates and
Sublicensees take all such reasonable steps and actions as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Third Party Claims (or potential losses or damages) under this Article 10 (Indemnification;
Damages). Nothing in this Agreement will or will be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 

  

	10.4	 Insurance. Each Party, at its own expense, will maintain liability insurance (or self-insure) with
respect to its activities under this Agreement in an amount consistent with industry standards. Each Party will provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. Without
limiting the foregoing, during the Term and thereafter for the period of time required below, each Party will maintain on an ongoing 

  
 45 

	 	
basis comprehensive general liability insurance policies which are consistent with normal business practices of prudent companies similar situated in such Party’s territory. Not later than
[***] days following receipt of written request from a Party, the other Party will provide to the requesting Party a certificate of insurance evidencing such insurance policies. Each Party will maintain such insurance or self-insurance coverage
without interruption during the Term and for a period of [***] thereafter, and, if applicable, will provide certificates or letters evidencing such insurance coverage without interruption as reasonably requested during the period of time for which
such coverage must be maintained. Each Party will be provided at least [***] days’ prior written notice of any cancellation or material decrease in the other Party’s insurance coverage limits described above. Notwithstanding the foregoing,
either Party’s failure to maintain adequate insurance will not relieve that Party of its obligations set forth in this Agreement. 

ARTICLE 11 
 LIMITATION
OF LIABILITY 
  

	11.1	 NO CONSEQUENTIAL OR PUNITIVE DAMAGES. EXCEPT AS SET FORTH IN SECTION 11.2 (EXCLUSION FROM LIABILITY
LIMITATION), NEITHER PARTY NOR ANY OF ITS AFFILIATES OR AFFILIATED ENTITIES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS OR THE
PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, OR ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH CASE, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE, REGARDLESS OF
ANY NOTICE OF SUCH DAMAGES. 

  

	11.2	 EXCLUSION FROM LIABILITY LIMITATION. THE LIMITATIONS AND DISCLAIMER SET FORTH IN SECTION 11.1 (NO
CONSEQUENTIAL OR PUNITIVE DAMAGES) WILL NOT APPLY TO A CLAIM: (A) FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT; (B) FOR A BREACH OF SECTION 2.9 (NON-COMPETE), Article 8 (CONFIDENTIALITY AND PUBLICITY);
OR (C) FOR INDEMNIFIABLE LOSSES PURSUANT TO SECTION 10.1 (INDEMNIFICATION BY LYRA) OR SECTION 10.2 (INDEMNIFICATION BY LIAN), AS APPLICABLE. 

ARTICLE 12 
 TERM AND
TERMINATION 
  

	12.1	 Term. Unless terminated earlier in accordance with this Article 12 (Term and Termination), this
Agreement will become effective as of the Effective Date and will continue in full force, on a Region-by-Region basis, until the expiration of the Royalty Term
applicable to such Licensed Product in such Region(the “Term”). 

  

	12.2	 Paid-Up License Upon End of Royalty Term. Upon the expiration of
the Royalty Term for a given Licensed Product in a given Region in the Territory, the licenses and rights of reference granted to Lian pursuant to Section 2.1 (License Grants; Rights of Reference) will become perpetual, irrevocable, fully paid-up, royalty free, fully sublicensable, and transferable with respect to such Licensed Product in such Region. 

  
 46 

	12.3	 Early Termination. 

 

	 	(a)	 Termination for Material Breach. Upon (i) any material breach of this Agreement by Lyra or
(ii) any material breach of this Agreement by Lian (the Party so allegedly breaching being the “Breaching Party”), the other Party (the “Non-Breaching Party”) will have
the right, but not the obligation, to terminate this Agreement by providing written notice to the Breaching Party within [***] days in the case of a payment breach, or [***] days in the case of any other material breach, which notice will, in each
case (A) expressly reference this Section 12.3(a) (Termination for Material Breach), (B) reasonably describe the alleged breach that is the basis of such termination, and (C) clearly state the
Non-Breaching Party’s intent to terminate this Agreement if the alleged breach is not cured within the applicable cure period. Notwithstanding the foregoing, if such material breach, by its nature, is
curable, but is not reasonably curable within the applicable cure period, then such cure period will be extended if the Breaching Party provides a written plan for curing such breach to the Non-Breaching Party
and uses reasonable efforts to cure such breach in accordance with such written plan; provided, however, that no such extension will exceed [***] days without the prior written consent of the
Non-Breaching Party. In addition, if the Breaching Party disputes (A) whether it has materially breached this Agreement, (B) whether such material breach is reasonably curable within the applicable
cure period, or (C) whether it has cured such material breach within the applicable cure period, then the dispute will be resolved pursuant to Article 13 (Dispute Resolution), and the applicable cure period will be tolled during the pendency of
such dispute resolution procedure. 

  

	 	(b)	 Termination by Lian for Convenience. Lian may, upon [***] days’ prior written notice to Lyra,
terminate this Agreement for convenience, without cause, and for any or no reason, in its entirety. 

  

	 	(c)	 Termination for Bankruptcy. This Agreement may be terminated, to the extent permitted by applicable
Laws, by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party;
provided, however, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding such right to terminate will only become effective if the Party subject to such proceeding consents to the
involuntary bankruptcy or such proceeding is not dismissed within [***] days after the filing thereof. 

  

	 	(d)	 Patent Challenge. Lyra has the right to terminate this Agreement upon written notice to Lian in the
event that Lian or any of its Affiliates or Sublicensees directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any Patent Rights within the Licensed Technology (a “Patent
Challenge”) and does not withdraw such Patent Challenge within [***] days of written notice from Lyra; provided that, if such Patent Challenge is brought by Lian or its Affiliates and it is withdrawn within such [***]-day period,
Lian shall promptly reimburse Lyra for all costs and expenses incurred by or on behalf of Lyra in defending and responding to such Patent Challenge; and provided further that this Section 12.3(d) (Patent Challenge) will not apply to any
Patent Challenge that (i) is first made by Lian or any of its Affiliates or Sublicensees in defense of a claim of patent infringement brought by the Lyra under the applicable Patent Rights or any Patent Challenge, (ii) was brought by an
Acquirer prior to the effective date of such Change of Control, or (iii) is brought by any non-Affiliate Sublicensee if Lian (A) causes such Patent Challenge to be terminated or dismissed (or in the
case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges in which the challenging party does not have the power to unilaterally cause the Patent Challenge to be withdrawn, causes such
Sublicensee to withdraw as a party from such Patent Challenge and to cease actively assisting any other party to such Patent Challenge), or (B) terminates such Sublicensee’s sublicense to the Patent Rights being challenged by the
Sublicensee, in each case, within [***] days after the Lyra’s notice to Lian under this Section 12.3(d) (Patent Challenge). 

  
 47 

	 	(e)	 Termination for Cessation of Development or Commercialization. Lyra may terminate this Agreement in the
event that Lian and its Affiliates and Sublicensees do not conduct any material Development or Commercialization activities with respect to any Licensed Product for a continuous period of longer than [***] and such failure to conduct any material
Development or Commercialization activity is not: (i) [***], (ii) [***], (iii) [***], or (iv) [***] or (v) [***]. Such termination will be effective [***] days after Lian’s receipt of written notice thereof, provided that, Lian may
submit a written plan within [***] Business Days after Lian’s receipt of such written notice that is reasonably calculated to remedy such failure to conduct any material Development or Commercialization activities with respect to a Licensed
Product. If such cure plan is reasonably acceptable to Lyra and Lian commences any material Development or Commercialization activities in accordance with the terms of such cure plan during such [***] day period and provides satisfactory written
documentation thereof to Lyra, then this Agreement will not terminate upon the expiration of such [***] day period. 

  

	12.4	 Alternative Remedy In Lieu of Termination. Lyra stipulates and agrees that Lian’s decision to enter
into this Agreement and invest in the Development of the Licensed Products is premised upon the assumption that Lyra will perform its obligations under this Agreement, and that a material breach of certain obligations under this Agreement as
explicitly set forth in this Section 12.4 (Alternative Remedy in Lieu of Termination) by Lyra will undermine the economic fundamentals of the transaction for Lian, and that in such event Lian’s damages arising from Lyra’s breach would
be of uncertain amount and difficult to prove. If Lian has a right to terminate this Agreement pursuant to Section 12.3(a) (Termination for Material Breach) as a result of a breach (i.e., such breach constitutes a material breach and is
not cured within the applicable cure period and following any dispute resolution proceedings) by Lyra of [***], then Lian may elect, in lieu of so terminating and as Lian’s sole and exclusive remedy with respect to such breach, to have this
Agreement continue on all the terms herein save that all Milestone Payments and royalties payable thereafter by Lian to Lyra hereunder will be reduced by [***]. [***]. 

 

	12.5	 Effects of Termination. 

 

	 	(a)	 Effects of Termination Generally. Upon any termination of this Agreement, then the Parties’ rights,
licenses and obligations under this Agreement will terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination, except as set forth in this Section 12.5 (Effects
of Termination). 

  

	 	(b)	 Winding Down of Activities. If there are any on-going
Development or Commercialization activities at termination or expiration of this Agreement, then the Parties will negotiate in good faith and adopt a plan to wind-down such activities in an orderly fashion or, at Lyra’s election, promptly
transition such activities from Lian to Lyra or its designee, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Trials of the Licensed Products, and take any actions it deems reasonably necessary
or appropriate to avoid any human health or safety problems and in compliance with all applicable Law. 

  

	 	(c)	 License Grant to Lyra. 

 

	 	(i)	 Upon termination of this Agreement, Lian, on behalf of itself and its Affiliates hereby grants (effective on
delivery of the notice of termination) to Lyra an irrevocable, perpetual, transferable, exclusive, sublicensable (through multiple tiers), license under the Lian Technology in existence and actually used by Lian or its Affiliates or Sublicensees, in
each case, as of the applicable effective date of termination to Develop, Manufacture, Commercialize and otherwise, 

  
 48 

	 	
use, offer for sale, sell, have sold, and import the Licensed Product in the Field in or for the Territory (the “Reversion License”). If any rights granted by Lian under the
Reversion License are Controlled by Lian or its Affiliates or Sublicensees pursuant to an agreement with a Third Party, then Lyra will pay all amounts due under any such agreement to the extent reasonably allocable to Lyra’s exercise of the
rights granted thereunder. 

  

	 	(ii)	 If Lyra or its or their Affiliates or Sublicensees exercises the Reversion License or the rights granted
pursuant to Section 12.5(h) (Transfer of Regulatory Filings and Regulatory Approvals) and this Agreement has been terminated by Lian pursuant to Section 12.3(a) (Termination for Material Breach), then Lyra will pay to Lian, in
consideration of the rights granted to Lyra, if Lyra (or its Affiliate, licensee or distributor) sells a Licensed Product under the Reversion License, within [***] after termination of this Agreement, then Lyra will pay to Lian [***]. The definition
of “Net Sales” in Section 1.86 of this Agreement shall apply to the Net Sales of such product for determining the foregoing mutatis mutandis, and the terms of Section 6.3 (Royalty Payment Adjustments) and Section 6.4
(Audits) shall apply mutatis mutandis. 

  

	 	(d)	 Discontinuation of JSC. Upon termination of this Agreement in its entirety, the JSC will cease to exist.

  

	 	(e)	 Accrued Obligations. Expiration or termination of this Agreement for any reason will not release either
Party from any obligation or liability that, on the effective date of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination. 

 

	 	(f)	 Survival. This Section 12.5(f) (Survival), the provisions set forth in the following Sections, as
well as, to the extent applicable, any other Sections or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive any expiration or termination of this Agreement in its entirety: Section 2.2(c)
(Sublicense Survival), Section 2.4 (License Grant to Lyra), Section 2.6 (Rights in Bankruptcy) (solely with respect to any termination under Section 12.3(c) (Termination for Bankruptcy)), Article 6 (Financial Provisions) (solely with
respect to payments payable prior to expiration and termination and as necessary to effectuate Section 12.5(c)(ii)), Section 7.1 (Ownership of Intellectual Property), Section 7.5 (Common Interest), Article 8 (Confidentiality and
Publicity), Section 9.5 (No Other Warranties), Article 10 (Indemnification; Damages), Article 11 (Limitation of Liability), Section 12.2 (Paid-Up License Upon End of Royalty Term), Section 12.5
(Effects of Termination), Article 13 (Dispute Resolution), and Article 14 (Miscellaneous). Furthermore, any other provisions required to interpret the Parties’ rights and obligations under this Agreement, including applicable definitions in
Article 1 (Definitions), will survive to the extent required. Except as otherwise expressly provided in this Agreement, including all rights and obligations of the Parties under this Agreement, including this Section 12.5(f) (Survival), any
licenses granted under this Agreement, will terminate upon expiration or termination of this Agreement for any reason. 

  

	 	(g)	 Inventory. 

  

	 	(i)	 Appointment as Exclusive Distributor. If Lian is Commercializing any Licensed Product in any Region in
the Territory as of the effective date of termination of this Agreement, then, at Lyra’s election (in its sole discretion) on a Region-by-Region basis in the
Territory, [***], Lian will appoint Lyra or its designee as its exclusive distributor of such Licensed Product in such Region and grant Lyra or its designee the right to appoint sub-distributors, to the extent
not prohibited by an written agreement between Lian or any of its Affiliates and any Third Party. 

  
 49 

	 	(ii)	 Sell-Off Period. At Lian’s request, for a period of [***]
following termination of this Agreement in any Region, Lian shall sell or otherwise dispose of any Licensed Products in such terminated Regions, as applicable, on hand at the time of such termination or in the process of Manufacturing (the “Sell-Off Period”). 

  

	 	(iii)	 Lyra Buy-Back. Upon expiration of any Sell-Off Period in any Region or in the event that Lyra exercises its right to be appointed Lian’s exclusive distributor pursuant to Section 12.4(g)(i) (Appointment as Exclusive Distributor), Lyra will
have the right to purchase all of Lian’s and its Affiliates’ remaining inventory of Licensed Products held as of the effective date of expiration of such Sell-Off Period or such appointment at a
price equal to (A) [***], if supplied by Lyra or (B) if Manufactured by Lian, [***]. 

  

	 	(h)	 Transfer of Regulatory Filings and Regulatory Approvals. Following the effectiveness of any termination
of this Agreement pursuant to Section 12.3 (Early Termination), after Lyra’s written request, Lian will, to the extent permitted under applicable Laws and not commercially infeasible, and at Lyra’s sole cost and expense (unless the
applicable termination giving rise to Lyra’s rights under this Section 12.5(h) (Transfer of Regulatory Filings and Regulatory Approvals) was for Lian’s material breach pursuant to Section 12.3(a) (Termination for Material
Breach), in which case such transfer will be at Lian’s sole cost and expense), assign and transfer to Lyra all Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations for Licensed Products that are held
by or owned by Lian or its Affiliates or Sublicensees as of the effective date of termination and will take such actions and execute such other instruments, assignments, and documents as may be necessary to effect the transfer of rights under such
Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing Authorizations to Lyra. If applicable Laws or relevant Regulatory Authorities prevent or delay the transfer of ownership of any such Regulatory Filing, filing for
Pricing and Reimbursement Approval and Marketing Authorizations to Lyra, or if it is commercially infeasible for Lian to do so, then Lian will grant, and hereby does grant, to Lyra and its Affiliates, Sublicensees, and licensees an exclusive and
irrevocable right of access and right of reference to such Regulatory Filing, filing for Pricing and Reimbursement Approval and Marketing Authorizations for Licensed Products in the Field in the Territory, as the case may be, and will reasonably
cooperate with Lyra, at Lyra’s expense (unless the applicable termination giving rise to Lyra’s rights under this Section 12.5(h) (Transfer of Regulatory Filings and Regulatory Approvals) was for Lian’s material breach pursuant
to Section 12.3(a) (Termination for Material Breach) in which case such transfer will be at Lian’s sole cost and expense), to make the benefits of such Regulatory Filings, filings for Pricing and Reimbursement Approval and Marketing
Authorizations available to Lyra or its designee(s). 

  

	 	(i)	 Transfer of Data. Following the effectiveness of any termination of this Agreement pursuant to
Section 12.3 (Early Termination), after Lyra’s written request, Lian will, [***], (A) promptly provide to Lyra copies of all data described in Section 2.5(b) (Lyra Right of Access and Reference) to the extent not previously provided
to Lyra under this Agreement, (B) provide access within the Territory to the data and samples obtained from trial subjects described in the third sentence of Section 2.5 (Lyra Right of Access and Reference), and (C) assign and
transfer, and hereby does assign and transfer, and shall ensure that its Affiliates and its and their Sublicensees, and its or 

  
 50 

 their employees, agents or independent contractors will assign, all of their rights, title
and interest in any and all such data and samples referenced in the foregoing clauses (A) and (B), provided that Lian’s obligations under the foregoing clauses (B) and (C) will be to subject to applicable Law and Lian’s
contractual rights and obligations with respect thereto. 
  

	 	(j)	 Assignment of Third Party Agreements. To the extent requested by Lyra, Lian will promptly upon request
assign and transfer to Lyra or its designee (i) all of Lian’s rights, title and interests in and to all clinical trial agreements, manufacturing and supply agreements, and distribution agreements (to the extent assignable) in Lian’s
Control, in each case, to the extent such agreements solely relate to such Licensed Product and are necessary or useful for the Development, Manufacture, or Commercialization of such Licensed Product, and (ii) all of Lian’s rights, title,
and interests in and to any promotional materials, training materials, medical education materials, packaging and labeling, and all other literature or other information related to such Licensed Product and copyrights and any registrations for the
foregoing. 

  

	 	(k)	 Return of Confidential Information. Within [***] after the effective date of termination (but not
expiration) of this Agreement in its entirety, each Party will, and cause its Affiliates to (i) destroy, all tangible items solely comprising, bearing or containing any Confidential Information of the other Party that are in such first
Party’s or its Affiliates’ possession or Control, and provide written certification of such destruction, or (ii) prepare such tangible items of the other Party’s Confidential Information for shipment to such other Party, as such
other Party may direct, at the first Party’s expense; provided, however, that, in any event, (A) each Party may retain copies of the Confidential Information of the other Party to the extent necessary to perform its
obligations or exercise its rights that survive expiration or termination of this Agreement; and (B) each Party may retain copies of the Confidential Information of the other Party for its legal archives. 

 

	 	(l)	 Cooperation. Each Party will cause its Affiliates, Sublicensees, and contractors to comply with the
obligations in this Section 12.5 (Effects of Termination). 

 ARTICLE 13 

DISPUTE RESOLUTION 
  

	13.1	 Dispute Resolution; Escalation. The Parties recognize that disputes as to certain matters arising out of
or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by
mutual cooperation. To accomplish this objective, any and all disputes between the Parties arising out of or in connection with this Agreement (other than (a) matters within the purview of the JSC, which will be resolved in accordance with
Section 5.5 (Decision-Making; Escalation to Senior Officers) and (b) matters for which this Agreement expressly provides are subject to a Party’s discretion or sole decision-making authority), will first be referred to the Senior
Officers for resolution. The Senior Officers will attempt to resolve the matter in good faith. If the Senior Officers fail to resolve such matter within [***] Business Days after the date on which the matter is referred to the Senior Officers
(unless a longer period is agreed to by the Parties), then either Party may submit the dispute for final resolution by binding arbitration in accordance with Section 13.2 (Arbitration). 

 

	13.2	 Arbitration. Except as set forth in Section 12.5(c) (License Grant to Lyra) and this
Section 13.2 (Arbitration), each dispute, difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that cannot be resolved pursuant to
Section 13.1 (Dispute Resolution; Escalation) will be 

  
 51 

 
referred to and finally resolved by arbitration in accordance with the International Chamber of Commerce (the “Rules”) by an arbitral tribunal composed of three arbitrators, all
of whom will have previous judicial experience and significant experience in the biopharmaceutical industry, with each Party appointing one arbitrator and the third arbitrator to be selected by agreement of the two arbitrators appointed by the
Parties. If the two initial arbitrators are unable to select a third arbitrator within [***] days, then the third arbitrator will be appointed in accordance with ICC rules. The foregoing arbitration proceedings may be commenced by either Party by
notice to the other Party. Unless otherwise agreed by the Parties, all such arbitration proceedings commenced by (a) Lyra will be held in [***] and (b) by Lian will be held in [***]; provided, however, that proceedings may be
conducted by telephone or video conference call with the consent of the Parties and the arbitrators. All arbitration proceedings will be conducted in the English language. The arbitrators will consider grants of equitable relief and orders for
specific performance as co-equal remedies along with awards of monetary damages. The arbitrators will have no authority to award punitive damages. Each Party will pay its own expenses. The Parties hereby agree
that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrators deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and
judgment. All rulings by the arbitrators will be final. Notwithstanding any provision to the contrary set forth in this Agreement, any Party may seek equitable measures of protection in the form of attachment of assets or injunctive relief
(including specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of either Party from any court of competent jurisdiction, pending a decision by the arbitral tribunal in accordance with this
Section 13.2 (Arbitration). The Parties hereby exclude any right of appeal to any court on the merits of such matter. The provisions of this Section 13.2 (Arbitration) may be enforced and judgment on the award (including equitable
remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets. Except to the extent necessary to confirm an award or as may be required by Laws,
neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. The Parties agree that, in the event of a dispute over the nature or quality of performance under
this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. Nothing in this Section 13.2 (Arbitration) will preclude either Party from seeking interim or
provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the
interests of such Party or to preserve the status quo pending the arbitration proceeding. Notwithstanding the Parties’ agreement to arbitrate, unless the Parties agree in writing in any particular case, claims and disputes between the Parties
relating to or arising out of, or for which resolution depends in whole or in part on a determination of the interpretation, scope, validity, enforceability or infringement of, Patent Rights or of any Licensed Marks will not be subject to
arbitration under this Agreement, and the Parties may pursue whatever rights and remedies may be available to them under law or equity, including litigation in a court of competent jurisdiction, with respect to such claims and disputes. 

 

	13.3	 JURY WAIVER. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY
WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN SECTION 13.2 (ARBITRATION). THIS WAIVER APPLIES TO ANY ACTION
OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. 

  
 52 

 ARTICLE 14 

MISCELLANEOUS 
  

	14.1	 Assignment. 

  

	 	(a)	 General. This Agreement and the rights and obligations of each Party under this Agreement will not be
assignable, delegable, transferable, pledged or otherwise disposed of by either Party without the prior written consent of the other Party; provided, however, that either Party may assign or transfer this Agreement together with all of
its rights and obligations hereunder, without such consent (but with written notice to the other Party), (i) to an Affiliate or (ii) to a successor in interest in connection with the transfer or sale of all or substantially all of its business
or assets to which this Agreement relates, or in the event of its merger or consolidation, reorganization, or similar transaction. Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure
to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party. Any assignment or attempted assignment in violation of this Section 14.1 (Assignment) will be null and void.

  

	 	(b)	 Securitization. Notwithstanding anything to the contrary in Section 14.1(a) (General) or elsewhere
in this Agreement, Lyra may assign to a Third Party its right to receive the milestone payments and the royalty payments owed under Article 6 (Financial Provisions) (such assignment, a “Securitization Transaction”) without the prior
written consent of Lian. Further, in connection with a contemplated Securitization Transaction, subject to Section 8.1(c) (Confidentiality Limitation), Lyra may disclose to such Third Party certain Confidential Information of Lian (including a
redacted version of this Agreement and the royalty reports contemplated under Section 6.2(c) (Royalty Payments and Reports)) without the prior written consent of Lian, solely to the extent necessary to enable such Third Party to evaluate the
Securitization Transaction opportunity (provided that such Third Party is under obligations of confidentiality and non-use with respect to such Confidential Information that are no less stringent than
the terms of Article 8 (Confidentiality and Publicity)), and to allow such Third Party to exercise its rights under this Section 14.1(b) (Securitization). As part of any consummated Securitization Transaction, Lyra may assign, without the prior
written consent of Lian, its right to receive the royalty reports under Section 6.2(c) (Royalty Payments and Reports) to the counterparty in such Securitization Transaction. Notwithstanding anything to the contrary set forth in this Agreement,
if Lyra proposes to enter into a Securitization Transaction with a Third Party that is engaged in the Development, Manufacture, or Commercialization of pharmaceutical products that compete with any product of Lian, then any disclosure of Lian’s
Confidential Information to such Third Party will be subject to Lian’s prior written consent, not to be unreasonably withheld. 

  

	14.2	 Choice of Laws. This Agreement will be governed by and interpreted under the Laws of the State of New
York, without regard to the conflicts of law principles thereof. Except as otherwise expressly provided under this Agreement, any dispute, controversy, claim or difference of any kind whatsoever arising out of or in connection with this Agreement
will be resolved exclusively in accordance with Section 13.2 (Arbitration); provided, however, that all questions concerning (a) inventorship of Patent Rights under this Agreement will be determined in accordance with
Section 7.1 (Ownership of Intellectual Property) and (b) the construction or effect of Patent Rights will be determined in accordance with the Laws of the country, Region or other jurisdiction in which the particular patent within such
Patent Rights has been filed or granted, as the case may be. Any communication or proceedings resulting from disputes under this Agreement will be in English language. The Parties agree to exclude the application to this Agreement of the United
Nations Conventions on Contracts for the International Sale of Goods (1980). 

  
 53 

	14.3	 Notices. All notices that are required or permitted hereunder will be in writing and sufficient if
delivered by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, and in each case, addressed as follows (with a courtesy copy sent by email, which will not constitute
notice): 

  

			
	If to Lyra:	  	 [***].
 [***]

[***]
 Attention: [***]

Email: [***]

		
	With copies to:	  	 [***]
 [***]

[***]
 Attention: [***]

Email: [***]

		
	If to Lian or LianBio:	  	 [***]
 [***]

[***]
 [***]

[***]
 [***]

Attention: [***]
 Email: [***]

		
	With copies to:	  	 [***]
 [***]

[***]
 [***]

[***]
 Fax: [***]

Email: [***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. Any such notice will be deemed to have been given: (a) on [***] after dispatch if sent by internationally-recognized overnight courier; or (b) on the [***] after dispatch if sent by registered or certified
mail, postage prepaid, return receipt requested. 
  

	14.4	 Severability. In the event that one or more provisions of this Agreement is held invalid, illegal or
unenforceable in any respect, then such provision will not render any other provision of this Agreement invalid or unenforceable, and all other provisions will remain in full force and effect and will be enforceable, unless the provisions
that have been found to be invalid or unenforceable will substantially affect the remaining rights or obligations granted or undertaken by either Party. The Parties agree to attempt to substitute for any invalid or unenforceable provision a
provision which achieves to the greatest extent possible the economic objectives of the invalid or unenforceable provision. 

  
 54 

	14.5	 Integration. This Agreement, together with all schedules attached hereto, constitutes the entire
agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements between the Parties with respect to the subject matter hereof, whether written or oral, including, effective as of the
Effective Date, the Prior CDA and the Term Sheet (provided that, in each case, all information disclosed or exchanged under such agreement will be treated as Confidential Information hereunder). In the event of a conflict between the
Development Plans or any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern. Each Party confirms that it is not relying on any representations or warranties of
the other Party except as specifically set forth in this Agreement. 

  

	14.6	 Waivers and Amendments. The failure of any Party to assert a right under this Agreement or to insist
upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. The exercise by any Party of any right or
election under the terms or covenants herein will not preclude or prejudice any Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder.
Notwithstanding the authority granted to the JSC under this Agreement, (a) no waiver will be effective unless it has been given in writing and signed by the Party giving such waiver, and (b) no provision of this Agreement may be amended or
modified other than by a written document signed by authorized representatives of each Party. 

  

	14.7	 Independent Contractors; No Agency. Neither Party will have any responsibility for the hiring, firing or
compensation of the other Party’s or such other Party’s Affiliates’ employees or for any employee benefits with respect thereto. No employee or representative of a Party or its Affiliates will have any authority to bind or obligate
the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on such other Party, without such other Party’s written approval. For all purposes, and notwithstanding any other provision to
the contrary set forth in this Agreement, each Party’s legal relationship under this Agreement to the other Party will be that of independent contractor, and the relationship between the two Parties will not constitute a partnership, joint
venture, or agency, including for all tax purposes, except as otherwise required by applicable Law. 

  

	14.8	 Affiliates, Sublicensees, and Contractors. To the extent that this Agreement imposes obligations on
Affiliates, Sublicensees, or contractors of a Party, such Party will cause its Affiliates and its Sublicensees and contractors to perform such obligations, as applicable. Either Party may use one or more of its Affiliates, Sublicensees, or
contractors to perform its obligations and duties or exercise its rights under this Agreement, solely to the extent permitted and as specified in this Agreement; provided that (a) each such Affiliate, Sublicensee, or contractor will
perform any such obligations delegated to it in compliance with the applicable terms and conditions of this Agreement as if such Affiliate, Sublicensee, or contractor were a party hereto, (b) the performance of any obligations of a Party’s
by its Affiliates, Sublicensees, or contractors will not diminish, reduce, or eliminate any obligation of such Party under this Agreement, and (c) subject to such Party’s assignment to an Affiliate pursuant to Section 14.1
(Assignment), such Party will remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement. Subject to this Section 14.8 (Affiliates, Sublicensees, and Contractors), if a Party
exercises its rights and performs its obligations under this Agreement through one or more of its Affiliates, “Lyra” will be interpreted to mean “Lyra or its Affiliates” and “Lian” will be interpreted to mean “Lian
or its Affiliates” where necessary to give each Party’s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability to perform its obligations under this Agreement. 

 

  
 55 

	14.9	 Force Majeure. Neither Party will be held liable to the other Party nor be deemed to have defaulted
under or breached this Agreement for failure or delay in achieving any objective, satisfying any condition, or performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from acts or events beyond
the reasonable control of such Party, including acts of God, embargoes, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts, or other labor disturbances (other than strikes,
lockouts, or labor disturbances involving a Party’s own employees), government actions, fire, earthquakes, floods, epidemics, pandemics, the spread of infectious diseases, and quarantines (“Force Majeure”) and for so long as
such failure or delay continues to be caused by or result from such Force Majeure. The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date (including related government
orders) may not be invoked as a Force Majeure for the purposes of this Agreement, because the pandemic is ongoing and those effects may be reasonably foreseeable as of the Effective Date. Notwithstanding the foregoing, a Party will not be excused
from making payments owed hereunder due to any such Force Majeure circumstances affecting such Party. The affected Party will notify the other Party in writing of any Force Majeure circumstances as soon as reasonably practical, will provide a good
faith estimate of the period for which its failure or delay in performance under this Agreement is expected to continue based on currently available information, and will undertake reasonable efforts necessary to mitigate and overcome such Force
Majeure circumstances and resume normal performance of its obligations hereunder as soon a reasonably practicable under the circumstances. If the Force Majeure continues, then the affected Party will update such notice to the other Party on a weekly
basis to provide updated summaries of its mitigation efforts and its estimates of when normal performance under this Agreement will be able to resume. 

  

	14.10	 No Third Party Beneficiary Rights. The representations, warranties, covenants and agreements set forth
in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they will not be construed as conferring any rights on any other Third Party. This Agreement is not intended to and will not be construed to
give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, other than, to the extent provided in Article 10
(Indemnification; Damages), the Indemnified Parties. 

  

	14.11	 Non-exclusive Remedy. Except as expressly provided
herein, the rights and remedies provided herein are cumulative and each Party retains all remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief, with respect to any breach of this Agreement.

  

	14.12	 Interpretation. The Article and Section headings used herein are for reference and convenience only, and
will not enter into the interpretation of this Agreement. Except as otherwise explicitly specified to the contrary, (a) references to an Article, Section or Schedule means an Article or Section of, or a Schedule to this Agreement and all
subsections thereof, unless another agreement is specified; (b) references in any Section to any clause are references to such clause of such Section; (c) references to any agreement, instrument, or other document in this Agreement refer
to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto;
(d) references to particular Laws mean such Laws as in effect as of the relevant time, including all rules and regulations thereunder and any successor Laws in effect as of the relevant time, and including the then-current amendments thereto;
(e) words in the singular or plural form include the plural and singular form, respectively; (f) unless the context requires a different interpretation, the word “or” has the inclusive meaning that is typically associated with
the phrase “and/or”; (g) the terms “including,” “include(s),” “such as,” “e.g.” and “for example” mean including the generality of any description preceding such term and will be deemed to
be followed by “without limitation”; (h) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or
Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (i) “monthly” means on a calendar 

  
 56 

 
month basis; (j) “quarter” or “quarterly” means on a Calendar Quarter basis; (k) “annual” or “annually” means on a Calendar Year basis; (l)
“year” means a 365-day period unless Calendar Year is specified; (m) references to a particular Person include such Person’s successors and assigns to the extent not prohibited by this
Agreement; (n) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (o) a capitalized term not defined herein but
reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner; (p) any definition of or reference to any agreement, instrument or other document herein will be construed as
referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (q) the words
“hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any Schedules); (r) neither Party or its Affiliates will be deemed to be acting “on behalf of” the other Party
under this Agreement, except to the extent expressly otherwise provided; (s) provisions that require that a Party, or the JSC hereunder “agree”, “consent” or “approve” or the like will be deemed to require that
such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging; and
(t) the word “will” will be construed to have the same meaning and effect as the word “shall”. 
  

	14.13	 Further Assurances. Each Party will duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement (including working collaboratively to correct and
clerical, typographical, or other similar errors in this Agreement). 

  

	14.14	 Ambiguities; No Presumption. Each of the Parties acknowledges and agrees that this Agreement has been
diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed,
represents the joint efforts of the Parties hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement
or any such provision, and ambiguities, if any, in this Agreement will not be construed against any Party under the rule of construction, irrespective of which Party may be deemed to have authored the ambiguous provision. 

 

	14.15	 Export Control. This Agreement is made subject to any restrictions required by applicable Laws
concerning the export of products or technical information from the U.S. or other countries which may be imposed upon or related to the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technology
licensed to it or other technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other
governmental approval, except in compliance with U.S. export Laws and regulations. 

  

	14.16	 Execution in Counterparts; Electronic Signatures. This Agreement may be executed in counterparts, each
of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart.
Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. 

  
 57 

	14.17	 LianBio Guarantee. LianBio hereby [***] guarantees, [***], the due and punctual
payment and performance of all obligations of Lian under this Agreement (the “Lian Obligations”). LianBio agrees that the Lian Obligations may be extended, modified, or renewed, in whole or in part, without notice or further assent
from it, and that it will remain bound upon its guarantee notwithstanding any extension, modification, or renewal of any Lian Obligation. [***]. 

[Remainder of this page intentionally blank.] 
  

  
 58 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its
authorized representative under seal, in duplicate on the Effective Date. 
  

	
	LYRA THERAPEUTICS, INC.
	
	 /s/ Maria Palasis

	Name: Maria Palasis
	Title: President and CEO
	
	LIANBIO INFLAMMATORY LIMITED
	
	 /s/ Yizhe Wang

	Name: Yizhe Wang
	Title: CEO
	
	LIANBIO
	(solely for purposes of Sections 2.9(a) and 14.17 (LianBio Guarantee))
	
	 /s/ Yizhe Wang

	Name: Yizhe Wang
	Title: CEO

  

  
 [Signature Page to
License and Collaboration Agreement] 

 SCHEDULE 1.73 

LICENSED KNOW-HOW 

[***] 

 SCHEDULE 1.75 

LICENSED PATENTS 
 [***] 

 SCHEDULE 1.79 

LYR-210 PRODUCT 

[***]. 

 SCHEDULE 1.80 

LYR-220 PRODUCT 

[***].EX-10.17

 Exhibit 10.17 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 DATED MARCH 1, 2021 

 
  

CO-DEVELOPMENT AND LICENSE AGREEMENT 

 
  

BETWEEN 
 (1) REVIRAL
LIMITED 
 AND 

(2) LIANBIO RESPIRATORY LIMITED 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 1.
	 	DEFINITIONS AND INTERPRETATION.	  	 	3	 
			
	 2.
	 	LICENSES	  	 	18	 
			
	 3.
	 	EXCLUSIVITY	  	 	20	 
			
	 4.
	 	GOVERNANCE	  	 	21	 
			
	 5.
	 	DEVELOPMENT	  	 	23	 
			
	 6.
	 	REGULATORY	  	 	26	 
			
	 7.
	 	MANUFACTURE AND SUPPLY	  	 	29	 
			
	 8.
	 	COMMERCIALISATION	  	 	31	 
			
	 9.
	 	ECONOMICS	  	 	32	 
			
	 10.
	 	INTELLECTUAL PROPERTY	  	 	35	 
			
	 11.
	 	CONFIDENTIALITY	  	 	40	 
			
	 12.
	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	 	43	 
			
	 13.
	 	INDEMNITY AND INSURANCE COVER	  	 	47	 
			
	 14.
	 	TERM AND TERMINATION OF THE AGREEMENT	  	 	49	 
			
	 15.
	 	CHANGE OF CONTROL/ASSIGNMENT/SUCCESSION	  	 	53	 
			
	 16.
	 	GOVERNING LAW AND DISPUTES	  	 	53	 
			
	 17.
	 	MISCELLANEOUS	  	 	55	 

  

 This Co-Development and License Agreement dated as
of March 1, 2021 (“Effective Date”) is entered into between:- 
  

	 	(1)	 ReViral Ltd., a corporation organized under the laws of England & Wales with principal
offices at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Herts, SG1 2FX, United Kingdom (“ReViral”); and 

  

	 	(2)	 LianBio Respiratory Limited, a company limited by shares organized and existing under the laws of Hong
Kong Special Administrative Region of the People’s Republic of China, with its principal place of business at Room 1902, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong (“Licensee”), 

  ReViral and the Licensee sometimes being referred to in this Agreement as a “Party” or together the
“Parties.” 
 RECITALS 
  

	 	(A)	 ReViral owns or has the exclusive right to certain technology, intellectual property rights and confidential or
proprietary information relating to the Licensed Product (as defined below); 

  

	 	(B)	 ReViral is interested in granting to Licensee the exclusive rights to carry out development, registration and
commercialization of the Licensed Product in the Territory (as defined below); 

  

	 	(C)	 Licensee, together with its Affiliates (as defined below) (“Licensee Group”), are engaged in
the development and commercialization of pharmaceutical products in the Territory. 

 The Parties now agree as follows:

  

	 	1.	 DEFINITIONS AND INTERPRETATION. Unless the context clearly indicates otherwise, the
following terms used in this Agreement will have the meanings set forth in this Section 1. 

  

	1.1	 “Accounting Standards” means, with respect to a Person, generally accepted accounting
principles (“GAAP”) as practiced in the United States or applicable international standards followed by such Person, in either case, currently used at the relevant time and consistently applied by the applicable Person.

  

	1.2	 “Acquiror/Partner” shall have the meaning set forth in Section 3.1.

  

	1.3	 “Affiliates” shall mean an entity directly or indirectly Controlled by, Controlling or under
common Control with another entity, where “Control” means possession, directly or indirectly, of the power to direct or cause the direction of the activities, management and policies of the relevant entity and in the case of a corporate
entity shall include the holding of more than fifty percent (50%) of the share capital of the entity or the equivalent voting power or authority to elect more than fifty percent (50%) of the board of directors of such entity or the equivalent
management body. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the USA, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent
(50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 

 

	1.4	 “Agreement” shall mean this Co-Development and License
Agreement together with its attached Schedules. 

  

	1.5	 “Alliance Managers” shall have the meaning set forth in Section 4.1.

  
 3 

	1.6	 “Anti-Bribery Law” shall mean the US Foreign Corrupt Practices Act, UK Bribery Act 2010 and
any other applicable law, rule, regulation, or other legally binding measure of any jurisdiction that relates to bribery or corruption. 

  

	1.7	 “API” shall mean active pharmaceutical ingredient 

 

	1.8	 “Applicable Laws” shall mean all applicable provisions of all national, supranational
regional, state and local, laws, treaties, statutes, rules, regulations, directives, administrative codes, ordinances, decrees, orders, decisions, guidance documents, injunctions, awards, judgments, and permits of or from any court, arbitrator,
stock exchange or Competent Authority having jurisdiction over or related to the subject item. 

  

	1.9	 “Average Cost Per Patient” shall mean the average per patient cost in [***], as
established either (i) [***]; or (ii) [***]. 

  

	1.10	 “Breaching Party” shall have the meaning set forth in Section 14.3.

  

	1.11	 “Business Day” shall mean 9.00 am to 5.00 pm local time on a day other than a Saturday,
Sunday, bank or other public holiday in China, USA or U.K. 

  

	1.12	 “Calendar Quarter” shall mean each period of three months ending on 31 March,
30 June, 30 September or 31 December and “Quarterly” shall be construed accordingly. 

  

	1.13	 “Calendar Year” shall mean each successive period of twelve calendar (12) months
commencing on 1 January. 

  

	1.14	 “Central Global Trial Services” shall mean centralised services provided by ReViral or a CRO
in relation to the centres within a Global Clinical Trial, including (i) electronic case report form data capture; (ii) electronic imaging data capture; (iii) other data collection, data management and data analysis services; or
(iv) coordination of safety and pharmacovigilance reporting and GCP auditing. 

  

	1.15	 “Central Global Trial Costs” shall mean the costs incurred by ReViral for Central Global Trial
Services. 

  

	1.16	 “cGMP” shall mean all applicable current Good Manufacturing Practices as set forth in 21
C.F.R. Parts 4, 210, 211, 601, 610 and 820, and all equivalent Applicable Laws in any relevant country or region in the Territory, each as may be amended and applicable from time to time. 

 

	1.17	 “Change in Tax Law” shall mean any change in legislation, regulation, practice or procedure
that results in an obligation on Licensee to make a withholding in respect of tax on any amount payable to ReViral pursuant to the terms of this Agreement. 

  

	1.18	 “Change of Control” shall mean, with respect to a Party, the occurrence of a tender offer,
stock purchase, other stock acquisition, merger, consolidation, recapitalisation, reverse split, sale or transfer of assets or other transaction, as a result of which any person gains control (as defined in Section 1.3) of an entity or group.
[***]. 

  

	1.19	 “Clinical Trial” shall mean any clinical testing of a pharmaceutical product in human subjects
that is designed to generate data in support or maintenance of an IND or MAA, or other similar marketing application. 

  

	1.20	 “Clinical Trial Material” or “CTM” shall mean product in a form suitable for
administration to humans in a Clinical Trial manufactured in accordance with the Specifications and GMP as required by any IND and appropriately packaged and labelled. 

  
 4 

	1.21	 “CMO” shall mean a person that conducts contract manufacture on behalf of another person.

  

	1.22	 “Combination Product” shall mean any Licensed Product that is sold for a single invoice price
together with any (i) delivery device or component therefor, (ii) companion diagnostic related to any Product, process, service, or therapy, (iii) product, process, service, or therapy other than the Licensed Product; or
(iv) defined as a “combination product” by the FDA pursuant to 21 C.F.R. §3.2(e) (2) or (3) or its foreign equivalent. 

  

	1.23	 “Commercial Information” shall mean all information Controlled by a Party or its Affiliates
relating to the pricing, reimbursement, marketing, promotion or selling of the Licensed Product, including (i) commercialization plans, strategic and implementation; (ii) pharmaco-economic studies justifying pricing; (iii) analysis of
competitive products and environment including market research reports; (iv) product positioning strategies (including unique selling proposition and understanding of competitors’ positioning strategies) and promotional strategies
(including promotional materials); (v) Pricing Approval submissions and the content of bids for tenders; (vi) virtual product and clinical support approaches and techniques via web page; (vii) medical education strategies; and
(viii) strategies used for building relationships with health insurance and managed care entities. 

  

	1.24	 “Commercialise” or “Commercialisation” shall mean any and all activities
directed to marketing, promoting, detailing, importing, distributing, warehousing, offering for sale, having sold, selling, or other commercialisation of a pharmaceutical product, including market research,
pre-launch marketing and educational activities, and sampling. 

  

	1.25	 “Commercialisation Plan” shall mean a [***] plan for the Commercialisation of the Licensed
Product in the Territory, that may include: (i) [***]; (ii) [***]; (iii) [***], (iv) [***]; (v) [***]; and (vi) other activities as the Parties shall agree should be included in the plan. 

 

	1.26	 “Commercially Reasonable Efforts” shall mean, in respect of a Party, [***].

  

	1.27	 “Competent Authority” shall mean any supranational, national or local parliament, commission,
department or agency, authority (including a listing authority in relation to a stock exchange), inspectorate, minister, ministry official, or other public or statutory person (whether autonomous or not) passing or enforcing Laws relevant to the
activities contemplated under this Agreement. 

  

	1.28	 “Competitive Activities” shall have the meaning set forth in Section 3.1.

  

	1.29	 “Competitive Product” shall mean [***]. 

 

	1.30	 “Composition of Matter Claim” shall mean a Valid Claim of a Licensed Patent in a given country
of the Territory that Covers the API of the Licensed Product as opposed to its process of manufacture (including formulation), use or method of treatment. 

  

	1.31	 “Compound” shall mean (i) ReViral’s proprietary compound, sisunatovir
(RV521), having the chemical structure described on Exhibit A, (ii) other fusion inhibitor candidates that (a) are Covered by Patents owned or Controlled by ReViral or any of its Affiliates as of the Effective Date or during the
Term that Cover RV521 or (iii) any other fusion inhibitor candidates used by ReViral in a product Developed in the ReViral Program, and all of the foregoing compounds and candidates (“RSV Candidates”). The RSV Candidates that
are the subject of the ReViral Program as of the Effective Date are listed in Exhibit B. Upon receipt of the first Marketing Authorization of a Licensed Product in PRC, this definition will mean only the Compound contained in the Licensed
Product so authorized. 

  

	1.32	 “Confidential Information” shall mean, with respect to a Party, all Know How or other
information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s technology, products, business information, or objectives, that is communicated by or on behalf of such Party (the
“Disclosing Party” with respect to such information) to the other Party (the “Recipient Party” with respect to such information) or its permitted recipients, including information disclosed by such Party prior to
the Effective Date pursuant to the Confidentiality Agreement, and including: 

  
 5 

	 	1.32.1    the	 terms and conditions of this Agreement; 

 

	 	1.32.2    the	 Licensed Know How; 

  

	 	1.32.3    the	 Licensee Know How, and 

 

	 	1.32.4	 any other non-public information disclosed or provided by one Party to
the other Party in connection with this Agreement, including information regarding such Party’s strategy, business plans, objectives, research, technology, products, business affairs or finances including any Commercialization Information.

  

	1.33	 “Control” (including variations such as “Controlled” and except as used in
Section 1.3) shall mean with respect to any Know How, Patent, Trademark, Regulatory Document, Regulatory Approval, other property right, or product, possession of the right, whether directly or indirectly, and whether by ownership, licence or
otherwise, to assign, or grant a licence, sublicense or other right to or under, such Know How, Patent, Trademark, Regulatory Document, Regulatory Approval, other property right, or product, without breaching the terms of any agreement with a Third
Party. 

  

	1.34	 “Cost of Manufacture” shall mean, with respect to any Licensed Product, the total cost of
manufacture, calculated in accordance with applicable Accounting Standards, which will be the sum of Direct Cost, Indirect Cost and Expensed Cost as defined below and as relevant to the circumstances. 

 

	 	1.34.1    “Direct	 Costs” within Cost of Manufacture include: 

 

	 	(i)	 [***]; 

  

	 	(ii)	 [***], plus [***]; and 

 

	 	(iii)	 [***]. 

  

	 	1.34.2    “Indirect	 Costs” within Cost of Manufacture include: 

 

	 	(i)	 [***]; and 

  

	 	(ii)	 [***]; 

  

	 	in	 each case, ((i) and (ii)), to the extent [***] allocable to the Manufacture of any Licensed Product (or any
component thereof). 

  

	 	Indirect	 Costs expressly exclude [***]. 

 

	 	1.34.3	 “Expensed Cost” within Cost of Manufacture includes [***]. For clarity, Expensed Cost may
include [***]. 

  

	1.35	 “Cover,” “Covering” or “Covered” means, with respect to a
particular subject matter at issue and a relevant Patent or individual claim in such Patent, as applicable, that the manufacture, use, sale, offer for sale, or importation of such subject matter would fall within the scope of one or more claims in
such Patent or the individual claim of such Patent. 

  

	1.36	 “CRO” shall mean a contract research organization to which certain Development services are
contracted. 

  
 6 

	1.37	 “CTD Format” shall mean the format of a common technical document recommended by ICH from time
to time. 

  

	1.38	 “Departing Licensee” shall have the meaning set forth in Section 15.2.

  

	1.39	 “Development (and the corresponding verb “to Develop”)” shall mean all
nonclinical, pre-clinical and clinical research and development activities, whether before or after Regulatory Approval, conducted with the aim of supporting, obtaining, or maintaining Regulatory Approval of a
Licensed Product, including: 

  

	 	(i)	 studies on the toxicological, pharmacological, metabolical or clinical aspects of a product conducted
internally or by individual investigators or consultants; and 

  

	 	(ii)	 preparing, submitting, reviewing or developing data or information for the purpose of submission to a
Regulatory Authority to obtain, maintain, or expand Regulatory Approval of a product, including data management, statistical designs and studies, document preparation, and other administration. 

Development will not include Commercialization activities or Manufacturing. 

 

	1.40	 “Development Costs” shall mean the total costs and expenses associated with Development
activities for the Licensed Product in the Territory, calculated in accordance with applicable Accounting Standards, and shall include (i) [***]; (ii) [***]; (iii) [***]; (iv) [***]; and (v) [***]. 

 

	1.41	 “Disclosing Party” shall have the meaning set forth in Section 1.32.

  

	1.42	 “Disclosure Letter” shall mean a disclosure letter in the form of Exhibit C.

  

	1.43	 “Documents” shall mean analyses, books, CD-ROM,
charts, comments, computations, designs, discs, diskettes, files, graphs, ledgers, notebooks, paper, photographs, plans, records, recordings, reports, research notes, tapes and any other graphic or written data or other media on which information
and data is permanently stored and other computer information storage means, and advertising and promotional materials of any nature whatsoever including preparatory materials for the same. 

 

	1.44	 “Dossier” shall mean a dossier for the Licensed Product in a country in CTD Format and as
registered with a Regulatory Authority for the Regulatory Approval containing the administrative, safety, efficacy, quality, non-clinical and clinical data and chemistry and manufacturing control data for the
Licensed Product as it may change from time to time. 

  

	1.45	 “Effective Date” shall have the meaning set forth in the Preamble. 

 

	1.46	 “EMA” shall mean the European Medicines Agency. 

 

	1.47	 “EU” shall mean the countries of the European Union from time to time, which are as of the
Effective Date Austria, Belgium, Bulgaria, Cyprus, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia,
Slovenia, Spain and Sweden. 

  

	1.48	 “Europe” shall mean that group of countries comprised of the EU plus (if they are not Member
States) Iceland, Liechtenstein, Norway and Switzerland. 

  

	1.49	 “FDA” shall mean the Food and Drug Administration of USA. 

  
 7 

	1.50	 “Exploit” shall mean to Develop, have Developed, make, have made, use, have used, offer for
sale, have offered for sale, sell, have sold, export, have exported, import, have imported, Manufacture, have Manufactured, Commercialize or have Commercialized. “Exploitation” and “Exploiting” will be construed
accordingly. 

  

	1.51	 “Field” shall mean (i) all uses and indications for the treatment, diagnosis, or
prevention of infections, diseases, or conditions caused by or associated with RSV, (ii) any other uses that involve, or indications that are treated, diagnosed or prevented by, targeting RSV, as a method of treatment or action and
(iii) any other uses or methods of treatment claimed in the Licensed Patents. 

  

	1.52	 “Final Report” shall mean the formal written report in relation to a Clinical Trial setting
out the final results and conclusions of such Clinical Trial. 

  

	1.53	 “First Commercial Sale Date” shall mean on a Licensed Product-by- Licensed Product and country-by-country or
region-by-region of the Territory basis, the first sale by Licensee or its Affiliates or Sublicensees to an end user or prescriber for use, consumption or resale of such
Licensed Product in a country or region in the Territory in the Field where Regulatory Approval and, if applicable, any Pricing Approval of the Licensed Product has been obtained and where the sale results in a recordable Net Sale. For avoidance of
doubt, any supply of Licensed Product for Clinical Trials or on a named patient or under compassionate or emergency use, expanded access program, patient assistance, pre-license sales made for non-commercial, compassionate purposes, or test marketing programs or other similar programs or studies where a Licensed Product is supplied at or below cost of goods therefor is not a First Commercial Sale.

  

	1.54	 “First Global Trial” shall mean the first Global Clinical Trial to be conducted after
the Effective Date under the Global Development Plan, the full Clinical Trial protocol for which will be prepared by ReViral for consideration and discussion at JSC. 

 

	1.55	 “FTO Issue” shall have the meaning set forth in Section 10.4.1.

  

	1.56	 “GAAP” shall mean generally accepted accounting principles in effect in the USA from time to
time. 

  

	1.57	 “GCP” means all applicable Good Clinical Practice standards for the design, conduct,
performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, as conducted within or outside the Territory, including, as applicable (a) as set forth in the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other applicable guidelines for good clinical practice for trials on medicinal products, (b) the
Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) 21 C.F.R. Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards)
and 312 (Investigational New Drug Application), as may be amended from time to time, and (d) the equivalent Applicable Laws in the Territory, each as may be amended and applicable from time to time and in each case, that provide for, among
other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity and confidentiality of trial subjects. 

 

	1.58	 “Generic Product” shall mean in any particular country [***]. 

 

	1.59	 “Global Brand Elements” shall have the meaning set forth in Section 10.6.2.

  

	1.60	 “Global Clinical Trial” means a Clinical Trial that is conducted in multiple countries and
jurisdictions, both in and outside the Territory, through the conduct of such Clinical Trial in multiple sites in such countries and jurisdiction as part of one unified Clinical Trial or separately but concurrently in accordance with a common
Clinical Trial protocol. 

  
 8 

	1.61	 “Global Development Plan” shall have the meaning set forth in Section 5.1.

  

	1.62	 “GLP” means all applicable Good Laboratory Practice standards, including, as
applicable, as set forth in the then current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration as defined in 21 C.F.R. Part 58, or the equivalent Applicable Laws in the country or region in the
Territory, each as may be amended and applicable from time to time. 

  

	1.63	 “Good Manufacturing Practice” or “GMP”—means all applicable standards
relating to manufacturing practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical products, for supply in a given country or group of countries including: 

 

	 	1.63.1	 in the case of the EU, Directive 2003/94/EC or any other applicable European Community legislation or
regulation; 

  

	 	1.63.2	 in the case of USA, the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts
210, 211, 601 and 610; and the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products; and 

 

	 	1.63.3	 the principles detailed in the ICH Q7A guidelines; and 

 

	 	1.63.4	 the equivalent Applicable Laws in any other countries. 

 

	 	each	 as may be applicable and as amended from time to time. 

 

	1.64	 “ICC” shall have the meaning set forth in Section 16.3. 

 

	1.65	 “ICH” shall mean the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use. 

  

	1.66	 “IND” shall mean an investigational new drug application filed with, and accepted by, the FDA
prior to beginning clinical trials in humans in the USA, or any comparable application (such as an application for a clinical trial authorization in the Territory) to the Regulatory Authority of a region, country or group of countries other than the
USA thereto including the NMPA prior to beginning clinical trials in humans in that country or in that group of countries, and all supplements or amendments that may be filed with respect to the foregoing. 

 

	1.67	 “Indemnification Claim Notice” shall have the meaning set forth in Section 13.3.

  

	1.68	 “Indemnified Party” shall have the meaning set forth in Section 13.3.

  

	1.69	 “Indemnifying Party” shall have the meaning set forth in Section 13.3.

  

	1.70	 “Indemnitee” shall have the meaning set forth in Section 13.3. 

 

	1.71	 “Indication” means a separate and distinct disease, disorder, or medical condition that a
Licensed Product is intended to treat, prevent, cure, or ameliorate in the indication section of the approved labeling for such Licensed Product, or that is the subject of a Clinical Trial and where it is intended that the data and results of such
Clinical Trial (if successful) will be used to support a Regulatory Documents and Regulatory Approval that is intended to result in distinct labeling in the indication section of the approved labeling relevant to usage of such Licensed Product in
such disease, disorder, or medical condition that is separate and distinct from another disease, disorder, or medical condition. 

  

	1.72	 “Insolvency Event” shall mean, in relation to either Party, any one of the following:

  
 9 

	 	1.72.1	 a notice having been issued to convene any meeting for the purpose of passing a resolution or seeking a
petition to wind up or liquidate that Party, or to seek bankruptcy or official administration, or such a resolution having been passed or such a petition having been issued (except in relation to a solvent reconstruction or reorganisation of that
Party); 

  

	 	1.72.2	 an involuntary petition in an insolvency proceeding is filed against a Party and is not dismissed or stayed
within ninety (90) days of the filing thereof; 

  

	 	1.72.3	 a trustee in bankruptcy, receiver, administrative receiver, receiver and manager, court appointed receiver,
interim receiver, custodian, sequestrator or similar officer is appointed in respect of that Party or over any part of that Party’s assets or any third party takes steps to appoint such an officer in respect of that Party; or

  

	 	1.72.4	 a Party makes any general assignment for the benefit of all or some of that Party’s creditors.

  

	1.73	 “Interim Report” shall mean a written report that contains an initial analysis of the results
of a Clinical Trial that is completed and the data from which has been collated and analysed and, in particular that includes a report as to whether and to what extent the endpoints of the Clinical Trial have been met, but which report is not the
Final Report and precedes the Final Report. 

  

	1.74	 “Inventions” shall mean any inventions for composition of matter, processes of manufacture,
methods of treatment or use, methods of modulation, formulations, dosing regimens, formulations and combinations, patentable or otherwise, that is invented or generated as a result of or in connection with a Party exercising its rights or carrying
out its obligations under this Agreement, whether directly or via its Affiliates, Sublicensees, agents or contractors. 

  

	1.75	 “Jointly Owned Inventions” shall have the meaning set forth in Section 10.1.2.

  

	1.76	 “JSC” shall mean the joint steering committee established under Section 4.1.

  

	1.77	 “Know How” means all proprietary chemical and biological materials and other tangible
materials, inventions, practices, methods, protocols, formulae, knowledge, know-how, trade secrets, processes, procedures, assays, skills, experience, techniques, information, data and results of
experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical and quality control data, whether patentable or otherwise. 

 

	1.78	 “Knowledge” shall mean a Party’s and its Affiliates’ understanding in good faith as
possessed by its senior executive management of the relevant facts and information after performing a diligent investigation with respect to such facts and information, provided that diligent investigation shall only include those patent
searches to investigate validity or freedom to operate that have actually been undertaken by that Party or its Affiliates prior to the Effective Date. 

  

	1.79	 “Law” or “Laws” shall mean all laws, statutes, regulations, directives,
ordinances, judgments, guidances, recommendations, orders or injunctions. 

  

	1.80	 “LianBio” shall mean LianBio, an exempted company organized and existing under the laws of
Cayman Islands. 

  

	1.81	 “License” shall have the meaning set forth in Section 2.1. 

 

	1.82	 “Licensed IPR” shall mean: 

 

	 	1.82.1	 Licensed Patents; 

  
 10 

	 	1.82.2	 Licensed Know How; 

  

	 	1.82.3	 Regulatory Documents (including Dossiers for any country outside the Territory); and 

 

	 	1.82.4	 the ReViral Trademark. 

 

	1.83	 “Licensed Know How” shall mean all Know How reasonably useful or necessary for the
Exploitation of the Licensed Product that is Controlled by ReViral or any of its Affiliates as of the Effective Date or is generated or arising under the ReViral Program or is actually used in the ReViral Program by ReViral or any of its Affiliates
or its or their licensees during the Term, including ReViral’s interest in the Know How within the Jointly Owned Inventions, and all Commercial Information Controlled by ReViral or its Affiliates. 

 

	1.84	 “Licensed Patents” shall mean all Patents that Cover the Development, Manufacture or
Commercialization of the Licensed Product or that otherwise Cover any Licensed Know How, in each case, that are Controlled by ReViral or any of its Affiliates as of the Effective Date or during the Term, including Patents within the ReViral
Inventions and [***], and including the patents and patent applications existing in the Territory at the Effective Date listed in Exhibit D (the “Patent List”). 

 

	1.85	 “Licensed Product” shall mean any product containing a Compound in any formulation or
dosage form [***]. 

  

	1.86	 “Licensee” shall have the meaning set forth in the Preamble. 

 

	1.87	 “Licensee Commercial Information” shall mean Commercial Information Controlled by
Licensee or its Affiliates relating to the Commercialization of the Licensed Product in the Territory. 

  

	1.88	 “Licensee Group” shall have the meaning set forth in the Recitals. 

 

	1.89	 “Licensee Indemnitee” shall have the meaning set forth in Section 13.2.

  

	1.90	 “Licensee IPR” means the intellectual property and other rights at any time during the Term
Controlled by Licensee or its Affiliates relating to the Licensed Product including: 

  

	 	1.90.1	 Licensee Patents, if any; 

 

	 	1.90.2	 Licensee Know How; and 

 

	 	1.90.3	 Regulatory Documents (including the Territory Dossiers). 

 

	1.91	 “Licensee Know How” shall mean any Know How Controlled by Licensee or its Affiliates generated
or arising during the conduct of activities under this Agreement relating to the Development or Commercialization of the Licensed Product in the Territory, including Licensee’s interest in the Know How within the Jointly Owned Inventions.

  

	1.92	 “Licensee Patents” shall mean any Patents that Cover Inventions owned by Licensee or its
Affiliates pursuant to Section 10.1.2. including Licensee’s interest in any Patents Covering Jointly Owned Inventions. 

  

	1.93	 “Licensee Shortfall” has the meaning set forth in Section 5.3. 

 

	1.94	 “Licensee Trademark” shall have the meaning set forth in Section 10.6.4.

  

	1.95	 “Losses” shall mean any and all losses, damages, liabilities, costs and expenses (including
reasonable attorneys’ fees and expenses). In calculating “Losses”, [***]. 

  
 11 

	1.96	 “Major Markets” shall mean the [***]. 

 

	1.97	 “Manufacture” shall mean all manufacturing operations for products, including all activities
related to the making, production, processing, purifying, formulating, filling, and finishing, of the Licensed Product, or any intermediate thereof including API, pre-clinical, clinical and commercial
production, product stability testing, quality assurance, and quality control. “Manufacturing” has a correlative meaning. 

  

	1.98	 “Manufacturing and Supply Agreement” shall have the meaning set forth in
Section 7.2. 

  

	1.99	 “Manufacturing Know How” shall mean all Know How owned or Controlled by ReViral that is
necessary or reasonably useful for the Manufacture of the Licensed Product, including (i) production facilities and processes including any drug master file, specifications, techniques, manufacturing line procedures, chemistry and manufacturing
control data, standard operating procedures, quality analysis, and quality control processes and techniques, and all other documentation retained to comply with GMP procedures; and (ii) information relating to contract manufacturers and the
Manufacturing supply chain of the Licensed Product, including API, fill finish, primary and secondary packaging. 

  

	1.100	 “Marketing Authorization Application” or “MAA” means any new drug
application, biologics license application, or other marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially
market or sell a pharmaceutical or biologic product in such country or jurisdiction (and any amendments thereto). In the context of imported drugs, MAA is also known as the Import Drug License (“IDL”) application.

  

	1.101	 “Net Sales” shall mean the gross amount invoiced by Licensee, its Affiliates, Sublicensees
(excluding distributors) for sale of Licensed Products to third parties (including distributors), less the following deductions relating to the Licensed Products as determined in accordance with the relevant Accounting Standards, in each case
without duplication: normal and customary trade, cash and quantity discounts [***], credits, price adjustments, repayments, chargebacks, or allowances for claims, spoiled, outdated, or damaged products, returns or rejections of Licensed Products,
including in connection with retroactive price reductions and recalls [***] or withdrawal; 

  

	 	1.101.1 	 [***]; 

  

	 	1.101.2 	 [***]; 

  

	 	1.101.3 	 [***]; 

  

	 	1.101.4 	 [***]; 

  

	 	1.101.5 	 [***]; 

  

	 	1.101.6 	 [***]; and 

  

	 	1.101.7 	 [***]. 

The transfer of Licensed Product by the Licensee or one of its Affiliates to another Affiliate or Sublicensee shall not be considered a sale.

 [***]. 
 In the event a
Licensed Product is sold as a Combination Product, Net Sales of the Combination Product will be calculated, on a country-by-country basis, as follows: 

  
 12 

 (i) If the Compoundand the other product(s) are also sold separately in the applicable
country, Net Sales of the Licensed Product for purposes of this Agreement will be calculated by multiplying the total Net Sales of the Combination Product by the fraction A/(A+B), where A is the invoice price in the applicable country of the
Compound sold separately, and B is the sum of the invoice prices in the applicable country of all other products in the Combination Product sold separately during the applicable Calendar Quarter. 

(ii) If the Compound is sold separately, but the invoice price of the other product(s) cannot be determined, Net Sales of the Licensed Product
for purposes of this Agreement shall be equal to the total Net Sales of the Combination Product multiplied by the fraction A/C wherein A is the invoice price of the Compound sold separately and C is the invoice price of the Combination Product, in
both cases in the Calendar Quarter in question. 
 (iii) If the other product(s) is/are sold separately, but the invoice price of the
Compound cannot be determined, Net Sales of the Licensed Product for purposes of this Agreement shall be equal to the total Net Sales of the Combination Product multiplied by the following formula: one (1) minus B/C wherein B is the invoice
price of the other product(s) and C is the invoice price of the Combination Product, in both cases in the Calendar Quarter in question. 

(iv) If the invoice price of neither the Compound nor the other product(s) can be determined, Net Sales of the Licensed Product for purposes
of this Agreement shall be equal to Net Sales of the Combination Product multiplied by [***]. 
 (v) The invoice price for such other
product(s) contained in the Combination Product shall be calculated for each Year by dividing the sales amount by the units of such other product(s), as published by IMS or another independent source agreed by the Parties. In the initial calendar
year during which a Combination Product is sold, forecasted invoice prices shall be used for royalty calculation purposes. [***]. 
  

	1.102	 “New License Agreement” shall have the meaning set forth in Section 14.6.3.

  

	1.103	 “NMPA” shall mean the National Medical Products Administration (formerly the China Food and
Drug Administration). 

  

	1.104	 “NDA” shall mean a new drug or biologic license application filed with the FDA to obtain
Regulatory Approval for a pharmaceutical product in the USA, or any equivalent application filed with the Regulatory Authority in or for a country or group of countries outside the USA to obtain Regulatory Approval for a pharmaceutical product in or
for that country or within that group of countries. 

  

	1.105	 “Non-Breaching Party” shall have the meaning set forth
in Section 14.3. 

  

	1.106	 “Notice of Rejection” shall have the meaning set forth in Section 7.2.4.

  

	1.107	 “Official” shall have the meaning set forth in Section 12.3.1. 

 

	1.108	 “Pharmacovigilance Agreement” shall have the meaning set forth in Section 6.7.

  

	1.109	 “Party” or “Parties” shall have the meaning set forth in the Preamble.

  

	1.110	 “Patents” shall mean: 

 

	 	1.110.1	 all national, regional and international patents and patent applications, including provisional patent
applications; and 

  
 13 

	 	1.110.2 	 all patent applications filed either from such patents, patent applications or provisional applications or from
an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued
prosecution applications; and 

  

	 	1.110.3 	 any and all patents that have issued or in the future issue from the foregoing patent applications in Sections
1.110.1 and 1.110.2 including author certificates, inventor certificates, utility models, petty patents and design patents and certificates of invention; and 

  

	 	1.110.4 	 any and all extensions or restorations by existing or future extension or restoration mechanisms, including
revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications in Sections 1.110.1 to 1.110.3
inclusive, and 

  

	 	1.110.5 	 any similar rights, including so-called pipeline protection (where the
subject matter previously disclosed was not previously patentable in a particular jurisdiction but subsequently becomes patentable subject matter in such jurisdiction), or any importation, revalidation, confirmation or introduction patent or
registration patent or patent of additions to any such foregoing patent applications and patents, and any other substantially equivalent form of government issued right substantially similar to any of the foregoing described in subsections 1.110.1
through 1.110.5, anywhere in the world. 

  

	1.111	 “Patient Commitment” shall have the meaning set forth in Section 5.3.

  

	1.112	 “Payment” shall have the meaning set forth in Section 9.13. 

 

	1.113	 “Person” shall mean an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organisation, including a government or political subdivision, department
or agency of a government. 

  

	1.114	 “Phase II Clinical Trial” means a Clinical Trial that is intended to explore the feasibility,
safety, dose ranging, or efficacy of a pharmaceutical product that is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial for such product, in a manner that is generally consistent with 21 C.F.R.
§ 312.21(b), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. 

 

	1.115	 “Phase III Clinical Trial” means a Clinical Trial (or any arm thereof) of a pharmaceutical
product on a sufficient number of patients, which trial is designed to: (i) establish that the pharmaceutical product is safe and efficacious for its intended use; (ii) define warnings, precautions and adverse reactions that are associated
with the pharmaceutical product in the dosage range to be prescribed; and (iii) support a Regulatory Approval by a Regulatory Authority for the pharmaceutical or biologic product, and that satisfies the requirements of U.S. federal regulation
21 C.F.R. § 312.21(c) and its successor regulation or equivalents in other jurisdictions. 

  

	1.116	 “Pivotal Global Clinical Trial” means a Global Clinical Trial that is a Phase III Clinical
Trial. 

  

	1.117	 “PRC” means the People’s Republic of China, which, for the purposes of this Agreement,
excludes Hong Kong, Macau and Taiwan. 

  

	1.118	 “Pricing Approval” shall mean (i) such approval, agreement, determination or governmental
decision establishing prices for a product that can be charged and will be reimbursed by Competent Authorities in countries in the Territory where Competent Authorities or Regulatory Authorities of such country approve or determine pricing for
pharmaceutical products for reimbursement or otherwise; and (ii) a price established in a supply contract with a governmental authority or hospital owned or controlled by the state following a tender process. 

  
 14 

	1.119	 “Product Infringement” shall have the meaning set forth in Section 10.3.1.

  

	1.120	 “Pediatric Target Profile” or “PTP” shall mean the target
profile to be determined [***] based on the draft set out in Exhibit E. 

  

	1.121	 “Recipient Party” shall have the meaning set forth in Section 1.32.

  

	1.122	 “Regulatory Approval” shall mean any final or conditional approval from a Regulatory Authority
necessary to market and sell a pharmaceutical product in any country or region of the Territory, but excluding any Pricing Approval for such country or region. 

 

	1.123	 “Regulatory Authority” shall mean any Competent Authority in any country of the Territory with
authority over the clinical development, Manufacture, marketing or sale of the Licensed Product, including the NMPA in the PRC. 

  

	1.124	 “Regulatory Documents” means any documentation comprising or relating to or supporting any
regulatory application, submission, notification, communication, correspondence, registration, approval and other filings made to, received from or otherwise conducted with a Regulatory Authority regarding the Licensed Products, including any IND or
MAA. 

  

	1.125	 “Regulatory Exclusivity” shall mean, with respect to a Licensed Product in a country or region
in the Territory, any exclusive marketing rights or data exclusivity rights under Applicable Laws or conferred by any Regulatory Authority in accordance with Applicable Laws with respect to such Licensed Product in such country or region.

  

	1.126	 “Relevant Material” shall have the meaning set forth in Section 16.3.4.

  

	1.127	 “Relevant Third Party Patent Right” shall mean a Patent owned or Controlled by a Third Party
that contains claims that Cover the Licensed Product in a country or region whether outside the Territory or in the Territory, or the Development, Manufacture or Commercialization thereof. 

 

	1.128	 “Remedial Action” shall have the meaning set forth in Section 6.9. 

 

	1.129	 “ReViral” shall have the meaning set forth in the Preamble. 

 

	1.130	 “ReViral Indemnitee” shall have the meaning set forth in Section 13.1.

  

	1.131	 “ReViral Program” shall mean the Development program being conducted by ReViral or its
Affiliates at the Effective Date or during the Term for [***]. 

  

	1.132	 “Representative” shall have the meaning set forth in Section 11.1. 

 

	1.133	 “Residual Knowledge” shall have the meaning set forth in Section 11.9

  

	1.134	 “ReViral Trademark” shall mean a trademark for the Licensed Product to be determined by
ReViral and any accompanying logos relating to the Licensed Product owned or Controlled by ReViral, either in English or Chinese. 

  

	1.135	 “Royalty Term” shall mean, on a Licensed Product-by-Licensed Product and country-by-country or
region-by-region basis, as applicable, the period that is from the First Commercial Sale Date until on the later to occur of: 

  
 15 

	 	(a)	 the expiration of the
last-to-expire Valid Claim of a Licensed Patent that is a Composition of Matter Claim in such country or region of the Territory; 

 

	 	(b)	 the expiry of Regulatory Exclusivity for the Licensed Product in such country or region; and

  

	 	(c)	 the [***] anniversary of the First Commercial Sale Date of such Licensed Product in such country or region in
the Territory. 

  

	1.136	 “RSV” shall mean respiratory syncytial virus. 

 

	1.137	 “Senior Officers” shall have the meaning set forth in Section 4.6.

  

	1.138	 “Specification” shall mean the specifications for the Licensed Product, as determined by the
JSC. 

  

	1.139	 “Subcontractor” shall mean a Third Party contractor (including contract research organizations
or contract manufacturing organizations) engaged by a Party on a fee-for-service to perform certain obligations of such Party or exercise certain rights on behalf of
such Party, in each case, under this Agreement. 

  

	1.140	 “Sublicensee” means any Third Party to whom a Party or any of its Affiliates grants a
sublicense of its rights hereunder to Exploit any Licensed Product. 

  

	1.141	 “Term” shall mean the period commencing on the Effective Date and, unless earlier terminated
in accordance with this Agreement, expiring country-by-country of the Territory at the end of the Royalty Term in such country. 

 

	1.142	 “Terminated Region” means any region or country in the Territory with respect to which this
Agreement is terminated or, if this Agreement is terminated in its entirety, all countries and regions of the Territory. 

  

	1.143	 “Territory” shall mean PRC, Macau, Hong Kong, and Singapore. 

 

	1.144	 “Territory Dossier” shall mean the Dossier for any country in the Territory.

  

	1.145	 “Territory-Specific Development Plan” shall have the meaning set forth in Section 5.1.

  

	1.146	 “Territory-Specific Supply” shall have the meaning set forth in Section 7.1.

  

	1.147	 “Third Party” shall mean a Person other than either of the Parties or any of their respective
Affiliates. 

  

	1.148	 “Third Party Claim” shall have the meaning set forth in Section 13.3.

  

	1.149	 “Trademarks” shall mean registered trade-marks and applications thereof, unregistered trade or
service marks, get up and company names in each case with any and all associated goodwill and all rights or forms of protection of a similar or analogous nature including rights that protect goodwill. 

 

	1.150	 “Valid Claim” shall mean, with respect to a particular country or region, either:

  

	 	1.150.1 	 a claim of an issued and unexpired Patent in such country or region whose validity, enforceability, or
patentability has not been terminated by any of the following: (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer, or (ii) a holding, finding or decision of invalidity, unenforceability or non-patentability by a court or other governmental agency of competent jurisdiction, unappealable or un-appealed within the time allowed for appeal; or 

  
 16 

	 	1.150.2 	 a claim of a pending Patent application, which claim was filed and is being prosecuted in good faith and has
not been abandoned or finally disallowed without the possibility of appeal or refiling of the application, provided that no more than [***] have passed since the earliest priority date for such application. 

 

	1.151	 “Visual Inspection” shall have the meaning set forth in Section 7.2.5.

  

	1.152	 “Year” shall mean each complete calendar year following the First Commercial Sale Date
in any country of the Territory. 

  

	1.153	 In this Agreement: 

  

	 	1.153.1 	 the table of contents and headings are inserted for convenience only and shall not affect the interpretation of
any provision of this Agreement; 

  

	 	1.153.2 	 unless the context otherwise requires all references to a particular Section, paragraph or Schedule shall be a
reference to that Section, paragraph or Schedule, in or to this Agreement as it may be amended from time to time pursuant to this Agreement; 

  

	 	1.153.3 	 unless the contrary intention appears words importing the masculine gender shall include the feminine and vice
versa and words in the singular include the plural and vice versa; 

  

	 	1.153.4 	 unless the contrary intention appears words denoting persons shall include any individual, partnership,
company, corporation, joint venture, trust, association, organisation or other entity, in each case whether or not having separate legal personality and that person’s legal representatives, successors and permitted assigns;

  

	 	1.153.5 	 the words “include” or “including” will be deemed to be followed by the phrase
“without limitation”; 

  

	 	1.153.6 	 the word “will” will be construed to have the same meaning and effect as the word “shall”;

  

	 	1.153.7 	 any definition of or reference to any agreement, instrument, or other document herein will be construed as
referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); 

 

	 	1.153.8 	 provisions that require that a Party, the Parties or any committee hereunder “agree,”
“consent,” “approve,” or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding e-mail and instant messaging); 

  

	 	1.153.9 	 reference to any statute or regulation includes any modification or
re-enactment that statute or regulation; 

  

	 	1.153.10 	 references to the singular includes the plural and vice versa (unless the context otherwise requires); and

  

	 	1.153.11 	 the term “or” will be interpreted in the inclusive sense commonly associated with the term
“and/or.” 

  
 17 

	2.	 LICENSES 

  

	2.1	 License Grant to Licensee 

ReViral hereby grants to Licensee: 
  

	 	2.1.1	 an exclusive license, with the right to grant sublicenses through multiple tiers (subject to Section 2.2),
under the Licensed IPR to Develop, Manufacture (subject to this Section 2.1), Commercialize, and otherwise Exploit the Compound and Licensed Products in the Field in the Territory, and 

 

	 	2.1.2	 a non-exclusive license, with the right to grant sublicenses through
multiple tiers (subject to Section 2.2), under the Licensed Know How and Licensed Patents to Manufacture (subject to the below proviso) the Compound and Licensed Products outside the Territory for Exploitation in the Territory (the foregoing
licenses set forth in Section 2.1.1 and 2.1.2, collectively, the “License”); 

 provided
that, subject to Section 3.1, Licensee will not Manufacture Licensed Products unless ReViral fails to fulfil its supply obligations under the supply provisions set forth in Section 7 and as otherwise provided under this Agreement. 

 

	2.2	 Sublicense 

Licensee may grant sublicenses of the rights granted to Licensee under the License to its Affiliates and Subcontractors [***] (but in
accordance with the applicable terms of this Agreement). In addition, subject to [***], Licensee shall have the right to grant sublicenses under the License to other Third Parties. Each sublicense to a Subcontractor or Third Party shall be subject
to a written agreement that is consistent with the terms and conditions of this Agreement. Without limiting the foregoing, each sublicense shall be consistent with the terms of this Agreement, and Licensee shall use reasonable efforts to include in
each sublicense to a Third Party provisions assigning to Licensee the right, title and interest in Inventions and Know How developed by the Sublicensee or its employees in the performance of activities under such sublicense to the extent relating to
the Development, Manufacture or Commercialization of Licensed Products, and confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective
of the Parties as those set forth in this Agreement. At least [***] prior to the anticipated closure of a sublicense agreement with a Third Party that is not a Subcontractor, Licensee will notify ReViral, provide a summary of the material terms of
the potential sublicense, [***], which notice and summary will be the Confidential Information of Licensee. Within [***] of ReViral’s receipt of such notice, [***]. Within [***] after the execution of any sublicense agreement to a Third Party
that is not a Subcontractor, Licensee shall provide ReViral with a true and complete copy of such sublicense agreement, which shall be deemed to be Licensee Confidential Information; provided that Licensee shall have the right to redact any
confidential or proprietary information contained to the extent that such information is not necessary for ReViral to confirm compliance with this Agreement. Licensee shall remain directly responsible for all of its obligations under this Agreement.
At the reasonable request of ReViral, Licensee will use reasonable efforts to enforce the terms of each sublicense. Any Sublicensee conduct, act, omission or state of affairs that would have constituted a breach of this Agreement shall be imputed to
Licensee and deemed a breach of this Agreement as if such conduct, act, omission or state of affairs had been directly attributable to Licensee. For avoidance of doubt, distributors, resellers, sales representatives, and other channel partners,
CROs, other service providers and other Subcontractors shall not be deemed to be Sublicensees under this Agreement unless granted a sublicense hereunder. 

  
 18 

	2.3	 ReViral Retained Rights 

Notwithstanding the exclusive license granted to Licensee under Section 2.1.1, ReViral hereby expressly retains the rights to use the
Licensed IPR in the Field in the Territory in order to perform its obligations under this Agreement, whether directly or through its Affiliates, licensees, Sublicensees or agents. In addition, ReViral retains the exclusive right to practice, license
and otherwise exploit the Licensed IPR outside the scope of the license granted to Licensee under Section 2.1, including the exclusive right to Develop, Manufacture and Commercialize the Products outside the Territory and the non-exclusive right to Manufacture and have Manufactured the Licensed Products in the Territory solely for purposes of Developing and Commercializing the Licensed Products outside of the Territory. 

 

	2.4	 License Grant to ReViral 

Licensee hereby grants to ReViral a fully paid, royalty free, perpetual, exclusive and sublicensable (through multiple tiers) license under
the Licensee IPR to (a) Develop, and Commercialize the Licensed Products outside the Territory; and (b) Manufacture and have Manufactured the Licensed Products anywhere in the world solely for purposes of Developing and Commercializing the
Licensed Products outside of the Territory; provided that, to the extent any such Licensee IPR is in-licensed by Licensee or one of its Affiliates from a Third Party (not being a Sublicensee),
(A) the rights and licenses outside the Territory that are granted to ReViral under this Section 2.4 shall apply only if and to the extent that Licensee or its Affiliate has obtained all of the corresponding rights from the Third Party
necessary to grant such rights and (B) [***]. During the Term, Licensee shall [***] avoid terminating, amending, or otherwise modifying any such agreement, or taking (or failing to take) any action, that would (i) permit such Third Party
to terminate such license or (ii) adversely affect ReViral’s sublicense thereunder. 
  

	2.5	 No Implied Licenses; Negative Covenant 

Except as set forth herein, neither Party shall acquire any license or other right or interest, by implication or otherwise, under any Know
How, Patent or other intellectual property of the other Party. Licensee shall not, and shall not permit any of its Affiliates or Sublicensees to, practice or utilize any Licensed IPR outside the scope of the License granted by ReViral to Licensee
under Section 2.1 of this Agreement. ReViral shall not, and shall not permit any of its Affiliates or Sublicensees to, practice or utilize any Licensee IPR outside the scope of the license granted by Licensee to ReViral under Section 2.4
of this Agreement. 
  

	2.6	 No Diversion 

Each Party hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and Sublicensees shall not, either directly or
indirectly, promote, market, distribute, import, sell or have sold any Licensed Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like in the other Party’s territory or
to any Third Party that such Party knows (or reasonably should know) has previously exported or is likely to export any Licensed Product to the other Party’s territory. Neither Party shall engage, nor permit its Affiliates and Sublicensees to
engage, in any advertising or promotional activities relating to any Licensed Product for use directed primarily to customers or other buyers or users of the Licensed Product located in any country or jurisdiction in the other Party’s
territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party’s territory. If a Party or its Affiliates or Sublicensees receive any order for any Licensed Product from a prospective
purchaser located in a country or jurisdiction in the other Party’s territory, then such Party shall immediately refer that order to such other Party and shall not accept any such orders. Neither Party shall knowingly, nor permit its Affiliates
and Sublicensees to, deliver or tender (or cause to be delivered or tendered) any Licensed Product to any Third Party for use in or distribution into the other Party’s territory. 

  
 19 

	2.7	 Each Party will perform its obligations under this Agreement in accordance with all Applicable Laws. Each Party
shall obtain from the requisite Competent Authorities or Regulatory Authorities any consents, licenses, permits, waivers, approvals, authorizations or orders required to be obtained or made by such Party in connection with the authorization,
execution and delivery by such Party of this Agreement and the performance by such Party of its obligations under this Agreement. 

  

	3.	 EXCLUSIVITY 

  

	3.1	 During the Term, neither ReViral or its Affiliates, nor Licensee or any Lian Affiliate will (by itself or with
or through an Affiliate or a Third Party) Develop, Manufacture, or Commercialize in the Territory any Competitive Product (“Competitive Activities”), except for the Compound and Licensed Products under this Agreement.

  

	3.2	 Notwithstanding the restrictions set forth in Section 3.1, if ReViral under goes a Change of Control with
a company or group of companies owning or Controlling a Competitive Product (an “Acquiror/Partner”), and, thereafter, if ReViral, the Acquiror/Partner, or its or their Affiliates is conducting or commences conducting Competitive
Activities with respect to a Competitive Product that does not contain a RSV Candidate in a country or region in the Territory, then: 

(i) ReViral, its Acquiror/Partner, and its or their Affiliates will not be in violation of the terms of Section 3.1, but only with
respect to Competitive Products that do not contain a RSV Candidate, provided that, immediately following the closing of such Change of Control and throughout the conduct of such Competitive Activities, (a) ReViral, its Acquiror/Partner,
and its or their Affiliates implements reasonable measures to ensure that none of the Licensee Know How or other Regulatory Documents dedicated to the Licensed Product, or Confidential Information of Licensee are used in connection with the conduct
of such Competitive Activities, including establishing appropriate firewalls between the personnel performing Competitive Activities and the personnel teams charged with working on any Licensed Product (or component thereof) and ensuring that the
personnel performing Competitive Activities are prevented from having access to data from activities performed under this Agreement or Confidential Information of the other Party, and establishing other technical and administrative safeguards to
prevent use of or access by the Acquiror/Partner and its Affiliates to Confidential Information relating to activities in the Territory, 

(ii) [***] 
 (iii) [***]. 

 

	3.3	 Notwithstanding the restrictions set forth in Section 3.1, if Licensee undergoes a Change of Control with
an Acquiror/Partner, and, thereafter, if Licensee, the Acquiror/Partner, or its or their Affiliates is conducting or commences conducting Competitive Activities in a country or region in the Territory, then (i) Licensee, its Acquiror/Partner,
and its or their Affiliates will not be in violation of the terms of Section 3.1, provided that, immediately following the closing of such Change of Control and throughout the conduct of such Competitive Activities, (a) Licensee,
its Acquiror/Partner, and its or their affiliates implements reasonable measures to ensure that none of the Licensed Know How or other Regulatory Documents relating to the Licensed Product, or Confidential Information of ReViral are used in
connection with the conduct of such Competitive Activities, including establishing appropriate firewalls between the personnel performing Competitive Activities and the personnel teams charged with working on any Licensed Product (or component
thereof) or and ensuring that the personnel performing Competitive Activities are prevented from having access to data from activities performed under this Agreement or Confidential Information of the other Party and establishing technical and
administrative safeguards to prevent use of or access by the Acquiror/Partner and its Affiliates to Confidential Information relating to ReViral’s activities related to the Licensed Product, and [***]. 

  
 20 

	4.	 GOVERNANCE 

  

	4.1	 To facilitate day-to-day
interaction between the Parties, within [***] after the Effective Date they shall each appoint and designate an alliance manager (together, the “Alliance Managers” and respectively “ReViral’s
Alliance Manager” or “Licensee’s Alliance Manager”, as the case may be). Each Alliance Manager will be the primary point of contact for the other Party on all matters relating to the operation of this
Agreement. They shall not have decision making powers, and will be appointed simply to assist liaison. 

  

	4.2	 With effect from the Effective Date the Parties shall establish and run a Joint Steering Committee
(“JSC”). 

  

	4.3	 The JSC shall be organized as follows: 

 

	 	4.3.1	 the JSC shall comprise [***] persons (“JSC Members”) and ReViral and Licensee respectively
shall be entitled to appoint [***] JSC Members, to remove any JSC Member appointed by it and to appoint any person to fill a vacancy arising from the removal or retirement of such JSC Member appointed by it. JSC Members must be appropriate for the
primary function of the JSC in terms of their seniority, decision-making authority, availability, function in their respective organisation, training and experience and there will be a chairperson (“JSC Chairperson”) who will
alternate between one of ReViral JSC Members and one of Licensee JSC Members [***]; and 

  

	 	4.3.2	 Licensee and ReViral respectively shall each notify the other of any change in the identities of their JSC
Members. Both sides shall use reasonable efforts to keep an appropriate level of continuity in representation. JSC Members may be represented at any meeting by another person designated in writing by the absent JSC Member; and 

 

	 	4.3.3	 JSC shall hold meetings in person as frequently as the members of the JSC may agree shall be necessary, and
otherwise by teleconference or a video-conference, but no less frequently than four (4) times each Year in total. Dates of meetings shall be agreed by the Parties not less than [***] days beforehand. Each Party shall submit the agenda items and
associated materials that it wishes to be considered no later than [***] days prior to the meeting. The first meeting of the JSC will take place as soon as practicable after the Effective Date, but in no event later than [***] days after the
Effective Date. Special meetings of the JSC may be called by any JSC Member upon written request to the then current chairman of the JSC; and 

  

	 	4.3.4	 the venue for meetings of the JSC shall alternate between the premises of the Parties, or a location agreed by
the Parties, if not held by teleconference or videoconference. Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with JSC meetings; and 

 

	 	4.3.5	 no later than [***] days prior to each meeting of the JSC, each Party will provide the other with written
copies of all materials that Party intends to present at the JSC meeting; and 

  

	 	4.3.6	 the JSC shall have power to invite persons whose special skills or influence might advance the Development or
Commercialisation of Licensed Product in the Territory, in confidence and upon behalf of the JSC, to attend and address meetings of the JSC. For the avoidance of doubt it is agreed that such persons shall not be JSC Members and shall not participate
in the decision making process of the JSC; and 

  
 21 

	 	4.3.7	 ReViral’s Alliance Manager shall record the minutes of each JSC meeting in writing. Such minutes shall be
circulated by ReViral’s Alliance Manager to Licensee’s Alliance Manager no later than [***] Business Days following the meeting for review, comment and approval of Licensee. If no comments are received within [***] Business Days of the
receipt of the minutes by Licensee’s Alliance Manager, then unless otherwise agreed by the Parties, they shall be deemed to be approved by Licensee. Furthermore, if the Parties are unable to reach agreement on the minutes within [***] days
after the applicable meeting, the sections of the minutes that have been agreed between the Parties by that date shall be deemed approved and, in addition, each Party shall record in the same document its own version of those sections of the minutes
on which the Parties were not able to agree. 

  

	4.4	 The JSC shall have the following purposes: 

 

	 	4.4.1	 guide the overall Development strategy and Commercialization strategy of the Licensed Product in the Territory
by Licensee, and for general liaison and communication between the Parties; 

  

	 	4.4.2	 review and discuss the Clinical Trial protocol for the First Global Trial; 

 

	 	4.4.3	 determine the Specifications for the Licensed Products; 

 

	 	4.4.4	 review and discuss the Global Development Plan and any updates thereto, and determine whether to approve any
elements or activities therein to be carried out in the Territory; 

  

	 	4.4.5	 review and discuss Clinical Trial study designs and study protocols within the Global Development Plan;

  

	 	4.4.6	 discuss the participation of Licensee, Lian Affiliate, CRO or Sublicensee in the Global Development Plan;

  

	 	4.4.7	 review, discuss, and determine whether to approve the Territory Specific Development Plan and any updates
thereto; 

  

	 	4.4.8	 review and discuss the progress of Licensee’s and ReViral’s Development activities, including
receiving the Interim Reports and Final Reports regarding the Parties’ activities under the Global Development Plan and Territory-Specific Development Plan, as applicable; 

 

	 	4.4.9	 discuss material regulatory developments related to the Licensed Product in the Territory;

  

	 	4.4.10	 review and discuss the Commercialization Plan prepared by Licensee, and any updates thereto;

  

	 	4.4.11	 review and discuss Licensee’s material Commercialization activities for the Licensed Product in the
Territory and ReViral’s material Commercialization activities for the Licensed Product outside of the Territory; 

  
 22 

	 	4.4.12	 discuss additional Indications for any Licensed Product proposed by ReViral to be Developed and Commercialized;

  

	 	4.4.13	 discuss any Inventions relating to the Licensed Product arising out of either Party’s activities under
this Agreement; and 

  

	 	4.4.14	 shall perform such other functions and responsibilities as are given to it under the express provisions of this
Agreement but shall have no authority to amend any terms of this Agreement or any matter that would cause any payments stated in this Agreement to be other than the amount of those terms as stated herein. 

 

	4.5	 Conclusions and decisions of the JSC shall be made by unanimous agreement of the JSC Members wherever possible
with Licensee JSC Members together having one vote on behalf of Licensee and ReViral JSC Members together having one vote on behalf of ReViral. Both Parties will use their reasonable efforts to build consensus. The JSC shall exercise this authority
in good faith. 

  

	4.6	 Any disputes among representatives at the JSC will be resolved by escalation to appropriate senior officers of
Licensee and ReViral (the “Senior Officers”). To the extent the Senior Officers cannot reach agreement on the matter at hand, then (i) ReViral will have final decision-making authority over [***]; provided that [***],
and (ii) Licensee will have final decision-making authority over (1) [***], except to the extent such matter [***]; (2) [***]. 

  

	5.	 DEVELOPMENT 

  

	5.1	 ReViral will be in control of and lead global strategy and planning for the further global nonclinical and
clinical Development of the Licensed Product [***], including the finalisation of formulations. ReViral will detail such global Development activities (the results of and data from which are intended to be used to obtain or maintain Regulatory
Approval of the Licensed Product both in and outside the Territory) in a global Development plan (“Global Development Plan”). The Global Development Plan will be discussed by the JSC [***]. From time to time, ReViral may make
updates to the Global Development Plan, provided that ReViral will submit such proposed updates to the JSC for review and discussion [***]. ReViral will be responsible for the study designs and study protocols for the Global Clinical
Trial(s), in each case, subject to consultation with Licensee on Territory-specific issues through the JSC and the remainder of this Section 5.1. In addition, Licensee will have the right to participate in the Territory in Global Clinical
Trials for the Licensed Product to be conducted by ReViral, subject to ReViral’s consent, not to be unreasonably withheld, and Licensee’s agreement to the study design and study protocols for such Global Clinical Trial and Global
Development Plan. Licensee will have the right to determine the activities of Development to be conducted in the Territory by Licensee, its Affiliates, or its or their respective Sublicensees or CROs, including whether there are local clinical study
sites in the Territory forming part of a Global Clinical Trial, whether to conduct separate Clinical Trials in the Territory that are not covered by a Global Clinical Trial, and, after considering in good faith ReViral’s suggestions, the
countries and regions in the Territory where the clinical study sites will be located. Licensee will participate in the Pivotal Global Clinical Trials for the Licensed Product for the pediatric and elderly adult Indications unless either
(i) prevented by Applicable Law or the requirements of any Regulatory Authority in the Territory or (ii) Licensee determines that such participation would not be reasonably likely to support the Regulatory Approval of the Licensed Product
in the applicable Indication in the Territory and that Licensee must conduct a separate Clinical Trial in the Territory to obtain or maintain Regulatory Approval for the Licensed Product in the Territory. In the case of the Licensee proposing to
conduct separate Clinical Trials in the Territory that are not covered by a Global Clinical Trial, the Licensee shall submit the study design and study protocols to the JSC for consideration and discussion, and shall, [***]. The Development activity
to be carried out in the Territory by Licensee, its Affiliate or a CRO as determined by JSC, including the timeline and details of all major Development work (including all Clinical Trials, whether included in or separate from any Global Clinical
Trial) to be conducted by or on behalf of Licensee to obtain and maintain Regulatory Approval of the Licensed Products in the Field in each country in the Territory will be set out in a written plan to be developed by Licensee (the
“Territory-Specific Development Plan”), [***]. From time to time, Licensee may make updates to the Territory-Specific Development Plan, provided [***]. 

  
 23 

	5.2	 Licensee will be responsible for all Development Costs. To the extent that ReViral incurs any Development Costs
in the performance of any Pivotal Global Clinical Trial for the Licensed Product in the Territory, ReViral shall invoice Licensee for reimbursement of the same as follows: within [***] after the end of each Calendar Quarter, ReViral shall prepare
and submit to Licensee an invoice that reasonably details the actual Development Costs of such Pivotal Global Clinical Trial for such Calendar Quarter, and Licensee shall pay the undisputed amount of such invoice within [***] days after the receipt
of such invoice. 

  

	5.3	 For each Global Clinical Study in which Licensee participates (a) that is a Pivotal Global Clinical Trial
pursuant to Section 5.1, (b) that targets either the pediatric Indication or elderly adult Indication, and (c) for which Licensee approves the study design and study protocol, Licensee will use Commercially Reasonable Efforts to enroll
study patients in the Territory equal to [***] of the total study patients in such Pivotal Global Clinical Trial (the “Patient Commitment”). In the event Licensee joins such a Pivotal Global Clinical Trial, fails to enroll
sufficient study patients in the Territory to meet the Patient Commitment (the “Licensee Shortfall”), and ReViral instead enrolls patients in such Pivotal Global Clinical Trial in lieu of Licensee in order to meet the Patient
Commitment, then Licensee will reimburse ReViral for the number of patients representing the Licensee Shortfall that ReViral so enrolls in such Pivotal Global Clinical Trial (up to the Patient Commitment) based on [***]. 

 

	5.4	 Subject to the remainder of this Section 5 (including ReViral’s obligations in Section 5.5, to
the extent Licensee’s performance of activities under the Territory-Specific Development Plan relies on ReViral’s performance of the Global Development Plan), Licensee shall use Commercially Reasonable Efforts to [***].

  

	5.5	 ReViral will use Commercially Reasonable Efforts to [***]. 

 

	5.6	 When ReViral believes the PTP has been achieved, it shall notify Licensee and, at the next scheduled meeting of
the JSC, it shall provide to Licensee all relevant Licensed Know How relating to (i) non-clinical data including pharmacological, toxicological and metabolic data and results of all non-clinical studies relevant to the Licensed Product; (ii) clinical safety and efficacy data relating to the Licensed Product, including data analyses, study reports and information contained in protocols,
filings or other submissions to and responses from ethical committees and Regulatory Authorities; and (iii) pharmacovigilance data. [***]. 

  

	5.7	 Technology Transfer and Exchange of Know How and Commercial Information 

 

	 	5.7.1	 As promptly as practicable after the Effective Date, the Parties shall coordinate and agree to a technology
transfer plan for ReViral to provide and transfer to Licensee the Licensed Know How (including associated Regulatory Documents) that is necessary or reasonably useful for Licensee to Exploit the Licensed Products in the Territory. For the avoidance
of doubt, this Section 5.7.1 and the technology transfer plan contemplated hereby shall not address technology transfer in connection with any future technology transfer necessary to Manufacture Licensed Products. ReViral shall transfer such
Licensed Know How to Licensee in accordance with such technology transfer plan, and Licensee shall cooperate with ReViral to facilitate the receipt of such transfer of Licensed Know How. On a Calendar Quarter basis during the Term, ReViral shall
similarly disclose and transfer to Licensee, through the JSC or as otherwise agreed, all additional Licensed Know How and Regulatory Documents that have been generated since the previous meeting or transfer; provided that ReViral will
promptly transfer to Licensee any Regulatory Documents requested by any Regulatory Authority in the Territory. 

  
 24 

	 	5.7.2	 Upon Licensee’s reasonable request, ReViral shall also provide Licensee with reasonable technical
assistance, including in connection with such initial technology transfer and reasonable access to ReViral’s technical personnel involved in the Development of the Licensed Products. The first [***] of such technical assistance shall be
provided by ReViral without charge, provided that both Parties shall use reasonable efforts to complete the technology transfer as expeditiously as possible. If Licensee nominates any Third Party to participate in the receipt of such
technical assistance, including any Affiliate or CRO, and this does not occur at the same time Licensee receives such technical assistance, each hour of technical assistance provided by ReViral shall count towards the [***] free assistance.
Thereafter ReViral shall be compensated for all additional assistance at an FTE rate to be agreed between the Parties in good faith. 

  

	 	5.7.3	 At the JSC meeting following the generation of any particular Commercial Information by ReViral, ReViral shall
supply Licensee or its nominated Affiliate with the then-existing Commercial Information in the same manner as with Licensed Know-How not being Commercial Information. 

 

	5.8	 Licensee Refusal to Participate 

If ReViral notifies Licensee of its intention to conduct a Pivotal Global Clinical Trial for a Product in an Indication other than the first
pediatric Indication or elderly adult Indication, then Licensee may either (a) elect to participate in such Pivotal Global Clinical Trial, subject to Licensee’s approval of the study design and study protocols and the relevant part of the
proposed Global Development Plan for such Pivotal Global Clinical Trial as it relates to the Territory or (b) conduct a separate Clinical Trial within the Territory with respect to such Indication (to be detailed in the Territory-Specific
Development Plan). In addition, if, under Applicable Law in the Territory, Licensee is neither required to participate in such Pivotal Global Clinical Trial nor to conduct a separate Clinical Trial within the Territory, in each case, in order to
obtain Regulatory Approval of the Product in the applicable Indication, then ReViral will grant to Licensee a right of reference with respect to Regulatory Documents submitted by or on behalf of ReViral relating to such Pivotal Global Clinical Trial
as necessary to support or maintain any existing or future Regulatory Approval for the Product in such Indication or any other Indication for which a Product has received Regulatory Approval in the Territory. 

 

	5.9	 Development Records 

Each Party shall maintain complete, current and accurate records of all Development activities conducted by or on behalf of such Party
hereunder, and all data and other Know How resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for
regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines
(e.g., ICH, GCP, GLP, and cGMP). 
  

	5.10	 Development Reports 

Licensee shall keep ReViral reasonably informed as to the progress and results of its and its Affiliates’ and Sublicensees’
Development of the Licensed Products, including the preparation of Interim Reports and Final Reports in relation to its performance of activities set forth in the Territory-Specific Development Plan. ReViral shall keep Licensee reasonably informed
as to the progress and results of its and its Affiliates’ and Sublicensees’ Development of the Licensed Products, including the preparation of Interim Reports and Final Reports in relation to its performance of activities set forth in the
Global Development Plan. Without limiting the foregoing, the status, progress and results of the Development of the Licensed Products within 

  
 25 

 
and outside the Territory shall be discussed at meetings of the JSC. At least [***] before each regularly scheduled JSC meeting, each Party shall provide the JSC with a written report summarizing
its respective Development activities and the results thereof, covering subject matter at a level of detail reasonably required by the JSC and sufficient to enable the other Party to determine compliance with the diligence obligations pursuant to
Section 5.4 and Section 5.5, as applicable. In addition, each Party shall use reasonable efforts to make available to the other Party such additional information about its Development activities as may be reasonably requested from time to
time. 
  

	6.	 REGULATORY 

  

	6.1	 General 

The Territory-Specific Development Plan shall set forth the regulatory strategy for seeking Regulatory Approvals of the Licensed Products in
the Field in each country and region in the Territory. Licensee shall be solely responsible for all regulatory activities necessary for obtaining and maintaining Regulatory Approvals of the Licensed Products in the Field in the Territory, which
regulatory activities shall be performed at Licensee’s own cost and expense and in accordance with the regulatory strategy set forth in the Territory-Specific Development Plan. Through the JSC, Licensee shall keep ReViral informed of material
regulatory developments related to the Licensed Products in the Territory, including any decision by any Regulatory Authority in the Territory regarding Regulatory Approval of the Licensed Products. 

 

	6.2	 Regulatory Documents 

Licensee shall provide ReViral with drafts [***] of all material Regulatory Documents within a reasonable time (in any event no less than [***]
prior to submission for review and comment and shall consider in good faith any comments thereon received in a timely manner from ReViral, provided that, with respect to any Regulatory Documents required by Applicable Law to be filed in
ReViral’s name in the Territory, Licensee will implement all timely comments received from ReViral thereon. In any event, Licensee may submit any Regulatory Document without regard to ReViral’s comments if such comments are not received by
Licensee at least [***] (or such lesser period required by Applicable Law) prior to the submission due date or earlier if necessary to comply with the requirements of any Regulatory Authority in the Territory. Notwithstanding the foregoing, from
time to time, the JSC may recommend to ReViral that no review or comment is necessary for certain categories of Regulatory Documents that are immaterial in nature, and ReViral may elect to waive its right to review and comment thereon in its sole
discretion, provided further that: (a) on a quarterly basis at the regularly scheduled JSC meetings, Licensee shall inform the JSC of the Regulatory Documents it has received or submitted that have not been reviewed by ReViral as
a result of such waiver by ReViral of its right to review the same; (b) ReViral shall have the right to request a copy of such Regulatory Documents at any time notwithstanding such waiver; and (c) ReViral shall have the right to rescind
such waiver with respect to future Regulatory Documents at any time in its sole discretion. Licensee shall not make any statement in a regulatory filing for the Licensed Product in the Territory that ReViral demonstrates to Licensee is inconsistent
with statements submitted or intended for submission by ReViral in regulatory filings outside for the Licensed Products of the Territory. In addition, Licensee shall notify ReViral of any [***] Regulatory Documents for the Licensed Products
submitted to or received from any Regulatory Authority in the Territory and shall provide ReViral with copies thereof within [***] after submission or receipt (or such lesser period required by Applicable Law) and shall notify ReViral of any other
material communication with any Regulatory Authority in the Territory regarding the Licensed Products within [***] after such communication (or such lesser period required by Applicable Law). If any such material Regulatory Document is not in the
English language, Licensee shall also, [***], provide ReViral with an English summary at the time of provision. Upon ReViral’s reasonable request from time to time, Licensee will provide other Regulatory Documents in English, subject to the
Parties’ agreement regarding cost-sharing and timing. 

  
 26 

	6.3	 Regulatory Meetings 

Licensee shall provide ReViral with reasonable (and in any event, to the extent practicable, no less than [***] advance notice of any
substantive meeting or discussion with any Regulatory Authority in the Territory related to the Licensed Products. Licensee shall lead such meeting or discussion; provided, however that, to the extent legally permissible and
practicable [***]. In addition, if reasonably requested by Licensee [***], ReViral or its designee shall attend and participate in such meeting or discussion to actively assist in addressing questions regarding the Licensed Products that may be
raised by the Regulatory Authority. Licensee shall provide ReViral with a written English summary of such meeting or discussion within [***] thereafter. At Licensee’s reasonable request, ReViral shall provide assistance in responding to or
otherwise addressing questions raised by the Regulatory Authority during any such meeting or discussion, according to a timeline reasonably agreed by the Parties. 
  

	6.4	 Regulatory Requests 

As soon as possible but no later than [***] after receipt, Licensee shall provide ReViral any formal or informal requests received from any
Regulatory Authority in the Territory related to the Licensed Products. Licensee shall manage preparation of a response to such requests; provided that, [***], ReViral or its designee shall provide assistance in preparing a response that
addresses matters raised by the Regulatory Authority in such request, according to a timeline reasonably agreed by the Parties. Licensee shall submit all responses before the due date set by the Regulatory Authority. 

 

	6.5	 Ownership of Regulatory Filings  

All Regulatory Documents will be made in the name of and exclusively owned by Licensee or Lian Affiliate; provided, however,
that, if Applicable Laws or Regulatory Authorities in a country or region in the Territory require Regulatory Documents to be filed in the name of and owned by ReViral, then Licensee will file such Regulatory Documents in the name of ReViral, with
the understanding that ReViral will designate Licensee (or its Affiliate or designee) to be its sole authorized agent in such country or region in the Territory. If Applicable Laws or Regulatory Authorities in such country or region in the Territory
later permit Licensee to file and own such Regulatory Documents in Licensee’s name, then ReViral will permit such Regulatory Documents then to be filed in the name of and exclusively owned by Licensee, and ReViral will cooperate with Licensee
to assign and transfer such Regulatory Documents to Licensee. 
  

	6.6	 Right of Reference 

Subject to Section 5.8, each Party hereby grants to the other Party the right of reference to all Regulatory Documents pertaining to the
Licensed Products in the Field submitted by or on behalf of such Party. Licensee may use such right of reference to ReViral’s Regulatory Documents in the Field solely for the purpose of seeking, obtaining, supporting, and maintaining Regulatory
Approval and Pricing Approval of the License Products in the Field in the Territory. ReViral may use such right of reference to Licensee’s Regulatory Documents in the Field solely for the purpose of seeking, obtaining, supporting, and
maintaining Regulatory Approval and Pricing Approval of the Licensed Products outside the Territory. Each Party will bear its own costs and expenses associated with providing the other Party with the right of reference pursuant to this
Section 6.6. Each Party will take such actions as may be reasonably requested by the other Party to give effect to the intent of this Section 6.6 and to give the other Party the benefit of the granting Party’s Regulatory Documents in
the other Party’s territory as 

  
 27 

 
provided herein. Such actions may include (i) providing to the other Party copies of correspondence and communications received from the applicable Regulatory Authorities related to such
Party’s application for Regulatory Approval of the Licensed Product in the Territory (if Licensee is the Party seeking Regulatory Approval) and of the Licensed Product outside of the Territory (if ReViral is the Party seeking Regulatory
Approval), or (ii) providing the other Party with any underlying raw data or information submitted by the granting Party to the Regulatory Authority with respect to any Regulatory Documents Controlled by such granting Party or its Affiliates
that relates to any Licensed Product. 
  

	6.7	 Pharmacovigilance 

No later than [***] days following the Effective Date, but in any event [***], the Parties shall enter into a pharmacovigilance agreement
setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Licensed Products (the “Pharmacovigilance Agreement”), which agreement will provide for coordination and sharing of relevant safety
information related to the Licensed Products between the Parties in order to facilitate prompt filing of accurate and consistent reports to Regulatory Authorities in compliance with Applicable Law. Each Party shall hold the primary responsibility
for reporting adverse events and other safety data related to the Licensed Products in its territory to the applicable Regulatory Authorities in its territory, as well as responding to safety issues and to all requests of Regulatory Authorities in
its territory related to the Licensed Products, in each case, at its own cost and to the extent required by Applicable Laws. ReViral shall be responsible for the establishment and maintenance of a global safety database at its own cost and expense.
Licensee may, at its own cost and expense, establish and maintain its own local safety database to store the safety information generated from the Development of the Licensed Products in the Territory, and to assure regulatory reporting compliance
in the Territory. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees and Sublicensees to comply with such obligations. Each Party will notify the other Party of
any new planned Clinical Trials for any Licensed Product and the Parties will update the Pharmacovigilance Agreement to the extent necessary to comply with any applicable requirements set forth under Applicable Law or of any Regulatory Authorities
related to adverse event reporting, drug safety, patient safety, pharmacovigilance, and risk management. Notwithstanding anything to the contrary in this Agreement or the Pharmacovigilance Agreement, each Party and its Affiliates, licensees, and
Sublicensees will have the right to disclose information related to the safety of the Compounds or Licensed Products to the extent that such disclosure is required for such Party to comply with its obligations under Applicable Law or the safety
requirements of the applicable Regulatory Authorities. To the extent that there is a conflict between the terms of this Agreement and the terms of the Pharmacovigilance Agreement, the terms of the Pharmacovigilance Agreement will govern with respect
to the subject matter set forth therein. 
  

	6.8	 No Harmful Actions 

If ReViral or Licensee believes that the other Party is taking or intends to take any action with respect to any Licensed Product that could
have a material adverse impact upon the regulatory status of any Licensed Product outside or inside the Territory (as the case may be), the concerned Party shall have the right to bring the matter to the attention of the JSC and the Parties shall
promptly meet to discuss in good faith to resolve such concern. Without limiting the foregoing, unless the Parties otherwise agree: (a) Licensee shall not communicate with any Regulatory Authority having jurisdiction outside the Territory,
unless so ordered by such Regulatory Authority, in which case Licensee shall immediately notify ReViral of such order; (b) unless requested by Licensee, ReViral shall not communicate with any Regulatory Authority having jurisdiction within the
Territory, unless so ordered by such Regulatory Authority, in which case ReViral shall immediately notify Licensee; and (c) Licensee shall not submit any Regulatory Documents or seek Regulatory Approvals for any Licensed Product outside the
Territory and ReViral shall not submit any Regulatory Documents or seek Regulatory Approval for any Licensed Product inside the Territory without Licensee’s prior written consent. 

  
 28 

	6.9	 Remedial Actions 

Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any
Licensed Product may be subject to any recall, corrective action or other regulatory action by any Competent Authority or Regulatory Authority (a “Remedial Action”). The Parties shall assist each other in gathering and evaluating
such information as is necessary to determine the necessity of conducting a Remedial Action. Licensee shall have sole discretion with respect to any matters relating to any Remedial Action in the Territory, including the decision to commence such
Remedial Action and the control over such Remedial Action. The cost and expenses of any Remedial Action in the Territory shall be borne solely by Licensee. 
  

	6.10	 Licensee or its Affiliate will have sole control over and decision-making authority with respect to responding
to medical questions or inquiries from members of the medical and paramedical professions and consumers regarding Licensed Product in the Territory. The Parties, through the JSC, will collaborate to develop consistent responses to common inquiries.
If ReViral receives questions about Licensed Product in a country in the Territory, then it will refer such questions to Licensee, and Licensee will have sole control over and decision-making authority with respect to responding thereto.

  

	7.	 MANUFACTURE AND SUPPLY 

 

	7.1	 ReViral shall, either by itself or through its Affiliates or Third Party contract manufacturers, Manufacture
and supply to Licensee, and Licensee shall purchase from ReViral, all of Licensee’s and its Affiliates’ and Sublicensees’ requirements for (i) CTM of the Licensed Product for use in Development and (ii) Licensed Products for
use in Commercialization in the Field in the Territory (the “Territory Specific Supply”). 

  

	7.2	 Supplies of CTM for use by the Licensee in Phase II Clinical Trials in the Territory shall be made under the
terms set forth in this Section 7.2: 

  

	 	7.2.1	 As part of the Territory-Specific Development Plan, Licensee shall prepare and provide ReViral at JSC with
forecasts of Licensee’s requirement for CTM for Phase II Clinical Trials for the Licensed Products for the Territory as it changes from time to time but covering at least [***] in advance. The quantities detailed in each forecast constitute a
good faith estimate of future requirement of Licensee and its Affiliates of CTM for Phase II Clinical Trials and do not comprise a minimum purchase requirement or a binding commitment on Licensee. 

 

	 	7.2.2	 The Licensee shall pay ReViral Cost of Manufacture for CTM. ReViral shall invoice Licensee for such costs
following delivery of such CTM to Licensee. ReViral’s invoices for CTM are due for payment no later than [***] following receipt of invoice. The CTM shall be delivered by ReViral to Licensee [***] accompanied by an associated certificate of
conformity and certificate of analysis. [***]. Title and risk of loss and damage to CTM purchased by Licensee hereunder shall pass to Licensee [***]. 

  

	 	7.2.3	 The CTM supplied by ReViral under this Agreement shall be in compliance with the Specifications and GMP.

  
 29 

	 	7.2.4	 Licensee or its designated agent shall, within [***] following receipt of a shipment of CTM at Licensee’s
warehouse in the Territory, carry out a Visual Inspection (as defined below) of such shipment and the associated certificate of conformity and certificate of analysis. If following Visual Inspection the Licensee determines i[***] that the shipment
is defective or deficient it shall promptly notify the ReViral in writing rejecting the shipment and specifying in detail the reasons therefor (“Notice of Rejection”). If Licensee does not notify ReViral in this manner within such
[***] day period, such shipment of CTM shall be deemed to have been accepted by the Licensee. 

  

	 	7.2.5	 For the purposes of this Agreement, “Visual Inspection” shall mean: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]. 

For the avoidance of doubt, Visual Inspection does not include [***]. 

 

	 	7.2.6	 Within [***] days after receipt by ReViral of a Notice of Rejection ReViral shall indicate in writing to
Licensee whether ReViral is issuing a return authorisation or not. In the event that a return authorisation is so issued, Licensee shall return to ReViral at [***] expense the quantities of CTM in question and ReViral shall replace such quantities
as soon as reasonably practicable thereafter. 

  

	 	7.2.7	 If ReViral does not issue a return authorisation under Section 7.2.6 Licensee shall analyse samples from
any batch of CTM rejected by Licensee for non-conformity with the Specifications or GMP within [***] days of issuance of the Notice of Rejection and shall present its findings with respect to such CTM to
ReViral. If such findings seem to confirm non-conformity with the Specification or GMP, but ReViral disputes such findings it may request Licensee to submit some samples from the batch to an independent
qualified laboratory nominated by ReViral, [***], to analyse such samples of CTM in question, and the definitive results of such laboratory shall be binding on the Parties. If ReViral accepts the Licensee’s findings or the laboratory confirms
such findings, then ReViral shall supply to Licensee at [***]cost and expense a conforming batch in the same quantity as the rejected batch as soon as reasonably practicable thereafter. In such circumstances ReViral shall also [***] incurred by
Licensee including shipping charges in relation to such non-conforming batch. The non-conforming CTM batch shall be held for ReViral’s disposition, or shall be
returned to ReViral, in each case, [***], as directed by ReViral. In circumstances where the independent laboratory finds the batch to be conforming, the Licensee shall be deemed to have accepted the shipment, notwithstanding the Notice of
Rejection. 

  

	 	7.2.8	 Notwithstanding Licensee’s acceptance of CTM pursuant to Section 7.2.4, if the CTM did not conform to
the Specifications, and if such nonconformity was not reasonably identifiable through the Visual Inspection, then Licensee may submit a Notice of Rejection to ReViral upon discovery of such nonconformity. 

 

	 	7.2.9	 Notwithstanding the provisions of the last sentence of Section 7.2.7, if ReViral subsequently discovers
facts causing it to have reasonable belief that any batch of CTM was defective in that it failed to meet Specification at the time of delivery, it may [***] appoint to an independent qualified laboratory nominated by ReViral, to analyse samples of
the batch in question and give an opinion whether in the reasonable belief of the laboratory CTM the batch of CTM was indeed defective in that it failed to meet Specification at the time of delivery. The definitive results of such laboratory shall
be binding on the Parties. The consequences of any such decision are as set out in Section 7.2.7. 

  
 30 

	 	7.2.10	 As soon as reasonably practicable after the Effective Date, the Parties shall negotiate and execute a related
quality agreement consistent with the terms and conditions of this Agreement governing the supply of CTM under this Agreement. 

  

	7.3	 If ReViral fails to supply at least [***]of the CTM ordered by Licensee [***], then Licensee may by written
notice to ReViral seek to take over responsibility for Manufacture of CTM. This shall not affect ReViral’s right under Section 7.4 to supply Licensee with the quantities of Licensed Product required for Phase III Clinical Trials in the
Territory and Commercialization. Upon receipt of such notice ReViral shall, [***], as soon as reasonably practicable transfer or procure its contract manufacturer to transfer to Licensee or its nominee the Manufacturing Know How within Licensed Know
How. 

  

	7.4	 ReViral shall supply Licensee, any Affiliate or Sublicensee with the quantities of Licensed Product they
require for the Phase III Clinical Trials to be conducted in the Territory, and for Commercialization in the Territory pursuant to a full, separate Manufacturing and supply agreement, covering supplies for the Phase III Clinical Trials in the
Territory, and for Commercialization in the Territory (“Manufacturing and Supply Agreement”), along with a related quality agreement. No later than [***] months prior to the [***], the Parties will negotiate and agree in good faith
the terms of the Manufacturing and Supply Agreement. 

  

	8.	 COMMERCIALISATION 

 

	8.1	 Licensee shall, either by itself or through its Affiliates, Sublicensees or Third Party contractor(s), be
solely responsible for the Commercialization of the Licensed Products in the Field in the Territory, at Licensee’s own cost and expense, including developing and executing a commercial launch plan, product marketing and promotion, marketing
access and pricing strategy, negotiating with Competent Authorities regarding the price and reimbursement mechanisms, booking sales, product distribution, providing customer support (including handling medical queries), and performing other related
functions. 

  

	8.2	 Licensee either by itself or through its Affiliates, Sublicensees or Third Party contractor(s), shall use
Commercially Reasonable Efforts to Commercialize the Licensed Products in each country of the Territory in which it or an Affiliate or Sublicensee receives Regulatory Approval and Pricing Approval. 

 

	8.3	 Licensee will have sole authority for determining and establishing the price and terms of sale (including any
rebates or discounts) of Licensed Product for each country in the Territory. [***]. 

  

	8.4	 Within [***] prior to the anticipated first launch of the Licensed Product in the Territory, Licensee will
prepare a Commercialization Plan covering: [***]. The Commercialization Plan will be updated [***] by Licensee. The Commercialization Plan, and updates thereto, will be shared with ReViral via the JSC for comment and discussion.

  

	8.5	 The Parties shall collaborate with respect to the Commercialization of the Licensed Products across their
respective territories. Through the JSC, ReViral shall keep Licensee reasonably informed of its plans (including any updates and amendment thereto) for the global Commercialization of the Licensed Products in sufficient detail for Licensee to make
related updates to align Commercialization of the Licensed Products in the Territory with ReViral’s global Commercialization plans, provided that any such update will be in Licensee’s sole discretion. 

  
 31 

	8.6	 The Parties recognize that they may benefit from the coordination of certain activities in support of the
Commercialization of the Licensed Products across their respective territories. As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and product positioning. If the Parties wish to
jointly conduct any specific Commercialization activities for the benefit of the Licensed Products in both Parties’ territories, the Parties may negotiate and agree on the details of such activities, including allocation of responsibilities,
budget and cost sharing. 

  

	8.7	 Licensee or its Affiliates or Sublicensees will have sole authority, consistent with the Commercialization
Plan, for the creation, preparation, production and reproduction of all promotional materials relating to Licensed Products in the Territory and for filing, as may be required, such promotional materials with Regulatory Authorities in the Territory.

  

	8.8	 Licensee shall not make any medical or promotional claims for any Licensed Product other than as permitted by
Applicable Laws. When distributing information related to any Licensed Product or its use in the Territory (including information contained in scientific articles, reference publications and publicly available healthcare economic information),
Licensee must comply with all Applicable Laws in the applicable country in the Territory. 

  

	8.9	 Licensee shall keep the JSC reasonably informed of its, its Affiliates’ and Sublicensees’
Commercialization activities with respect to the Licensed Products. Without limiting the foregoing, Licensee shall update the JSC at least [***] at each [***] regarding the Commercialization activities with respect to the Licensed Products in the
Territory. Each such update shall be in a form to be agreed by the JSC and shall summarize Licensee’s, its Affiliates’ and Sublicensees’ significant Commercialization activities with respect to the Licensed Products in the Territory.
In addition, Licensee shall make available to the JSC such additional information about its Commercialization activities as may be reasonably requested by the JSC from time to time. 

 

	9.	 ECONOMICS 

UPFRONT FEE 
  

	9.1	 Licensee will pay to ReViral an upfront fee of [***] within [***] after the Effective Date following receipt by
Licensee of an invoice therefor from ReViral. 

 DEVELOPMENT MILESTONE PAYMENTS 

 

	9.2	 Licensee shall pay ReViral the following Development milestone payments on the occurrence of the following
milestone events: 

  

	 	9.2.1	 [***]: 

  

	 	(i)	 [***]: [***] 

  

	 	(ii)	 [***]: [***] 

  

	 	(iii)	 [***]: [***] 

  

	 	(iv)	 [***]: [***] 

COMMERCIALIZATION MILESTONE PAYMENTS     

 

	9.3	 The following one-time payments shall be paid by Licensee to ReViral in
USD upon first achievement of the following Commercial sales milestone events: 

  

	 	9.3.1	 [***]: [***]; 

  

	 	9.3.2	 [***]: [***]; 

  
 32 

	 	9.3.3	 [***]: [***]; 

  

	 	9.3.4	 [***]: [***]. 

  

	9.4	 Each of the milestone payments subject to Sections 9.2 and 9.3, shall only be payable by Licensee upon the
first occurrence of the applicable event whenever it occurs. Upon the occurrence of the applicable event the milestone payment shall be payable even if more than one occurs in a Year. Such milestone payments are
non-refundable in any circumstances whatsoever and are not creditable against the royalties due under Section 9.7. 

 

	9.5	 ReViral shall report the occurrence of each milestone event under Sections 9.2.1(i) and 9.2.1(ii) to Licensee
within [***] of its occurrence and at the same time shall invoice Licensee, which invoice shall be payable by Licensee within [***] of the occurrence after the milestone event. 

 

	9.6	 Licensee shall report the occurrence of each milestone event under Sections 9.2.1(iii) and 9.2.1(iv) and 9.3 to
ReViral within [***] after its occurrence and shall make the milestone payment to ReViral within [***] after Licensee’s receipt of an invoice therefor from ReViral. 

ROYALTIES 
  

	9.7	 Licensee will pay to ReViral royalties during the Royalty Term as set forth below: 

royalty = A + B + C + D where: 

A equals [***] of that portion of annual Net Sales of Licensed Product in the Territory, which, during the Calendar Year in question,
is less than or equal to [***]; 
 B equals [***] of that portion of annual Net Sales of Licensed Product in the Territory, which,
during the Calendar Year in question, is greater than [***]; 
 C equals [***] of that portion of annual Net Sales of Licensed
Product in the Territory, which, during the Calendar Year in question, is greater than [***]; and 
 D equals [***] of that portion
of annual Net Sales of Licensed Product in the Territory, which, during the Calendar Year in question, is greater than [***]. 

ROYALTY REDUCTIONS—NO VALID CLAIMS 
  

	9.8	 In countries of the Territory where, during the Royalty Term, [***], then, subject to Section 9.11, the
royalty rates set out in Section 9.7 shall be reduced by [***]. 

 ROYALTY REDUCTIONS –
GENERIC PRODUCTS 
  

	9.9	 If there is market entry of a Generic Product in a country or region in the Territory [***], then subject to
Section 9.11, the royalty rates set out in Section 9.7 shall be reduced by [***]. 

 ROYALTY
REDUCTIONS – THIRD PARTY IP 
  

	9.10	 If Licensee pays license fees or other consideration to a Third Party to obtain rights to or a license under
[***], then, subject to Section 9.11, Licensee will be entitled to deduct such license fees or other consideration paid by Licensee to such Third Party [***]. If Licensee pays license fees or other consideration to a Third Party to obtain
rights to or a license under [***], then, subject to Section 9.11, Licensee will be entitled to deduct [***]. 

  
 33 

	9.11	 Notwithstanding the above, any royalty reduction made pursuant to Section 9.8, Section 9.9 or
Section 9.10 shall in no event reduce the royalties due from Licensee to ReViral in any Calendar Quarter by [***], provided that, [***]. 

  

	9.12	 Within [***] of the end of each Calendar Quarter Licensee shall send to ReViral a written report setting out,
on a Licensed Product-by-Licensed Product and country-by-country or region-by-region basis, (i) the amount of Net Sales in such country during such Calendar Quarter expressed in the local currency of that country; and (ii) the amount
of the royalties due to ReViral in relation to such Calendar Quarter. Licensee shall make all payments to ReViral under this Agreement in USD. To convert the local currency amounts set out in the report to USD [***]. Upon receipt of such report
ReViral shall invoice the Licensee for the royalties due and Licensee shall pay the same to ReViral within [***] of Licensee’s receipt of such invoice. 

  

	9.13	 The Licensee shall and shall cause its Affiliates, Sublicensees and distributors to keep full, true and
accurate records and books of account containing all particulars that may be necessary for the purpose of calculating all payments due to ReViral under this Section 9 (“Payments”) for a minimum period of [***] after the time of
the generation. Upon timely request by ReViral it shall have the right to instruct an independent accountant to perform an audit as it reasonably necessary to enable such accountant to report to ReViral whether or not Licensee’s calculation of
the Payments due to ReViral were calculated correctly in accordance with this Agreement on the following basis: 

  

	 	9.13.1	 such accountant shall be given access to and shall be permitted to examine and copy such books and records of
both the Licensee and any of its Affiliates, Sublicensees or distributors upon [***] notice having been given by ReViral; 

  

	 	9.13.2	 prior to any such examination taking place, such accountant shall undertake to Licensee or a Sublicensee or
distributor as appropriate that it shall keep all information and data contained in such books and records strictly confidential and shall not disclose such information or copies of such books and records to any third person other than ReViral and
shall only use the same for the purpose of the reviews and calculations that they need to perform in order to issue the report to ReViral; 

  

	 	9.13.3	 any such audit shall occur no more frequently than [***] per Calendar Year and will not go back over records
more than [***] unless a discrepancy is found; 

  

	 	9.13.4	 Licensee, its Affiliates, Sublicensees and distributors shall make available personnel to answer queries on all
books and records required for the purpose of the report; and 

  

	 	9.13.5	 if the report indicates that Licensee’s prior reports to ReViral of the amount of Payments were
inaccurate, then ReViral shall notify Licensee of the accountant’s calculations and within thirty (30) days of receipt of these by Licensee it shall notify ReViral whether or not Licensee agrees with the accountant’s calculation.

  

	 	9.13.6	 if Licensee notifies its agreement with the calculation within the [***], then the amount calculated by the
accountant shall be used for purposes of calculating any monies owed by Licensee to ReViral (in the event of an underpayment) or ReViral to Licensee (in the event of an overpayment). In the event of an underpayment, ReViral shall invoice Licensee
for any balance due and Licensee shall pay the same within [***]. In the event of an overpayment, Licensee will credit the amount of such overpayment against future Payments to ReViral or, if no additional Payments are owed, then Licensee shall
invoice ReViral for any balance due and ReViral shall pay the same within [***]. The cost of the accountant shall be the responsibility of ReViral unless the calculation shows that Licensee’s previous figures to be inaccurate by more than
[***]. 

  
 34 

	 	9.13.7	 If Licensee notifies its disagreement with the calculation within the [***] period and within [***] after such
notice the parties have not agreed about the calculation, either Party may refer the items in dispute to a partner of at least ten (10) years qualified experience at an independent, internationally recognised, public accounting firm for final
and binding resolution. Such person appointed shall act on the following basis: 

  

	 	(1)	 [***]; 

  

	 	(2)	 [***]; 

  

	 	(3)	 Licensee and ReViral shall each provide such person with all information relating to the items in dispute which
such person reasonably requires and such person shall be entitled (to the extent he considers appropriate) to base his determination on such information; 

  

	 	(4)	 the decision of such person is, in the absence of fraud or manifest error, [***]; and 

 

	 	(5)	 [***]. 

  

	9.14	 All payments made to ReViral under this Agreement shall be made by wire transfer to the account of ReViral or
any other bank account that may be notified by ReViral to Licensee from time to time. 

  

	9.15	 All payments to be made hereunder are exclusive of any applicable taxes, including withholding taxes and
value-added taxes. In the event any withholding, value added, or other tax (including any tax based on income to ReViral) is required to be withheld and deducted from payments by Licensee under Applicable Laws, Licensee will make such deduction and
withholding and will pay the remainder to ReViral, any amounts so withheld and deducted will be remitted by Licensee on a timely basis to the appropriate Competent Authority, and Licensee will be deemed to have fulfilled all of its payment
obligation to ReViral with respect to such payments. 

  

	9.16	 If Licensee fails to make any payment due to ReViral hereunder on the due date for payment and the payment is
not in dispute between the parties, or the dispute has not been resolved, without prejudice to the other right or remedy available to ReViral, ReViral shall be entitled to charge Licensee interest (both before and after judgment) on the amount
unpaid at the annual rate of [***] computed from the date such payment was due until the date Licensee makes the payment. 

  

	10.	 INTELLECTUAL PROPERTY 

 

	10.1	 Disclosure and Ownership of new Inventions and Know How 

 

	 	10.1.1	 Each Party shall [***] disclose to the other Party, [***], the making, conception, or reduction to practice of
any Inventions relating to the Licensed Product arising when conducting any activities pursuant to this Agreement. 

  

	 	10.1.2	 All right, title and interest in any and all Inventions (and all Patents and all Know How embodied in such
Inventions) shall be owned by the Party or the Parties based on inventorship, as determined in accordance with the rules of inventorship under United States patent laws. Each Party shall solely own any Inventions made solely by its and its
Affiliates’ employees, agents, or independent contractors. Each Party shall require any such agents and contractors to assign to such Party all right, title and interest in and to such Inventions. The Parties shall jointly own any Invention
that is made jointly by employees, agents, or independent contractors of one Party 

  
 35 

	 	
and its Affiliates together with employees, agents, or independent contractors of the other Party and its Affiliates (“Jointly Owned Inventions”). Except to the extent either
Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign and otherwise exploit any Jointly Owned Inventions without the duty of accounting or seeking consent from
the other Party. 

  

	 	10.1.3	 Subject to Section 10.1.2 all right, title and interest in and to any Know How generated by a Party, its
Affiliates, licensees or contractors pursuant to activities carried out under this Agreement shall be owned by such Party. 

  

	10.2	 Patent Prosecution  

 

	 	10.2.1	 As between the Parties, ReViral shall have the first right (but not the obligation) to file, prosecute and
maintain all Licensed Patents and Patents claiming Jointly Owned Inventions, if any throughout the world. For clarity, this shall include all filings for patent term extension. On a Quarterly basis and within [***] after the receipt of [***].

  

	 	10.2.2	 ReViral shall consult with Licensee and keep Licensee reasonably informed of the status of the Licensed Patents
in the Territory and shall promptly provide Licensee with all material correspondence received from any patent authority in the Territory in connection therewith. In addition, ReViral shall promptly provide Licensee with drafts of all proposed
material filings and correspondence to any patent authority in the Territory with respect to the Licensed Patents for Licensee’s review and comment reasonably in advance of the submission of such proposed filings and correspondences. ReViral
shall confer with Licensee and consider in good faith Licensee’s reasonable business interests and incorporate Licensee’s reasonable comments thereon prior to submitting such filings and correspondences in the Territory, provided
that [***] shall provide such comments within [***] of receiving the draft filings and correspondences from ReViral. 

  

	 	10.2.3	 ReViral shall notify Licensee of any decision to cease prosecution or maintenance of any Licensed Patents in
the Territory. ReViral shall provide such notice at least [***] prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Patent in the Territory. In such event, ReViral shall permit
Licensee, at its discretion and at its sole expense, to continue prosecution or maintenance of such Licensed Patent in the Territory. Licensee’s prosecution or maintenance of such Licensed Patent shall not change the Parties’ respective
rights and obligations under this Agreement with respect to such Licensed Patent other than as expressly set forth in this Section 10.2.3. If Licensee makes such election to continue prosecution and maintenance, then ReViral shall (and shall
cause its patent attorneys to) promptly transfer all applicable patent prosecution files (but, for clarity, not the ownership of the Licensed Patent) to Licensee or its designee. 

 

	 	10.2.4	 [***] any available patent term extensions or supplementary protection certificates with respect to any Patents
(“Patent Term Extensions”), in each country and region [***]. [***] shall have final decision-making authority with regard to the filing of Patent Term Extensions for the Licensed Patents in the Territory. Licensee agrees to
consider in good faith any comments of ReViral as to whether to file any such Patent Term Extension. ReViral shall cooperate with Licensee with regard to obtaining Patent Term Extensions and shall provide to Licensee prompt and reasonable assistance
as requested by Licensee, [***], including by taking such action as may be required of the patent holder under any Applicable Laws to obtain such Patent Term Extension. 

  
 36 

	 	10.2.5	 Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution
efforts under this Section 10.2, including providing any necessary powers of attorney and executing any other required documents or instruments relating to such prosecution. 

 

	 	10.2.6	 For avoidance of doubt, Licensee shall have the sole right to file, prosecute and maintain all Licensee Patents
(but excluding Patents claiming Jointly Owned Inventions, if any), at Licensee’s own cost and expense. 

  

	10.3	 Patent Enforcement 

 

	 	10.3.1	 Each Party shall promptly notify the other Party if it becomes aware of any suspected, threatened, or actual
infringement by a Third Party of any of the Licensed Patents, which infringement adversely affects or could reasonably be expected to adversely affect the Licensed Products in the Territory, or any declaratory judgment, opposition, or similar action
alleging the invalidity, unenforceability or non-infringement of any of the Licensed Patents in the Territory (collectively “Product Infringement”). 

 

	 	10.3.2	 As between the Parties, Licensee shall have the first right to bring and control any legal action in connection
with such Product Infringement in the Territory at its own expense as it reasonably determines appropriate. If Licensee does not bring such legal action or take any other reasonable action within [***] after the notice provided pursuant to
Section 10.3.1 (or such shorter time period as may be required to avoid material prejudice to such action), then ReViral shall have the right to bring and control any legal action in connection with such Product Infringement in the Territory at
its own expense as it reasonably determines appropriate. 

  

	 	10.3.3	 At the request and expense of the Party bringing an action under this Section 10.3, the other Party shall
provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required by Applicable Laws to pursue such action. In connection with
any such enforcement action, the enforcing Party shall keep the other Party reasonably informed on the status of such action and shall not enter into any settlement admitting the invalidity or non-infringement
of, or otherwise impairing the other Party’s rights in the Licensed Patents without the prior written consent of the other Party. The non-enforcing Party shall be entitled to separate representation in
such enforcement action by counsel of its own choice and at its own expense. 

  

	 	10.3.4	 Any recoveries resulting from enforcement action relating to a claim of Product Infringement in the Territory
shall be first applied against payment of each Party’s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses shall be retained by the enforcing Party, provided that, [***].

  

	 	10.3.5	 ReViral shall have the exclusive right to bring and control any legal action to enforce the Licensed Patents
against any infringement that is not a Product Infringement or that is outside the Territory, in each case, at its own expense and as it reasonably determines appropriate, and shall have the right to retain all recoveries. 

  
 37 

	10.4	 Infringement of Third Party Rights 

 

	 	10.4.1	 Each Party shall bring to the attention of the other Party any Relevant Third Party Patent Right that it
discovers where it believes that the conduct of Development, Manufacture, or Commercialisation of Licensed Products in a country or region of the Territory or outside the Territory would infringe the Relevant Third Party Patent Right. [***].

  

	 	10.4.2	 [***]. 

  

	 	10.4.3	 [***]. 

  

	 	10.4.4	 If the Development, Manufacture or Commercialization in the Territory of any Licensed Product or other activity
of either of the Parties pursuant to the Agreement is alleged by a Third Party to infringe a Third Party’s Patents, the Party becoming aware of such allegation shall promptly notify the other Party. If any such allegation subsequently results
in the Third Party bringing infringement proceedings, Licensee has the first right, but not the obligation, to control any defense of any such claim involving alleged infringement of Third Party Patents by Licensee’s activities under this
Agreement, at its own expense and by counsel of its own choice. ReViral shall provide reasonable assistance to Licensee for such defence and shall join in any such action if reasonably required by Licensee in order to defend such claim or to assert
all available defences and claims, and shall cooperate reasonably with the Licensee. 

  

	 	10.4.5	 With regard to any information (including materials) disclosed pursuant to this Agreement by one Party to the
other Party regarding intellectual property rights owned or Controlled by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the
Development, Manufacturing, or Commercialization of any Licensed Product, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual
property rights relating to the Development, Manufacturing, or Commercialization of any Licensed Product. Accordingly, the Parties agree that all such information obtained by one Party from the other Party will be used solely for purposes of the
Parties’ common legal interests with respect to the conduct of this Agreement. All information will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be
applicable. By sharing any information, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other
Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party. 

 

	10.5	 Patent Marking 

Licensee shall mark the Licensed Products sold in the Territory in accordance with the applicable patent marking laws, and shall require all
of its Affiliates and Sublicensees to do the same. To the extent permitted by Applicable Laws, Licensee shall indicate on the product packaging, advertisement and promotional materials that the Licensed Products are
in-licensed from ReViral. 

  
 38 

	10.6	 Trademarks  

  

	 	10.6.1	 Licensee may use the ReViral Trademark in relation to the Commercialisation of Licensed Product in the
Territory and will make such determination in good faith and in consultation with ReViral through the JSC. The use by Licensee of the ReViral Trademark shall not constitute or imply any assignment or transfer of the ReViral Trademark or any goodwill
associated therewith. Any goodwill accrued in connection with the use of the ReViral Trademark shall accrue solely to the benefit of ReViral. Licensee shall ensure that each reference to and use of the ReViral Trademark by Licensee in promotional
materials is acceptable to ReViral and is accompanied by an acknowledgement that the ReViral Trademark is owned by ReViral and used by Licensee under licence. 

 

	 	10.6.2	 Licensee acknowledges that ReViral may develop a global branding strategy for the Licensed Products and adopt
key distinctive colors, logos, images, symbols, and trade dress to be used in connection with the Commercialization of the Licensed Products throughout the world (such branding elements, collectively, the “Global Brand Elements”).
ReViral shall own all rights in the Global Brand Elements and shall register and maintain the Global Brand Elements in any country in the world as it determines reasonably necessary, at ReViral’s own cost and expense. Subject to
Section 10.6.4, Licensee, its Affiliates and Licensees shall use reasonable efforts to Commercialize the Licensed Products in the Territory using the Global Brand Elements in a manner consistent with ReViral’s global branding strategy for
the Licensed Products. 

  

	 	10.6.3	 In circumstances where under local Applicable Law in a country or region of the Territory Licensee or its
Affiliate is required to own the Trademark as part of holding Regulatory Approval for the Licensed Product in such country, Licensee shall supply ReViral with proof of this, and in such case the ReViral shall assign the ReViral Trademark in such
country or region to Licensee or the Affiliate as relevant. Thereafter, Licensee shall be responsible, at its own cost and expense, for prosecution and maintenance of the ReViral Trademark in the Territory. 

 

	 	10.6.4	 In circumstances where Licensee determines in good faith that it would not be appropriate to Commercialize the
Licensed Product under the ReViral Trademark in a given country in the Territory, Licensee or an Affiliate as relevant may register a different trademark in such country in their name (“Licensee Trademark”). 

 

	 	10.6.5	 Licensee shall not directly or indirectly challenge the validity of the ReViral Trademark and shall not aid or
assist third parties to do so. ReViral shall not directly or indirectly challenge the validity of the Licensee Trademark and shall not aid or assist third parties to do so. Whatever use Licensee makes of the ReViral Trademark shall inure to the sole
and exclusive benefit of the Licensed Product in accordance with this Agreement. 

  

	 	10.6.6	 Neither Party shall use the other Party’s corporate name, or use any trademarks of the other Party (other
than the ReViral Trademark or Licensee Trademark) in connection with any promotional materials or publication without the other Party’s prior written consent, which shall not be unreasonably withheld. The above restriction will not apply to
representations that Licensee is the exclusive licensee of ReViral for the Licensed Product in the Territory. 

  

	 	10.6.7	 In the case of infringement or misuse of the ReViral Trademark in the Territory, if ReViral fails to initiate
proceedings within [***] of Licensee’s delivery of notice to ReViral identifying the infringement, Licensee may give ReViral notice requesting ReViral to take such proceedings within [***] of the date of this second notice. If ReViral fails to
initiate such proceedings within such period, Licensee shall be entitled to do so at its own cost and expense in which case it shall have sole conduct of any claim or proceedings. ReViral shall, and shall procure that its Affiliates shall,
reasonably assist and cooperate with Licensee in any such claim, provided that 

  
 39 

	 	
[***]. Such reasonable assistance and cooperation of ReViral and its Affiliates shall include the execution of such documents and the performance of such other acts as may be reasonably required
to facilitate such claim, including such documents and acts that may, upon Licensee’s request, be required for the registration of the Licensee as exclusive licensee of the ReViral Trademark in the Territory at the trademark office in the
relevant countries of the Territory. Licensee shall have sole right to settle such proceedings provided such settlement does not adversely affect ReViral’s rights and interests outside of the Territory, and shall be entitled to retain any
financial payment awarded in such proceedings or agreed in any such settlement for its own account. 

  

	11.	 CONFIDENTIALITY 

 

	11.1	 Licensee and ReViral, on behalf of themselves and their respective directors, officers, employees, agents,
advisors, consultants and Affiliates (“Representatives”), undertake that during the Term and for [***] after the expiration or any termination of the Agreement for any reason: (i) all Confidential Information shall be treated
in confidence by Recipient Party Representatives and shall only be used by Recipient Party Representatives or furnished to any third party for purposes consistent with the Agreement and (ii) Recipient Party Representatives shall treat all
Confidential Information provided by the Disclosing Party with the same degree of care as the Recipient Party uses for its own similar information, and in any event shall take reasonable and appropriate precautions to observe confidentiality of, and
not disclose, the Confidential Information. Recipient Party shall take all commercially reasonable measures to ensure that Representatives other than itself observe strict secrecy in respect of any of the Confidential Information and that disclosure
to such Representatives is limited to only those persons who have a need to know same for the purpose of performing the Agreement. Representatives who are not employees of Licensee or an Affiliate must be obligated to substantially the same extent
as set forth in this Section 11.1 to hold in confidence and not make use of such Confidential Information for any purpose other than those permitted by this Agreement. 

 

	11.2	 ReViral shall be considered the Disclosing Party and Licensee the Recipient Party with respect to the Licensed
Know How and, to the extent Confidential Information, Regulatory Documents within the Licensed IPR; Licensee shall be considered the Disclosing Party and ReViral the Recipient Party with respect to the Licensee Know How and, to the extent
Confidential Information, Regulatory Documents within the Licensee IPR; and each Party will be considered a Disclosing Party and a Recipient Party with respect to the terms and conditions of this Agreement. 

 

	11.3	 The following information shall not be Confidential Information, and the obligations set out in
Section 11.1 shall not apply to such information, if the Recipient Party can show such information: 

  

	 	11.3.1	 was generally available in the public domain at the time it was disclosed to the Recipient Party or
subsequently came into the public domain through no fault of the Recipient Party; 

  

	 	11.3.2	 was known to the Recipient Party at the time it was disclosed and either (i) the person that was the
source of such Confidential Information had itself received it from the Disclosing Party but under no obligation of confidence to the Disclosing Party; or (ii) the person that was the source of such Confidential Information was an independent
third party, with no connection or relationship with the Disclosing Party, and had generated the Confidential Information independently; 

  

	 	11.3.3	 is subsequently disclosed to the Recipient Party or any of its Affiliates without obligation of confidentiality
by a Third Party who may rightfully do so and is not under a conflicting obligation of confidentiality to the Disclosing Party; 

  
 40 

	 	11.3.4	 is developed by the Recipient Party or any of its Affiliates independently and without use of or reference to
any Confidential Information received from the Disclosing Party, as documented by the Receiving Party’s business records. 

  

	11.4	 For clarity, specific aspects or details of Confidential Information shall not be deemed to be within the
public domain or in the possession of the recipient party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient party. Further, any combination of Confidential
Information shall not be considered in the public domain or in the possession of the recipient party merely because individual elements of such Confidential Information are in the public domain or in the possession of the recipient party unless the
combination is in the public domain or in the possession of the recipient party. 

  

	11.5	 Notwithstanding the above obligations of confidentiality and non-use, a
Recipient Party may: 

  

	 	11.5.1	 disclose Confidential Information of the Disclosing Party to: (i) such Recipient Party’s Affiliates,
licensees and Sublicensees; and (ii) employees, directors, officers, agents, contractors, consultants, attorneys, accountants, and advisors of the Recipient Party and its Affiliates, licensees, and Sublicensees, in each case ((i) and (ii)), to
the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such Persons are bound by legally enforceable obligations of confidentiality and
non-use with respect to the Disclosing Party’s Confidential Information no less stringent than the confidentiality and non-use obligations set forth in this
Agreement. Each Party will remain responsible for any failure by its Affiliates, licensees, and Sublicensees, and its and its Affiliates’, licensees’, and Sublicensees’ respective employees, directors, officers, agents, consultants,
attorneys, accountants, advisors, and contractors, in each case, to treat such Confidential Information as required under this Section 11 (as if such Affiliates, licensees, Sublicensees, employees, directors, officers agents, consultants,
advisors, attorneys, accountants, banks, investors, and contractors were Parties directly bound to the requirements of this Section 11); and 

  

	 	11.5.2	 disclose Confidential Information to a Regulatory Authority as reasonably necessary to obtain Regulatory
Approval in a particular jurisdiction to the extent consistent with the licenses granted under terms of this Agreement; and 

  

	 	11.5.3	 disclose Confidential Information: (i) to the extent such disclosure is reasonably necessary to comply
with the order of a court; or (ii) to the extent such disclosure is required to comply with Applicable Laws, including to the extent such disclosure is required in publicly filed financial statements or other public statements under rules
governing a stock exchange; provided, to the extent possible bearing in mind such Applicable Laws and subject to the next subsequent sentence of this Section 11.5.3, such Party shall provide the other Party with a copy of the proposed
text of such statements or disclosure [***] in advance of the date on which the disclosure is to be made to enable the other Party to review and provide comments, which the disclosing Party will consider in good faith. If the compliance with an
Applicable Law requires filing of this Agreement, the filing Party shall to the extent possible seek confidential treatment of portions of this Agreement from the relevant Competent Authority and shall provide the other Party with a copy of the
proposed filings at least [***] prior to filing for the other Party to review and comment on any such proposed redactions, and the filing Party will consider such comments in good faith. Confidential Information that is disclosed in order to comply
with Applicable Law or by judicial or administrative process pursuant to this Section 11.5.3 in each case, will remain otherwise subject to the confidentiality and non-use provisions of this
Section 11 with respect to the Party disclosing such Confidential Information, and such Party will take all steps reasonably necessary, including seeking of confidential treatment or a protective order for a period of at least [***] (to the
extent 

  
 41 

	 	
permitted by Applicable Law or Competent Authority), to ensure the continued confidential treatment of such Confidential Information. Each Party agrees that it will obtain its own legal advice
with regard to its compliance with Applicable Laws and will not rely on any statements made by the other Party relating to such Applicable Laws; and 

  

	 	11.5.4	 disclose Confidential Information: (i) to its actual or potential investment bankers; (ii) to
existing and potential investors, (sub)licensees, lenders, and other financial or commercial partners (including in connection with any royalty factoring transaction), and their respective attorneys, accountants, banks, investors, and advisors,
solely for the purpose of evaluating or carrying out an actual or potential investment, (sub)license, debt transaction, or collaboration; and (iii) to a bona fide potential acquirer or merger partner for the purposes of evaluating entering into
a merger or acquisition, provided, however, any such persons must be obligated to substantially the same extent as set forth in Section 11 to hold in confidence and not make use of such Confidential Information for any purpose
other than those permitted by this Agreement; and 

  

	 	11.5.5	 disclose Confidential Information to its legal advisers for the purpose of seeking advice.

  

	11.6	 Notwithstanding anything to the contrary set forth in this Agreement, if a Party is required or permitted to
make a disclosure of the other Party’s Confidential Information pursuant to Section 11.5.2 or Section 11.5.3 then it will, to the extent not prohibited by Applicable Law or judicial or administrative process, except where
impracticable, give reasonable advance notice to the other Party of such proposed disclosure and use reasonable efforts to secure confidential treatment of such information and will only disclose that portion of Confidential Information that is
legally required to be disclosed as advised by its legal counsel. In any event, each Party agrees to take all reasonable action to avoid disclosure of Confidential Information of the other Party hereunder. 

 

	11.7	 Nothing in this Section 11 will limit either Party in any way from disclosing to any Third Party such
Party’s U.S. or foreign income tax treatment and the United States or foreign income tax structure of the transactions relating to such Party that are based on or derived from this Agreement, or materials of any kind (including opinions or
other tax analyses) relating to such tax treatment or tax structure, except to the extent that nondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws. 

 

	11.8	 Nothing in this Section 11 restricts either Party from using or disclosing any of its own Confidential
Information for any purpose whatsoever, subject always to the rights granted in this Agreement and provided always that Licensee shall not under any circumstances publish the results of any Clinical Studies on Licensed Product without the prior
written approval of the ReViral. 

  

	11.9	 Notwithstanding anything to the contrary set forth in this Agreement, Confidential Information will not include
any knowledge, technique, experience, or Know How that is retained in the unaided memory of any authorized representative of the Recipient Party after having access to such Confidential Information (“Residual Knowledge”). Any use
made by the Recipient Party of any such Residual Knowledge is on an “as is, where is” basis, with all faults and all representations and warranties disclaimed and at its sole risk. 

 

	11.10	 Other than the press releases pertaining to this transaction that the Parties have agreed upon and attached as
Exhibit F to this Agreement and save as permitted in Section 11.5 neither Party shall make any public announcement or statement to the public containing Confidential Information without the prior written consent of the other. No such
public announcements or statements shall be made without the prior review and consent of the appropriate individual designated for the purpose by the other Party. 

  
 42 

	12.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

BY REVIRAL 
  

	12.1	 ReViral makes the following representations, warranties and covenants at the Effective Date:

  

	 	12.1.1	 ReViral is duly organized and validly existing under the laws of England and Wales and has full corporate power
and authority to enter into the Agreement and to carry out its provisions. 

  

	 	12.1.2	 ReViral is duly authorized to execute and deliver the Agreement and to perform its obligations under the
Agreement. The person executing the Agreement on ReViral’s behalf has been duly authorized to do so by all requisite corporate action. 

  

	 	12.1.3	 The Agreement is a legal and valid obligation binding upon ReViral and enforceable in accordance with its terms
(subject to the applicable laws of bankruptcy and moratorium). The execution, delivery and performance of the Agreement by ReViral will not (i) be prevented or impaired by any agreement, instrument or understanding, oral or written, to which
ReViral or is Affiliates is a party or by which they are bound; or (ii) violate any Legal Requirement to which they are subject. 

  

	 	12.1.4	 ReViral is not aware of any action, suit, inquiry, investigation or proceeding instituted by any Competent
Authority or by any other person or Licensee that might question or threaten the validity of the Agreement. 

  

	 	12.1.5	 Except as disclosed in the Disclosure Letter: 

 

	 	(a)	 ReViral is the sole owner of the entire right, title and interest in and to the Licensed Patents and Licensed
Know How existing at the Effective Date and ReViral has not previously entered into any agreement, whether written or oral, with respect to, or otherwise assigned, licensed, transferred, conveyed or otherwise encumbered its right, title or interest
in or to such Licensed Patents or Licensed Know How for the Territory (including by granting any covenant not to sue with respect thereto). There are no Patents or Know How owned but not Controlled by ReViral or any of its Affiliates that would
constitute Licensed Patents or Licensed Know How, as applicable, if Controlled by ReViral or its Affiliate. The conception, development and reduction to practice of the Licensed Patents and Licensed Know How existing as of the Effective Date have
not constituted or involved, nor has any Person alleged, the misappropriation of trade secrets or other rights or property of any Person; 

  

	 	(b)	 The Patent List sets forth a complete and accurate list of all Patents existing as of the Effective Date that
are Controlled by ReViral relating to the Licensed Product in the Territory which as of the Effective Date are necessary or reasonably useful for Licensee to perform its obligations hereunder and enjoy the benefit of the licenses and rights granted
to it hereunder; 

  

	 	(c)	 [***] (i) all Licensed Patents are being diligently prosecuted in the respective patent offices in accordance
with Applicable Law; ReViral and its Affiliates have presented all references, documents, or information for which it and the inventors had a duty to disclose under the Applicable Law, including 37 C.F.R. 1.56 or its foreign equivalent, to the
relevant patent examiners at the relevant patent offices for each Licensed Patent; (ii) the inventorship of the Licensed Patents is properly identified on each issued patent or patent application in the

  
 43 

	 	
Licensed Patents; and (iii) all fees required to be paid by ReViral in any jurisdiction in the Territory order to maintain the Licensed Patents have been timely paid and such Licensed
Patents are subsisting and, [***] , the claims of all issued, unexpired Licensed Patents are valid under applicable patent laws and ReViral is not aware of any reason why those claims would not be enforceable under applicable patent laws;

  

	 	(d)	 Licensee has been provided copies of all patent searches relating to the Licensed Patents to investigate
freedom to operate that have actually been undertaken by ReViral or its Affiliates prior to the Effective Date; 

  

	 	(e)	 [***], there is no current unauthorized use, infringement, or misappropriation of any Licensed IPR by any Third
Party; 

  

	 	(f)	 No notification has been received by ReViral or its Affiliates of any claim or litigation brought (and no such
claim has been brought) or threatened in writing by any Person (i) challenging the ownership, scope, duration, validity, enforceability, priority, or right to use any Licensed Patent (including, by way of example, through the institution of or
written threat of institution of interference, inter partes review, reexamination, protest, opposition, nullity, or similar invalidity proceeding before the United States Patent and Trademark Office or any foreign patent authority or court), (ii)
alleging that the disclosing, copying, making, licensing, assigning or exploiting of Licensed IPR in the Territory violates, infringes or otherwise conflicts or interferes with any intellectual property or proprietary right of any Person;

  

	 	(g)	 To the extent permissible under Applicable Law, (i) all employees, agents, consultants, contractors or
other representatives of ReViral or its Affiliates performing activities under this Agreement are under an obligation to assign all rights, title, and interests in and to their Inventions and other Know How, whether or not patentable, and
intellectual property therein, to ReViral or its Affiliates as the sole owner thereof; (ii) Licensee will have no obligation to contribute to any remuneration of any inventor employed or previously employed by ReViral or any of its Affiliates
in respect of any such Inventions and other Know How and intellectual property therein that are so assigned to ReViral or its Affiliate(s); and (iii) ReViral will pay all such remuneration due to such Inventions and other Know How and
intellectual property rights therein; 

  

	 	(h)	 [***], the practice by Licensee under the Licensed IPR or the Exploitation by Licensee or ReViral (or their
respective Affiliates or Sublicensees) of any Licensed Product, in each case, as contemplated under this Agreement in the Territory, will not infringe, misappropriate, or otherwise violate any intellectual property of any Third Party;

  

	 	(i)	 ReViral has taken commercially reasonable measures consistent with industry practices to protect the secrecy,
confidentiality, and value of all Licensed Know How that constitutes trade secrets under Applicable Law. [***], the Licensed Know How existing at the Effective Date has been kept confidential or has been disclosed to Third Parties only under terms
of confidentiality; 

  

	 	(j)	 ReViral and its Affiliates have conducted all Development of Compounds and Licensed Products in accordance with
all Applicable Law in all material respects; 

  
 44 

	 	(k)	 As of the Effective Date, ReViral maintains Control over all Regulatory Documents pertaining to the Licensed
Products in the Field; 

  

	 	(l)	 ReViral has furnished or made available to Licensee or its agents or representatives (i) all information
requested by Licensee, (ii) all material (as determined by ReViral in its reasonable discretion) safety and efficacy data existing as of the Effective Date, and (iii) all material (as determined by ReViral in its reasonable discretion)
Regulatory Documents and other material correspondence with Regulatory Authorities, in each case ((i) through (iii)), concerning the Licensed Product (in each case in the form being Developed by ReViral or any of its Affiliates as of the Effective
Date); and 

  

	 	(m)	 (i) [***], there are no scientific or technical facts or circumstances that have not been disclosed to
Licensee, and that would adversely affect the scientific, therapeutic, or commercial potential of the Licensed Product; (ii) there is nothing within ReViral’s Control that has not been disclosed to Licensee and that could adversely affect
the acceptance, or the subsequent approval, by any Regulatory Authority of any Regulatory Documents; and (iii) [***], there are no safety, efficacy, or regulatory issues that would preclude Licensee from Exploiting the Licensed Products in the
Territory in compliance with the Applicable Law. 

 BY THE LICENSEE 

 

	12.2	 Licensee makes the following representations, warranties and covenants as of the Effective Date:

  

	 	12.2.1	 Corporate Power. Licensee is duly organized and validly existing under the laws of Delaware and has full
corporate power and authority to enter into the Agreement and carry out the provisions of the Agreement. 

  

	 	12.2.2	 Due Authorization. Licensee is duly authorized to execute and deliver the Agreement and to perform its
obligations under the Agreement. The person executing the Agreement on Licensee’s behalf has been duly authorized to do so by all requisite corporate action. 

 

	 	12.2.3	 Binding Agreement. The Agreement is a legal and valid obligation binding upon Licensee and enforceable
in accordance with its terms (subject to the applicable laws of bankruptcy and moratorium). The execution, delivery and performance of the Agreement by Licensee will not (i) be prevented or impaired by any agreement, instrument or
understanding, oral or written, to which Licensee or is Affiliates is a party or by which they are bound; or (ii) violate any Legal Requirement to which they are subject. 

 

	 	12.2.4	 Validity. Licensee [***] any action, suit, inquiry, investigation or proceeding instituted by any
Competent Authority or by any other person or Licensee that might question or threaten the validity of the Agreement. 

  

	 	12.2.5	 To the extent permissible under Applicable Law, (i) all employees, agents, consultants, contractors or
other representatives of Licensee or its Affiliates performing activities under this Agreement are under an obligation to assign all rights, title, and interests in and to their Inventions and other Know How, whether or not patentable, and
intellectual property therein, to Licensee or its Affiliates as the sole owner thereof; (ii) ReViral will have no obligation to contribute to any remuneration of any inventor employed or previously employed by Licensee or any of its Affiliates
in respect of any such Inventions and other Know How and intellectual property therein that are so assigned to Licensee or its Affiliate(s); and (iii) Licensee will pay all such remuneration due to such Inventions and other Know How and
intellectual property rights therein 

  
 45 

	12.3	 Each Party additionally represents and warrants to the other Party that, as of the Effective Date:

  

	 	12.3.1	 neither such Party, its Affiliates, nor any director, officer, employee, agent or shareholder of any such
person (“Official”), has made any unlawful bribe, rebate, payoff, influence payment or kickback or has taken any other action that would violate any Anti-Bribery Law to which it is subject; 

 

	 	12.3.2	 it has or will promptly institute and maintain policies and procedures designed to ensure, and that are
reasonably expected to continue to ensure, continued compliance with any Anti-Bribery Law to which it is subject in particular as regards interactions with healthcare professionals and provides regular training to its employees on such policies and
procedures; 

  

	 	12.3.3	 during the past [***], it has not received any written communication indicating or alleging that any Official
is or may be in violation of any Anti-Bribery Law, or that any Official is or may be subject to any investigation or inquiry by a Competent Authority related to any Anti-Bribery Law, and [***] no such investigation or inquiry is pending or
threatened. 

  

	12.4	 Each Party covenants and agrees that: 

 

	 	12.4.1	 it will not utilize in connection with the Development or Commercialization of the Licensed Product any person
or entities that are debarred by the FDA pursuant to the provisions of the Generic Drug Enforcement Act of 1992 (21 U.S.C. § 335) or any similar legislation in the Territory; 

 

	 	12.4.2	 neither such Party, its Affiliates, nor any director, officer, employee, agent or shareholder of any such
person (“Official”), will make any unlawful bribe, rebate, payoff, influence payment or kickback or take any other action that would violate any Anti-Bribery Law to which it is subject; and 

 

	 	12.4.3	 it will maintain policies and procedures designed to ensure, and that are reasonably expected to continue to
ensure, continued compliance with any Anti-Bribery Law to which it is subject in particular as regards interactions with healthcare professionals, and will provide regular training to its employees on such policies and procedures.

  

	 	12.4.4	 Should Licensee breach the covenants of this Section 12.4 at any time, such breach shall constitute a
material breach of this Agreement. 

  

	12.5	 EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS AND EXCLUDES ANY AND ALL REPRESENTATIONS
AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 

  

	12.6	 Except with respect to (i) claims for gross negligence or wilful misconduct, (ii) breaches of
Section 3, Section 11, or Section 12.1.5(a), and (iii) Third Party claims the subject of Sections 13.1 and 13.2, neither Party shall be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for
any loss, damage, costs or expenses of any nature whatsoever incurred or suffered by the other or its Affiliates: 

  
 46 

	 	12.6.1	 of a direct nature where the same is a loss of turnover, profits, business or goodwill; or

  

	 	12.6.2	 an indirect or consequential or punitive nature, including any indirect or consequential economic loss or other
indirect or consequential loss of turnover, profits, loss of enterprise value, business or goodwill or otherwise. 

  

	12.7	 Nothing in this Agreement shall be taken to exclude or limit either Party’s liability to the extent that
such liability cannot be excluded or limited in law including for fraud or fraudulent misrepresentation. 

  

	13.	 INDEMNITY AND INSURANCE COVER  

 

	13.1	 Except as otherwise provided in Section 13.2, Licensee shall defend, indemnify and hold ReViral, its
Affiliates and their directors, officers, employees and agents (each, a “ReViral Indemnitee”) harmless from and against any Losses resulting from any Third Party claims, suits, actions or demands to the extent such Losses
arise directly or indirectly out of: (i) the breach by Licensee of any of its representations, warranties, or covenants under this Agreement; (ii) the gross negligence or wilful misconduct of Licensee or its Affiliate or Sublicensee, or
any officer, director, employee, agent, or representative thereof; or (iii) any claims of any nature arising out of the Exploitation of any Licensed Product by or on behalf of Licensee (other than by any ReViral Indemnitee), including any claim
based on alleged or actual bodily injury or death or other product liability type claims resulting from the use of the Licensed Product in the Territory including Losses that are specifically and proximately due to intrinsic defects or defects in
the Licensed Product, but excluding Losses to the extent due to manufacturing defects existing in CTM when it is delivered to Licensee, its Affiliate or Sublicensee by or on behalf of ReViral under Section 7, as these Losses are the subject of
Section 13.2. 

  

	13.2	 ReViral shall defend, indemnify and hold Licensee, its Affiliates and their directors, officers, employees and
agents (each, a “Licensee Indemnitee”) harmless from and against any Losses resulting from any Third Party claims, suits, actions or demands to the extent such Losses arise directly or indirectly out of: (i) the breach by
ReViral of any of its representations, warranties, or covenants under this Agreement; (ii) any claims of any nature arising out of any Exploitation of any Licensed Product by or on behalf of ReViral; (iii) the gross negligence or wilful
misconduct of ReViral or its Affiliate or Sublicensee, or any officer, director, employee, agent, or representative thereof; or (iv) any claim based on alleged or actual bodily injury or death or other product liability type claims resulting
from use of the Licensed Product in the Territory to the extent due to manufacturing defects existing in CTM when it is delivered to Licensee, its Affiliate or Sublicensee by or on behalf of ReViral under Section 7. 

 

	13.3	 An indemnified person under Sections 13.1 or 13.2 (“Indemnified Party”) shall give the
indemnifying party (“Indemnifying Party”) prompt written notice of any Loss or discovery of any relevant Third Party claim (“Third Party Claim”) upon which such Indemnified Party intends to base a request for
indemnification (an “Indemnification Claim Notice”). Where required the Indemnifying Party shall promptly send a copy of the Indemnification Claim Notice to its relevant insurers and shall permit them to exercise their rights of
subrogation and hereafter in this Section 13.3 “Indemnifying Party” shall be deemed to include any such insurers. Failure by an Indemnified Party to give an Indemnification Claim Notice as provided in this Section 13.3
will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is materially prejudiced as a result of such failure to give notice. Each Indemnification
Claim Notice shall contain a description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party
copies of all correspondence, communications and official documents (including court documents) received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or their respective
directors, officers, employees and agents (each, an “Indemnitee”) shall be made solely by a Party to this Agreement or its insurers, provided that a Party can make a claim on behalf of its Indemnitees. 

  
 47 

	13.4	 The obligations of an Indemnifying Party under this Section 13 shall be governed by and contingent upon
the following: 

  

	 	13.4.1	 At its option, the Indemnifying Party may assume control of the defense of any Third Party Claim (which, for
the avoidance of doubt, shall include the conduct of all dealings with such third party) by giving written notice to the Indemnified Party within [***] after the Indemnifying Party’s receipt of an Indemnification Claim Notice.

  

	 	13.4.2	 Upon the assumption of the control of the defense of a Third Party Claim by the Indemnifying Party:

  

	 	(a)	 subject to the provisions of Section 13.4.3, it shall have the right to and shall assume sole control and
responsibility for dealing with the third party and the Third Party Claim, including the right to settle the claim on any terms the Indemnifying Party chooses, but at all times in accordance with the provisions of Section 13.4.5;

  

	 	(b)	 if it chooses, the Indemnifying Party may appoint as counsel in the defense of the Third Party Claim any law
firm or counsel reasonably satisfactory to the Indemnified Party; and 

  

	 	(c)	 except as expressly provided in Section 13.4.3, the Indemnifying Party shall not be liable to the
Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim. 

 

	 	13.4.3	 If the Indemnifying Party chooses not to control the defense of any Third Party Claim, the Indemnified Party
may control such defense (with counsel reasonably selected by the Indemnified Party and approved by the Indemnifying Party, such approval not to be unreasonably withheld). 

 

	 	13.4.4	 Without limiting the remainder of this Section 13.4, the Party not controlling the defense of a Third
Party Claim may participate therein at its own expense. 

  

	 	13.4.5	 The Party controlling the defense of any Third Party Claim will keep the other Party advised of the status and
material developments of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto. The other Party will reasonably cooperate with the Party controlling such defense and
its Affiliates and agents in defense of the Third Party Claim, with all out-of-pocket costs of such cooperation to be borne by the Party controlling such defense.

  

	 	13.4.6	 The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, which consent
shall not be unreasonably withheld or delayed (unless such compromise or settlement involves (i) any admission of legal wrongdoing by the Indemnified Party, (ii) any payment by the Indemnified Party that is not indemnified under this
Agreement, or (iii) the imposition of any equitable relief against the Indemnified Party (in which case, (i) through (iii), the Indemnified Party may withhold its consent to such settlement in its sole discretion)), agree to any settlement
of such Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the
Indemnified Party (other than a monetary obligation on the Indemnifying Party). 

  
 48 

	 	13.4.7	 The Indemnified Party shall not admit any liability with respect to, or settle, compromise or discharge, any
Third Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld or delayed. The Indemnifying Party shall not be liable for any settlement or other disposition of Losses by an
Indemnified Party under such a Third Party Claim that is reached without the written consent of the Indemnifying Party not to be unreasonably withheld or delayed. 

 

	 	13.4.8	 Except as expressly provided above, the reasonable and verifiable costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party where it participates in the defence under Section 13.4.3 or Section 13.4.5 shall be reimbursed on a quarterly basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

  

	13.5	 Each Party shall maintain, at its own cost, the insurance coverages set forth in this Section 13.5:

  

	 	13.5.1	 Commencing as of the date Licensee files an IND for Licensed Product in the Territory, and thereafter for the
period of time required under Section 13.6, each Party shall obtain and maintain on an ongoing basis, products liability insurance, including contractual liability, in the minimum amount of [***] per occurrence, combined single limit for bodily
injury and property damage liability. 

  

	13.6	 The following provisions apply: 

 

	 	13.6.1	 All insurance coverages shall be primary insurance with respect to each Party’s own participation under
this Agreement, and shall be maintained with an insurance Licensee or companies having an A.M. Best’s rating (or its equivalent) of A-XII or better. 

 

	 	13.6.2	 The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a
Party, then in such a case, such Party shall maintain the insurance coverage for at least [***] following such Party’s completing performance of its obligations under this Agreement. 

 

	 	13.6.3	 Each Party’s aggregate deductibles under its commercial general liability and products liability and other
insurance policies shall be reasonably satisfactory to the other Party, taking into account the deductibles that are prudent and customary with respect to the activities in which it is engaged under this Agreement. 

 

	 	13.6.4	 Each Party shall provide to the other Party its respective certificates of insurance evidencing the insurance
coverages set forth in Section 13.5 Each Party shall provide to the other Party at least [***] prior written notice of any cancellation, non-renewal or material change in any of the insurance coverages.
Each Party shall, upon receipt of written request from the other Party, provide renewal certificates to the other Party for as long as such Party is required to maintain insurance coverages hereunder. 

 

	14.	 TERM AND TERMINATION OF THE AGREEMENT 

 

	14.1	 The Agreement shall enter into force and effect on the Effective Date and shall remain in full force and effect
on a country-by-country or region-by-region basis in the Territory for the duration of
the Royalty Term, subject to earlier termination as provided in this Agreement. At the expiry of the Royalty Term in each country or region of the Territory the licenses granted to the Licensee hereunder in such country or region shall become
perpetual, irrevocable, fully paid up, royalty free and fully sublicenseable and transferable in such country. 

  
 49 

	14.2	 Licensee shall have the right during the Term to terminate this Agreement at will and for any reason by giving
not less than [***] prior written notice to ReViral at any time prior to the First Commercial Sale Date, or [***]. Until the effective date of termination, Licensee shall be responsible for performing all of its obligations hereunder. For clarity,
any milestone and other payments due to ReViral during such [***] or [***] period, as applicable, shall remain payable by Licensee. Licensee shall terminate the Agreement as set forth under this Section 14.2 if it determines, in its sole
discretion, to permanently terminate all Development and Commercialization of all Licensed Products throughout the Territory. 

  

	14.3	 Either Party (“Non-Breaching Party”) shall have the
right to terminate this Agreement if the other Party (“Breaching Party”) has materially breached this Agreement, effective (i) upon [***] written notice, if the nature of the breach is incapable of remedy or if the breach is of
a financial obligation capable of remedy that shall not have been remedied within such [***] period; or (ii) in the case of all other material breaches of this Agreement capable of remedy, upon giving [***] written notice, if the breach has not
been remedied within such [***] period. The written notice describing the alleged material breach will provide sufficient detail to put the Breaching Party on notice of such material breach. Notwithstanding any provision in this Agreement to the
contrary, if such material breach (other than a material breach arising from a financial obligation) cannot be reasonably cured during the foregoing cure period, but is capable of cure within [***], then the Breaching Party may submit to the Non-Breaching Party a reasonable cure plan to remedy such material breach that is reasonably acceptable to the Non-Breaching Party, and upon such submission, the applicable
cure period will automatically be extended for so long as the Breaching Party continues to use commercially reasonable efforts to cure such material breach in accordance with such cure plan, but for no more than [***] from receipt of written notice
of such breach. If the Breaching Party is Licensee and the breach relates to one region or country only or a group of regions or countries of the Territory, then ReViral shall only have the right to terminate this Agreement in relation to such
region(s) or country(ies). If the Breaching Party in good faith disputes such material breach or disputes the failure to cure or remedy such material breach and provides written notice of that dispute to the
Non-Breaching Party within the above time period, then the matter will be addressed under the dispute resolution provisions in Section 16.3, the relevant cure period will be tolled during the pendency of
such dispute resolution proceeding, and the Non-Breaching Party may not terminate this Agreement until (a) it has been determined under Section 16.3 that the Breaching Party is in material breach of
this Agreement and (b) such cure period expires without the material breach having been cured by the Breaching Party. For clarity, a failure by ReViral to supply CTM ordered by Licensee shall not constitute a material breach of this Agreement,
provided that any breach of this Agreement by Licensee proximately caused by ReViral’s failure to supply CTM shall not give rise to a right of ReViral to terminate this Agreement. 

 

	14.4	 If an Insolvency Event occurs in relation to a Party, the other Party may terminate this Agreement immediately
on written notice to insolvent Party. 

  

	14.5	 ReViral may terminate this Agreement in its entirety upon [***] written notice to Licensee if Licensee or any
of its Affiliates (directly or indirectly, including in association with any other Person) challenges the validity of the Licensed Patents in a legal proceeding before a court of competent jurisdiction. Any such termination shall only become
effective if Licensee or its Affiliate or the other Person has not withdrawn or settled such action before the end of the above notice period. Licensee shall use reasonable efforts to bind any Sublicensees to similar provisions. For the avoidance of
doubt, ReViral may not terminate this Agreement if ReViral or its Affiliate is required by legal process to be joined as a party in any patent challenge by a Third Party. In addition, notwithstanding the foregoing, ReViral will have no right to
terminate this Agreement pursuant to this Section 14.5 with respect to: (i) any affirmative defense or other validity, enforceability, or non-infringement challenge, whether in the same action or in
any other agency or forum of competent jurisdiction, advanced by Licensee, or any of its Affiliates in response to any claim or action brought in the first instance by, or on behalf of, ReViral or any Third Party, or (ii) any patent challenge
to the extent commenced by a Third Party that after the Effective Date acquires or is acquired by Licensee or any of its Affiliates or its or their business or assets, whether by stock purchase, merger, asset purchase, or otherwise; provided
that such proceeding commenced prior to the closing of such acquisition. 

  
 50 

	14.6	 Termination of this Agreement by the Licensee under Section 14.2, or by ReViral under Sections 14.3, 14.4,
or 14.5 shall result in the following consequences in the applicable Terminated Region(s): 

  

	 	14.6.1	 All licenses and rights granted by ReViral to Licensee under the Agreement shall terminate in the Terminated
Region. The Licensee shall immediately cease all use of the Licensed IPR and shall cease all Development, Manufacturing and Commercialisation activity (subject to the remainder of this Section 14.6) in the Terminated Region.

  

	 	14.6.2	 The rights and licenses granted to ReViral in the Terminated Region under Section 2.4 shall be irrevocable
with respect to Licensee IPR owned by Licensee. In the case of Licensee IP that is in-licensed by Licensee or one of its Affiliates from a Third Party, the rights and licenses granted to ReViral under
Section 2.4 shall survive termination of this Agreement and shall be co-terminus with the license received by Licensee or such Affiliate, as applicable. 

 

	 	14.6.3	 Upon the request of any Sublicensee in the Terminated Region not then in breach of its sublicense agreement or
the terms of this Agreement applicable to such Sublicensee, ReViral will enter into a direct license from ReViral to such Sublicensee on the same terms as this Agreement, taking into account any difference in license scope, territory, and duration
of sublicense grant (each a “New License Agreement”). Under any such New License Agreement between ReViral and such former Sublicensee, such Sublicensee will be required to pay to ReViral the same amounts in consideration for such
direct grant as ReViral would have otherwise received from Licensee pursuant to this Agreement on account of such Sublicensee’s Exploitation of the Licensed Products had this Agreement not been terminated. Under such New License Agreement, the
Parties agree that ReViral will not be bound by any grant of rights broader than, and will not be required to perform any obligation other than those rights and obligations contained in, this Agreement and all applicable rights of ReViral set forth
in this Agreement will be included in such New License Agreement. 

  

	 	14.6.4	 Licensee will promptly re-assign to ReViral any ReViral Trademarks
Controlled by Licensee in the Terminated Region. 

  

	 	14.6.5	 If there are any on-going Development or Commercialization activities
in the Terminated Region at the time of termination, the Parties will negotiate in good faith and adopt a plan to wind-down such activities in an orderly fashion or, at ReViral’s election, promptly transition such activities from Licensee to
ReViral or its designee, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Trials of the Licensed Products, and take any actions it deems reasonably necessary or appropriate to avoid any human
health or safety problems and in compliance with all Applicable Laws. 

  

	 	14.6.6	 Each Party will destroy all Confidential Information of the other Party relating to the Terminated Region in
its possession as of the effective date of termination (with the exception of one copy of such Confidential Information, which may be retained by the legal department of the applicable Receiving Party to confirm compliance with the non-use and non-disclosure provisions of this Agreement). Notwithstanding the foregoing, such Receiving Party shall not be required to destroy any computer files created
during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received such Confidential Information under this Agreement. 

  
 51 

	 	14.6.7	 Licensee hereby grants to ReViral an exclusive, perpetual, sublicenseable license (through multiple tiers), on
the financial terms described below, to use the Licensee IPR and Licensee Commercial Information as such Licensee IPR and Licensee Commercial Information exists as of the effective date of date of termination, inside the Terminated Region to further
Develop and Commercialise the Licensed Products (in the form such Licensed Products exist as of the effective date of termination.) Licensee shall within [***] of the effective date of termination transfer to ReViral the Licensee Know How, Licensee
Commercial Information, and Territory Dossiers for the Terminated Region (including any of the same in the possession of a Sublicensee or distributor of the Licensee, to the extent Controlled by Licensee). Licensee shall as soon as [***] after the
effective date of termination (i) assign to ReViral any Licensee Trademark and the domain name for any website established by Licensee or an Affiliate for the Licensed Product in the Terminated Region; and (ii) transfer, or cause its
Affiliates to transfer, to ReViral or its nominee all right, title and interest in all Regulatory Documents (including Regulatory Approvals) held by Licensee and its Affiliates related solely to the Licensed Products in the Terminated Region, and
Licensee or such Affiliates shall execute all necessary and appropriate letters to the NMPA and other Regulatory Authorities in the Terminated Region to ensure that ownership of such Regulatory Documents are transferred to ReViral. In the event that
such a transfer is not possible under Applicable Laws of the Terminated Region, Licensee shall use reasonable efforts to ensure that ReViral has the benefit of the relevant Regulatory Documents and, to this end, consents to any Regulatory Authority
in the Terminated Region cross-referencing to the data and information on file with any Regulatory Authority as may be necessary to facilitate the granting of duplicate Regulatory Documents to ReViral in the Terminated Region. In such circumstance
as soon as the duplicate Regulatory Documents are given to ReViral, the Licensee will, so far as possible under Applicable Laws, cancel the corresponding original Regulatory Documents. Licensee agrees, at its own cost and expense, to complete
whatever other procedures are necessary under Applicable Laws and to do such other acts and things reasonably necessary to enable ReViral (either itself or in conjunction with a Third Party) to Develop and Commercialise the Licensed Product in the
Terminated Region in substitution for Licensee and its Affiliates. 

  

	 	14.6.8	 The consideration for the license granted under Section 14.6.7 shall be established as follows. The
financial terms for such license shall be [***]. The Parties shall in good faith seek to agree to such financial terms within [***] of the date of the notice of termination (based on the valuation methodology specified below). If the Parties fail to
agree to terms during such [***] period, they shall, at their joint expense, appoint a financial advisory firm specializing in the valuation and licensing of pharmaceutical products, which firm has not been retained by either Party at any time
during the previous [***], to conduct a valuation of the Licensee IPR related to the Licensed Product in the Terminated Region. The valuation methodology shall [***]. The decisions of the financial advisory firm shall be final and binding on the
Parties. 

  

	 	14.6.9	 Licensee shall have the right to sell off existing stocks of Licensed Products in a Terminated Region until
such time as the MAA and Regulatory Documents for the Licensed Product in such Terminated Region have been transferred to ReViral in accordance with Section 14.6.7. ReViral shall, following the transfer of the MAA for the Licensed Product in
the Terminated Region, purchase from Licensee at a price equal to [***] all of or any part of stocks of the Licensed Product held by Licensee or its Affiliates that are not subject to orders from customers and are in good and saleable condition and
can be re-labelled under Applicable Law. 

  
 52 

	14.7	 If Licensee has a right to terminate this Agreement Section 14.3, Licensee may elect, in lieu of so
terminating, to have this Agreement continue on all the terms herein save that [***]. 

  

	14.8	 If Licensee has the right to terminate this Agreement under Section 14.4, Licensee may elect, in lieu of
so terminating, to have this Agreement continue on all the terms herein save that (i) [***]; (ii) [***]; and (iii) [***]. 

  

	14.9	 Termination of the Agreement shall be without prejudice to any rights that shall have accrued to the benefit of
either party before such termination, including the right of either party to receive or recover: (i) damages sustained by reason of the breach of the Agreement by the other party, or (ii) any payments which may then be owing under the
terms of the Agreement. In addition, the following provisions of this Agreement shall survive termination of this Agreement: Sections 1, 2.4, 9.13 through 9.16 (with respect to any payment obligation arising prior to such termination), 10.1.2,
10.1.3, 11, 12.5, 12.6, 12.7, 13, 14.6, 14.9, 16, and 17. 

  

	15.	 CHANGE OF CONTROL/ASSIGNMENT/SUCCESSION 

 

	15.1	 In the event that Licensee Group undergoes a Change of Control, this Agreement continues in force with its
obligations on Licensee following any such Change of Control. 

  

	15.2	 In the event that there is a Change of Control of an Affiliate of Licensee (the “Departing
Licensee”) without a Change of Control of the whole Licensee Group Licensee will ensure that in the documentation giving rise to such Change of Control all activities and related documentation previously carried out by the Departing
Licensee under this Agreement are transferred to Licensee together with all related Licensee IPR Controlled by the Departing Licensee. 

  

	15.3	 This Agreement shall not be assignable nor the rights licensed hereunder be transferable in any way by either
Party except by prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed; provided, however, that (i) either Party may assign this Agreement in whole or in part to a corporate Affiliate on
the condition that the assigning Party shall remain liable hereunder for the prompt payment and performance of all obligations of the assignee; (ii) this Agreement may be assigned by a Party to a Third Party in connection with a sale or
transfer of all or substantially all of such Party’s business or assets to which this Agreement relates or in connection with a merger or consolidation transaction involving such Third Party provided always that at the time of such assignment
such Third Party gives a written deed of undertaking to the non-affected Party agreeing to abide by all the obligations under this Agreement of the assigning Party. 

 

	15.4	 This Agreement shall be binding upon, and shall inure to the benefit of, all permitted assigns. Any assignment
or attempted assignment by either Party in violation of the terms of Section 15.3 will be null, void and of no legal effect. 

  

	16.	 GOVERNING LAW AND DISPUTES 

 

	16.1	 The interpretation and construction of this Agreement shall be governed by the laws of the State of New York,
USA excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

 

	16.2	 With the exception of those matters within the purview of the JSC, which will be resolved in accordance with
the procedures set forth in Section 4.6, any dispute, controversy or claim arising out of or relating to this Agreement or the alleged breach, termination or invalidity of this Agreement, shall be submitted in the first instance [***].

  
 53 

	16.3	 Disputes not resolved under Section 16.2 shall, unless Section 16.4 applies, be finally resolved by
arbitration in accordance with the International Chamber of Commerce (“ICC”) in effect on the date of filing of the arbitration, except as modified herein, and the arbitrator(s) shall be engaged on terms consistent with those set
forth herein:- 

  

	 	16.3.1	 If the amount in controversy, including claims and counterclaims, in terms of a monetary amount is less than
[***] and does not relate to [***] there shall be one arbitrator, who shall be selected jointly by Licensee and ReViral within [***] of receipt by respondent of a copy of the demand for arbitration. If the amount in controversy is [***], or if the
dispute involves [***], there shall be three neutral and impartial arbitrators, one appointed by Licensee and one appointed by ReViral within [***] of receipt by respondent of a copy of the demand for arbitration, and the third arbitrator, who shall
serve as chair of the arbitral tribunal, shall be appointed by agreement of the Party-appointed arbitrators within [***] of the appointment of the second arbitrator and who must be an experienced judge, barrister or trial lawyer admitted to practice
law in the same jurisdiction as the governing law. Any arbitrator not timely appointed shall be appointed by the ICC from the ICC’s large, complex case panel, using the listing, ranking and striking procedure in the ICC rules, with each Party
having no more than 2 peremptory strikes. Any arbitrator appointed by the ICC shall have significant experience with the arbitration of similar large, complex, commercial disputes and shall be an experienced judge, barrister or trial lawyer admitted
to practice law in the same jurisdiction as the governing law. 

  

	 	16.3.2	 The arbitration proceeding shall be conducted in the English language. 

 

	 	16.3.3	 The arbitration proceeding shall be held and the award/decision shall be issued in [***], although the Parties
may agree in writing to conduct individual hearings in other locations. 

  

	 	16.3.4	 During the course of the arbitration, each Party shall provide to the other copies of Relevant Material.
“Relevant Material” is defined as all documents or other material relevant to the matters at issue in the arbitration with the exception of (i) communications to and from lawyers admitted to practice law or practicing law
(whether or not employed by a Party) for the purpose of obtaining and giving legal advice; (ii) communications between the Parties or their respective advisers in relation to the terms of a settlement of the particular dispute or disputes which
is or are the subject of the arbitration proceedings; 

  

	 	16.3.5	 The arbitrators may, if requested by one of the Parties, order the preparation of lists of the Relevant
Material for initial evaluation by the requesting Party prior to disclosure or inspection of the Relevant Material. The arbitrators shall also have the power to order production of the Relevant Material on whatever terms the arbitrators deem fit
including the need for production to take place on an urgent basis and the reimbursement of all reasonable costs of production by the requesting party to the furnishing party. Any dispute as to whether a particular document or other material should
be classified as Relevant Material or otherwise disclosed in the course of the arbitration shall be determined in the sole discretion of the arbitrators. The classification of a document or other material as Relevant Material shall not determine
whether such material shall be admissible in evidence in the arbitration. Questions of admissibility shall be decided by the arbitrators in their sole discretion. In the event that the Parties seek to take deposition discovery in the course of a
proceeding, each Party agrees that it will limit the number of depositions that it will take to [***] depositions, unless the arbitrators determine that additional depositions are warranted; 

  
 54 

	 	16.3.6	 The arbitration shall be confidential. No Party shall use or disclose any Relevant Material obtained under this
paragraph for any purpose except in the course of the conduct of the arbitration and (as far as applicable) proceedings before any court, and then only to the extent necessary for the implementation and enforcement of any award of the arbitrators;

  

	 	16.3.7	 The arbitration shall be conducted as expeditiously as practicable, and the Parties and the arbitrators shall
use their best efforts to hold the hearing on the merits no later than [***] after the appointment of a sole arbitrator and no later than [***] after the appointment of a third arbitrator (as the case may be), and the arbitrator(s) shall use their
best efforts to issue a final award within [***] after the close of the hearing. 

  

	 	16.3.8	 In addition to damages, the arbitral tribunal may award [***]. 

 

	 	16.3.9	 The arbitration award shall be in writing and shall briefly state the findings of fact and conclusions of law
on which it is based. 

  

	 	16.3.10 	 The arbitration award shall be final and binding on the Parties and shall not be appealable to any court in any
jurisdiction. 

  

	 	16.3.11 	 The award may be entered and enforced in any court having competent jurisdiction. 

 

	 	16.3.12 	 Each Party shall pay its own expenses of arbitration and the expenses of the arbitrators shall be equally
shared, except that if, in the opinion of the arbitrators, any claim by a Party hereto or any defence or objection thereto by the other Party was unreasonable, the arbitrators may in their discretion assess as part of the award all or any part of
the arbitration expenses of the other Party (including reasonable attorneys’ fees) and the fees and expenses of the arbitrators and the ICC against the party raising such unreasonable claim, defence or objection. 

 

	16.4	 Any dispute concerning the ownership or inventorship of any Inventions arising hereunder in a given
jurisdiction shall be determined by the courts of the jurisdiction in question. 

  

	17.	 MISCELLANEOUS 

 

	17.1	 Force Majeure. Both Parties will be excused from the performance of their obligations under this
Agreement to the extent that such performance is prevented by force majeure; provided the non-performing Party promptly provides notice of the start and stop of such force majeure event to the other
Party. Such excuse will continue for so long as the condition constituting force majeure continues and the non-performing Party takes reasonable efforts to remove the condition as soon as possible. For
purposes of this Agreement, force majeure is a condition beyond the reasonable control of the affected Party and without fault of such Party affected, including an act of God, government order, war, civil commotion, terrorist act, epidemic or
pandemic, public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. The Parties agree the effects of the COVID-19 pandemic that is
ongoing as of the Effective Date (including related government orders) may be invoked as a force majeure for the purposes of this Agreement even though the pandemic is ongoing and those effects may be reasonably foreseeable (but are not known for
certain) as of the Effective Date. In addition, a force majeure may include reasonable measures affirmatively taken by a Party or its Affiliates to respond to any epidemic, pandemic, or spread of infectious disease (including the COVID-19 pandemic), such as requiring employees to stay home, closures of facilities, delays of Clinical Trials, or cessation of activities in response to an epidemic or other force majeure event. Notwithstanding
the foregoing, a Party will not be excused from making payments owed hereunder due to any such force majeure circumstances affecting such Party. The affected Party will notify the other Party in writing of any force majeure circumstances that may
affect its performance 

  
 55 

	 	
under this Agreement as soon as reasonably practical, will provide a good faith estimate of the period for which its failure or delay in performance under the Agreement is expected to continue
based on currently available information, and will undertake reasonable efforts necessary to mitigate and overcome such force majeure circumstances and resume normal performance of its obligations hereunder as soon a reasonably practicable under the
circumstances. If a force majeure persists for more than [***], then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement [***] to mitigate the delays caused by such force majeure.

  

	17.2	 Notices 

  

	 	17.2.1	 Any notice (which term shall in this Section include any other formal written communication) required to be
given under this Agreement or in connection with the matters contemplated by it shall, except where otherwise specifically provided, be in writing in the English language. 

 

	 	17.2.2	 Any such notice shall be addressed as provided in Section 17.2.3 and may be: 

 

	 	(a)	 Delivered by courier, in which case it shall be deemed to have been given upon delivery at the relevant address
if it is delivered not later than 17.00 hours on a business day, or, if it is delivered later than 17.00 hours on a business day or at any time on a day which is not a Business Day, at 08.00 hours on the next business day; or 

 

	 	(b)	 sent by electronic mail, in which case it shall be deemed to be given when the
E-mail leaves the E-mail gateway of the sender where it leaves such gateway before 17.00 hours on any business day or in any other case at 08.00 hours on the next
business day after it leaves such gateway and the onus shall be on the sender to prove the time that the E-mail left its gateway. 

 

	 	17.2.3	 The addresses and other details of the Parties for notices are, subject to Section 17.2.4:

 If to ReViral, addressed to: 

Attention: [***] 
 Address:
[***]. 
 E-mail address: [***] 

If to Licensee, addressed to: 

LianBio 
 c/o Ogier Global
(Cayman) Limited 
 89 Nexus Way 

Camana Bay 
 Grand Cayman 

Cayman Islands KY1-9009 

Attention: [***] 

  
 56 

 With copies to:     

Ropes & Gray LLP 
 36F
Park Place 
 1601 Nanjing Road West 

Shanghai, China 200040 

Attention: Eric Wu and David R. Chen 

Fax: 86-21-6157-5299 

Email: Eric.Wu@ropesgray.com and David.Chen@ropesgray.com 
  

	 	17.2.4	 Any Party to this Agreement may notify the other Party of any change to the address or any of the other details
specified in Section 17.2.3, provided that such notification shall only be effective on the date specified in such notice or [***], whichever is later. 

  

	17.3	 No Other Rights. Except as otherwise expressly provided in the Agreement, no other right, express or
implied, is granted by the Agreement. 

  

	17.4	 Further Actions. Each party agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

  

	17.5	 LianBio Guarantee. LianBio hereby [***] guarantees [***] the due and punctual payment and
performance of all obligations of Licensee under this Agreement (the “Licensee Obligations”). LianBio agrees that the Licensee Obligations may be extended, modified, or renewed, in whole or in part, without notice or further assent
from it, and that it will remain bound upon its guarantee notwithstanding any extension, modification, or renewal of any Licensee Obligation. [***]. 

  

	17.6	 Amendment. No amendment, modification or supplement of any provision of the Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer or director of each party. 

  

	17.7	 Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of any party or
its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer or director of the waiving party. 

 

	17.8	 Counterparts. The Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one party but all such counterparts taken together shall constitute one and the same agreement. A signed Agreement received by a party hereto via facsimile will be deemed an original, and binding upon the party who
signed it. 

  

	17.9	 Severability. Whenever possible, each provision of the Agreement shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of the Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of the Agreement. 

  

	17.10	 Affiliates. Each Party may discharge any obligations and exercise any rights hereunder through
delegation of its obligations or rights to any of its Affiliates, provided that each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement and will cause its Affiliates to comply with
the provisions of this Agreement in connection with such performance. Any reference to a “Party” will be interpreted to mean “a Party or its Affiliates” where necessary to give each Party’s Affiliates the benefit of the
rights provided to such Party in this Agreement and the ability to perform its obligations. 

  
 57 

	17.11	 Independent Contractors. The relationship between ReViral and Licensee created by the Agreement is one
of independent contractors and neither party shall have the power or authority to bind or obligate the other. There is no employee-employer relationship or partnership relationship between ReViral and Licensee or any of its representatives.

  

	17.12	 Local Law Requirements. Except as otherwise specifically provided herein, each party shall at their own
expense in their respective countries, take such steps as may be required to satisfy any laws or requirements with respect to declaring, filing, recording or otherwise rendering the Agreement valid. 

 

	17.13	 Expenses. Each party shall bear its own expenses and costs incurred in the negotiations leading up to
and in preparation of the Agreement and of matters incidental to the Agreement. 

  

	17.14	 Entire Agreement of the Parties. The Agreement (including the Schedules) shall constitute and contain
the complete, final and exclusive understanding and agreement of the parties and cancels and supersedes any and all prior negotiations, correspondence, understanding and agreements, whether oral or written, between ReViral and Licensee respecting
the subject matter thereof. 

  

	17.15	 Exclusion. The Parties exclude the application of any international statutes on the sales of goods,
including the United Nations Convention on International Contracts for the Sales of Goods. 

  

	17.16	 Language. The English version of the Agreement shall be deemed the official and governing instrument,
notwithstanding any translations thereof. 

 [Signature Page Follows] 

  
 58 

 IN WITNESS WHEREOF, intending to be legally bound, the parties have caused the Agreement to be executed by
their duly authorized officers or directors as of the Effective Date. 
  

			
	REVIRAL LIMITED
		
	By:	 	 /s/ Alex Sapir

	Name:	 	Alex Sapir
	Title:	 	CEO
	
	LIANBIO RESPIRATORY LIMITED
		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director
		
	LIANBIO	 	
	(solely for the purposes of Section 17.5)
		
	By:	 	 /s/ Konstantin Poukalov

	Name:	 	Konstantin Poukalov
	Title:	 	Director

 [Signature Page to Co-Development and License Agreement]

 EXHIBIT A    CHEMICAL STRUCTURE RV521 

[***] 

 EXHIBIT B RSV CANDIDATES AT EFFECTIVE DATE 

[***] 

 EXHIBIT C DISCLOSURE LETTER 

[***] 

 EXHIBIT D LIST OF DOCUMENTS IN DISCLOSURE BUNDLE 

[***] 

 EXHIBIT E LIST OF DOCUMENTS DISCLOSED IN DATAROOM 

[***] 

 EXHIBIT F 

LICENSED PATENTS AT EFFECTIVE DATE 
 [***]

 EXHIBIT G DRAFT PEDIATRIC TARGET PROFILE 

[***] 

 EXHIBIT H AGREED PRESS RELEASE 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]